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Abstract 
Histone deacetylases (HDAC) shift the balance towards chromatin condensation and silence 
gene expression. Aberrant recruitment of HDACs to alter transcription suggests the use of HDAC 
inhibitors (HDAC-Is) as potential therapeutic candidates for neurodegenerative disorders such as 
Parkinson’s disease (PD). Post mortem studies of PD, characterised by progressive loss of 
dopaminergic neurones in the substantia nigra, have linked α-synuclein toxicity and oxidative 
stress to the pathogenesis of the disorder. Interestingly HDAC-Is have been shown to prevent α-
synuclein and 1-methyl-4-phenylpyridinium (MPP+)-induced cellular toxicity in vitro, but there is 
limited reports on the inhibition HDACs in in vitro and in vivo models of PD.   
 
For this reason, the effects of the HDAC-Is, suberoylanilide hydroxamic acid (SAHA) and valproic 
acid (VPA) were investigated in in vitro and in vivo models of PD. Neither inhibitors protected 
dopaminergic cell lines, SH-SY5Y and N1E-115, against hydrogen-peroxide (H2O2) and MPP
+-
induced toxicity. Except, at the highest concentrations (10-3M), where SAHA tended to decrease 
cell death. However, in the more complex rat ventral mesencephalic cultures, although HDAC-Is 
did not protect dopaminergic neurones against MPP+- or Lipopolysaccharide (LPS)-induced 
toxicity, interestingly, they reduced the number of astrocytes and activated microglia suggesting 
a positive anti-inflammatory effect. The effects of the HDAC-Is were then assessed in the 6-
hydroxydopamine- and LPS-lesioned mouse models of PD. Both SAHA and VPA protected 
dopaminergic neurones and decreased the number of astrocytes in substantia nigra pars 
compacta (SNpc), although the number of active microglial cells were not reduced except at the 
highest dose of VPA. 
 
The results suggest that although the HDAC-Is, SAHA and VPA, are toxic to the immortalised 
dopaminergic cells in vitro, they protect nigral dopamine cells from toxin-induced cell loss in 
vivo. The reduction in astrocyte and microglia activation induced by the HDAC-Is suggest they 
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1.1 Parkinson’s disease 
Parkinson’s disease (PD) is a chronic progressive neurological movement disorder affecting 
approximately 1 % of the population older than 65 years (Bossy-Wetzel et al., 2004) and raising 
to approximately 4 % of the population over 80 years. However, 10 % of cases classified as young 
onset, occurs between 20 and 50 years (Dexter & Jenner, 2013). It is the second most prevalent 
neurodegenerative disorder after Alzheimer’s disease (AD). The motor symptoms are clinically 
characterised by four cardinal features: resting tremor, rigidity, bradykinesia and postural 
instability (Carlsson, 1959; Lang & Lozano, 1998). Non-motor symptoms are also exhibited and 
these include depression, anxiety, cognitive impairment, constipation, pain, genitourinary 
problems, sexual dysfunction and sleep disorders (Chaudhuri et al., 2006; Jankovic, 2008; 
Schapira, 2008; Bandopadhyay & de Belleroche J., 2010). 
 
1.1.1 Pathology 
The motor symptoms of PD results primarily from the death of dopaminergic neurones in the 
substantia nigra pars compacta (SNpc), and the resultant depletion of terminal dopamine (DA) in 
the caudate putamen (Hornykiewicz, 2008). The onset of the motor symptoms of PD occur after 
about 50 – 60 % of dopaminergic neurones have degenerated in the substantia nigra, and 
approximately 70 – 80 % of striatal DA is depleted (McGeer et al., 1988a; Agid, 1991; Fearnley & 
Lees, 1991). This is due to the compensatory mechanisms of the basal ganglia, where DA 
turnover is increased and post-synaptic DA D2-type receptor sensitivity is increased in the 
striatum to maintain normal function in the early stages of neuronal loss (Bezard & Gross, 1998; 
Bezard et al., 2003). 
 
In addition to nigral dopaminergic neuronal degeneration, there is also loss of noradrenaline 
neurones of the locus coeruleus (LC), cholinergic neurones of the nucleus basalis of Meynert 
(NBM), serotonin neurones of the dorsal raphe nuclei (RN), as well as degeneration of neurones 
in the olfactory system, the dorsal motor nucleus of the vagus (DMNV) and the peripheral 
nervous system (PNS) (Javoy-Agid et al., 1984; Lang & Lozano, 1998; Olanow et al., 2004).  
Degeneration of these neurones in other brain regions has been suggested to underlie the 
prevalence of non-motor symptoms of PD. For example, non-motor symptom such as depression 
in PD has been implicated to relate to the loss of noradrenergic transmission in the limbic 
system, whereas dementia has been linked to the destruction of the cholinergic system (Remy et 
al., 2005; Langston, 2006). 
 
PD is also defined pathologically by the presence of Lewy bodies (LB) and Lewy neurites (LN). LBs 
are intracytoplasmic proteinaceous aggregates, consisting of spherical bodies and dense cores 
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whereas LNs display thread-like structures found in neuronal processes (Forno, 1996). They 
contain a wide variety of proteins including ubiquitin and neurofilaments with α-synuclein being 
the major component (Spillantini et al., 1997). They are typically found in the SNpc, but also seen 
in brain areas that experience degeneration (Olanow et al., 2004). The mechanism by which LBs 
and LNs are formed or their contribution to disease progression is unknown. However, by 
staining for α-synuclein immunoreactive aggregates through the brain at different stages of the 
disease, Braak and colleagues (2003) hypothesised a topographical and chronological spread of 
the disease through the brain. They concluded that the pathological process in PD occurs in 6 
stages. Lewy bodies are initially confined to the medulla oblongata in the dorsal 
glossopharyngeal-vagus complex before progressing to other parts of the brain in an ascending 
manner (Braak et al., 2003) (Figure 1-1). According to the Braak’s hypothesis, SNpc degeneration 
occurs at stage 3 but motor symptoms are not evident until stage 4 (Braak et al., 2004).  
 
Even though there is evidence in support of Braak’s hypothesis, the use of α-synuclein as a 
pathological marker to mark disease progression has criticised the validity of the hypothesis 
(Lang, 2007; Burke et al., 2008a). This is because Braak’s hypothesis assumes that patients with 
α-synuclein immunoreactive inclusions in any part of the central nervous system (CNS) have PD, 
but it is unclear whether the α-synuclein pathological changes correlate with neuronal 
dysfunction or loss. In addition, α-synuclein is not the only protein found in LBs, and he failed to 
consider other LB-associated proteins. Furthermore, clinico-pathological studies showed that α-
synuclein inclusions, even though were present in the SN and cortical regions, were not present 
in the LC and DMNV of some PD cases (Parkkinen et al., 2005; Kalaitzakis et al., 2008).  
 
Recently, an alternative hypothesis has emerged that PD starts in the intestinal nerve cells prior 
to brain stem pathology. Initial evidence from investigations on 5 autopsies with Parkinson-
associated synucleinopathy, found α-synuclein immunoreactive inclusions in the neurones of the 
gastrointestinal submucosa (Braak et al., 2006). This has been confirmed recently by 
immunohistochemistry studies for α-synuclein on biopsy specimens of untreated PD patients. 
Positive staining of α-synuclein in nerve fibres in the colonic submucosa was found to be 
dissimilar to the pattern in control samples and patients with inflammatory bowel disease (IBD) 
(Shannon et al., 2012). In addition, questionnaires completed by 129 PD patients to determine 
the onset of gastrointestinal symptoms (GIS) with respect to motor symptoms, showed that 
gastrointestinal dysfunction preceded motor symptoms (Cersosimo et al., 2012). Despite these 
evidences, whether the pathological process begins in the brain or elsewhere in the nervous 
system is still unknown and remains under investigation.  
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However, Braak’s staging concept has gained support from recent findings, as it has been 
demonstrated that α-synuclein transfers from cell-to-cell in a prion-like manner in cell culture, 
animal models and embryonic brain tissue transplanted into PD patients (Dunning et al., 2012). 
Exactly how this occurs is unknown, but it does suggest that mutated α-synuclein proteins 
released by affected neurones could be taken up by healthy neurones to spread the α-synuclein 
pathology and continue the cycle of protein misfolding and lewy body formation (Dunning et al., 
2012). Nevertheless, this theory requires further investigation to clarify the molecular 
understanding of the pathogenesis of PD. 
 
Although there is progressive neurodegeneration in various parts of the brain, pathological 
findings show cell loss in the SNpc to be undoubtedly the main contributor of the onset of motor 
symptoms.  Whether this cell loss is primarily due to the presence of LBs is yet to be determined, 
as they are also present in the brainstem of the elderly, and the link between LBs and PD is yet 
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Figure 1-1 Overview of the 
Braak staging hypothesis in PD. 
(A) The areas of the brain under 
degeneration at each stage; (B) 
Sagittal section of brain showing 
the spread of pathology (red 
arrows) in an ascending pathway 
with colour intensity showing 
areas with severe degeneration. 
(Adapted from Braak et al., 
2004). 
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1.1.2 Treatments of PD 
The current and most effective treatment for PD tackles the motor deficits of the disease 
whereas management of the non-motor symptoms are limited. Current treatment involves 
dopamine replacement therapy using levodopa (L-DOPA; L-3,4-dihydroxyphenylalanine), a 
precursor of dopamine (Jenner, 2002; Schapira et al., 2006). This is administered in conjunction 
with the dopa-decarboxylase inhibitor, carbidopa or benserazide, which inhibits the peripheral 
dopamine production from L-DOPA (Celesia & Wanamaker, 1976; Hornykiewicz, 2002). This 
makes L-DOPA more readily and rapidly available for brain metabolism and allows a reduction in 
L-DOPA dose, in addition to limiting its side effects such as nausea, hypotension and vomiting 
(Cedarbaum, 1987; Hauser, 2009). This drug combination effectively improves motor disability in 
PD, resulting in a reduction in morbidity and mortality, and overall improvement in the quality of 
life (Olanow, 2004). Despite the therapeutic benefits of L-DOPA, chronic administration is 
associated with motor complications or fluctuations, such as ‘wearing off’ effect, ‘ON-OFF’ 
periods and dyskinesia. These develop in 40 – 60 % of patients after 4 – 6 years of L-DOPA 
therapy, and 70 - 80 % of patients after 10 years of usage experience significant social and 
functional disability (Marsden & Parkes, 1977). 
 
Dopamine agonists (pergolide, pramipexole, ropinirole, rotigotine, apomorphine, cabergoline 
and bromocriptine) are used as monotherapy or in combination with L-DOPA and can delay the 
onset of motor fluctuations. Monotherapy is used in early stages of the disorder and can delay 
the need for L-DOPA for up to 5 years (Lees, 2005). They act on dopamine receptors located on 
the striatal cholinergic interneurones and GABAergic efferent neurones, but can enhance the 
non-motor symptoms such as confusion, depression and hallucinations via activation of non-
striatal dopamine receptors (Rascol et al., 2000). Monoamine oxidase-B (MAO-B) inhibitors such 
as rasagiline and selegiline reduce endogenous dopamine breakdown. In early disease, they 
provide only mild improvement of the motor symptoms (Ives et al., 2004; Goetz et al., 2005), but 
are used in late stage disease, as they enhance the effects of L-DOPA (Rascol et al., 2000; 
Schapira, 2009). Catechol-O-methyl transferase (COMT) inhibitors such as entacapone and 
tolcapone are also co-administered with L-DOPA. They inhibit the metabolism of L-DOPA and 
dopamine into 3-O-methyldopa (3-OMD) and 3-methoxytyramine (3-MT), respectively (Thanvi & 
Lo, 2004). Similar to decarboxylase inhibitors, COMT inhibitors also extend the plasma half-life of 
L-DOPA, thereby prolonging the duration of action of each L-DOPA dose (Rinne et al., 1998). This 
reduces the L-DOPA requirement in patients (Kurth et al., 1997).  
 
At present, as these treatments only alleviate the motor symptoms and remain symptomatic in 
nature, there is an urgent need for a neuroprotective agent that can prevent further loss of 
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dopaminergic neurones in the SNpc and eventually halt disease progression. In order to find 
neuroprotective strategies, it is important to understand the aetiology of PD and the processes 
involved in neuronal degeneration. 
 
1.1.3 Aetiology of PD  
The aetiology of PD is unknown, however numerous studies have shown genetics and 
environmental factors are both involved. In most cases, PD appears to be sporadic, but the 
discovery of an increase in the incidence of PD in rare families  have identified a number of cases 
to be genetically related and have thus been termed as familial PD (Polymeropoulos et al., 1997; 
Gasser, 1998; Kitada et al., 1998). Using genetic linkage analysis in large families and genome-
wide association studies, 18 autosomal dominant and autosomal recessive gene mutations 
responsible for variants of the disease have been identified (Klein & Westenberger, 2012). The 
chromosomal loci are given the nomenclature ’PARK’ and include α-synclein (SNCA) (PARK 1 & 
4), parkin (PARK 2), ubiquitin-C-terminal hydroxylase-L1 (UCH-L1) (PARK 5), PTEN (Phosphatase 
and tensin homologue)-induced kinase 1 (PINK1) (PARK 6), DJ-1 (PARK 7), Leucine-rich repeat 
kinase 2 (LRRK2) (PARK 8), ATP13A2 (PARK 9) (Wirdefeldt et al., 2011; Klein & Westenberger, 
2012) (Table 1-1). 
 
These 8 genes have been extensively validated and they express proteins that are involved in 
one or more pathological pathway of PD, such as the impairment of the protein degradation 
system, mitochondrial dysfunction and oxidative stress (Figure 1-2). In summary:  
• SNCA codes for the protein α-synuclein, which forms fibril-like aggregates found in LBs and 
LNs. It is a feature of both familial and sporadic PD (Spillantini et al., 1997). Point mutations 
in this gene, have been shown to increase protein expression (Polymeropoulos et al., 1997; 
Farrer et al., 2004) which is associated with enhanced protofibril formation (Miller et al., 
2004). Triplication of the locus has also been identified (Singleton et al., 2003) and shown to 
result in the development of PD (Devine et al., 2011b).  
• Parkin, an E3 ubiquitin ligase (Kitada et al., 1998) and UCH-L1, a deubiquitinating enzyme 
(Leroy et al., 1998), are both involved in the ubiquitin-proteasome system (UPS) which 
degrades unwanted proteins. Investigations in parkin-null mice resulted in mitochondrial 
dysfunction and oxidative stress (Palacino et al., 2004). UCH-L1 inhibition reduced the 
availability of free monomeric ubiquitin molecules and contributed to the impaired 
clearance of unwanted proteins by the UPS (Cartier et al., 2009). This resulted in 
accumulation of abnormal proteins in the brain of knock-out mice (Saigoh et al., 1999). 
• PINK1, is a mitochondrial membrane anchored-kinase protein (Valente et al., 2004). 
Overexpression and loss of function investigations implicate PINK1 in apoptosis, impaired 
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dopamine release, motor deficits and decreased complex I activity (Kitada et al., 2007; 
Morais et al., 2009). It also plays a role in the survival of neurones, especially against MPTP-
induced toxicity (Haque et al., 2008). 
• DJ-1 acts as an anti-oxidant and protects cells from oxidative stress (Nagakubo et al., 1997; 
Bonifati et al., 2003). Overexpression of DJ-1 results in mice being resistant to MPTP. 
Mutations in DJ-1 are associated with increased oxidative stress (Takahashi-Niki et al., 2004) 
and impaired mitochondrial dynamics and function (Wang et al., 2012).    
• LRRK2, is a tyrosine kinase-like protein (Zimprich et al., 2004). It is localised in membrane 
microdomains, multivesicular bodies and autophagic vesicles (Lynch-Day et al., 2012). Its 
function is unknown and its contribution to PD pathology is also unclear, but there is 
evidence that the mutation I2020T causes an increase in LRRK-2 kinase activity (Gloeckner et 
al., 2006).  
• ATP13A2 gene encodes a transmembrane lysosomal P5-type ATPase (ATP13A2) (Dehay et 
al., 2012a). Mutations in ATP13A2 gene results in several lysosomal defects such as impaired 
lysosomal acidification, decreased proteolytic processing of lysosomal enzymes, reduced 
degradation of lysosomal substrates, and diminished lysosomal-mediated clearance of 
autophagosomes (Dehay et al., 2012b). These result in dysfunction of the autophagy 
degradation system and contributes to the accumulation of unwanted proteins. 
 
Table 1-1 Genes underlying monogenic parkinsonism 
AD, autosomal dominant; AR, autosomal recessive. (Adapted and modified from Klein & 
Westenberger, 2012).  
PARK locus Gene Gene locus Inheritance 
PARK1 SNCA 4q21-22 AD 
PARK2 Parkin 6q25.2–q27 AR 
PARK3 Unknown 2p13 AD 
PARK4 SNCA 4q21–q23 AD 
PARK5 UCHL1 4p13 AD 
PARK6 PINK1 1p35-p36 AR 
PARK7 DJ-1 1p36 AR 
PARK8 LRRK2 12q12 AD 
PARK9 ATP13A2 1p36 AR 
PARK10 Unknown 1p32 Not clear 
PARK11 GIGYF2 2q36-27 AD 
PARK12 Unknown Xq21-q25 Not clear 
PARK13 HTRA2 2p12 Not clear 
PARK14 PLA2G6 22q13.1 AR 
PARK15 FBXO7 22q12-q13 AR 
PARK16 Unknown 1q32 Not clear 
PARK17 VPS35 16q11.2 AD 
PARK18 EIF5G1 3q27.1 AD 
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 Genetic mutations accounts for 5 – 10 % of PD cases, therefore the disease is commonly 
sporadic accounting for approximately 90 % of cases (Lesage & Brice, 2009). But as the search 
for genetic links to PD continues, there are approximately 40 % of the population at risk (Hardy, 
2010). This is due to the autosomal dominant and recessive genes, as well as susceptibility genes 
which have recently been discovered by genome-wide association studies in idiopathic PD, 
including α-synuclein and LRRK2 (Nalls et al., 2011; International Parkinson's Disease Genomic 
Consortium, 2011) (Table 1-2). This indicates that even though familial and sporadic forms of PD 
are clinically and pathologically distinct from each other, they do overlap, and this has enabled 
genetic mutations to provide insights into the molecular mechanisms underlying the disease 
process. Such as mitochondrial dysfunction, oxidative stress and impairment in protein handling 
processes (Houlden & Singleton, 2012). Nevertheless, they do not explain the cause or 
mechanistic of the sporadic  cases (Hardy et al., 2006), but they do imply that environmental 
factors and genetics can result in PD.   
 
Accumulating evidence from epidemiological studies found increased exposure to the pesticide 
rotenone, and the weed killer paraquat induces loss of nigral dopaminergic neurones 
(Priyadarshi et al., 2000; Tanner et al., 2011). In addition, other factors such as well water 
consumption (Gatto et al., 2009), residing in close proximity to agricultural industries 
(Priyadarshi et al., 2001), chronic exposure to welding fumes with high manganese levels 
(Jankovic, 2005), carbon monoxide poisoning and hydrogen sulphide intoxication (Dexter & 
Jenner, 2013) have been associated with increased risk of PD. Despite the evidence, 
environmental factors tend to increase the risk of PD but are not the cause of all cases.  
 
The heterogeneous nature of PD causes patients to exhibit differences in the severity of their 
clinical features. One thing all PD patients have in common is the demise of the dopaminergic 
neurones in the SNpc. Even though a combination of genetic and environmental factors can be 
attributed to the cause of PD, the exact cause is unknown, and the molecular mechanisms 
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 Table 1-2 Susceptibility genes for PD.  
(Adapted and modified from Nalls et al., 2011; International Parkinson's Disease Genomic 
Consortium, 2011). 
Gene Protein 
ACMSD Aminocarboxymuconate semialdehyde decarboxylase 
BST1 Bone marrow stromal cell antigen 1 
FGF20 Fibroblast growth factor 20 
GAK Cyclin G-associated kinase 
GPNMB Glycoprotein NMB 
HIP1R Huntingtin-interacting protein 1-related 
HLA-DRB5 Major histocompatibility complex class II, DR β5 
LRRK2 Leucine-rich repeat kinase 2 
LAMP3 Lysosomal-associated membrane protein 3 
MAPT Microtubule-associated protein tau 
SNCA a-synuclein 
STK39 Serine threonine kinase 39 
STX1B Syntaxin 1B 
SYT11 Synaptotagmin-11 
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Figure 1-2 Genetics and 
aetiology of PD. 
Diagram links common gene 
mutations in familial PD to 
key molecular mechanisms 
that contribute to neuronal 
loss in the SN. (Adapted and 
modified from Vila & 
Przedborski, 2004; Schapira, 
2008; Bandopadhyay & de 
Belleroche J., 2010; Shadrina 
et al., 2010). 
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1.1.4 Pathogenesis of PD 
Many factors are implicated in the neuronal cell death cascade observed in PD. The initiator of 
the cascade is unknown, but they are deleterious and potential targets for disease-modifying 
agents. For this reason, it is essential to fully understand the mechanisms associated with cell 
death. These mechanisms described in detail below include the dysfunctions in the protein 
degradation systems: ubiquitin-preoteasome system (UPS) and autophagy, mitochondrial 
dysfunction, oxidative and nitrative stress and inflammation.  
 
1.1.4.1 Ubiquitin-proteasome dysunction 
Dysfunction of the UPS has been implicated in the nigrostriatal neuronal loss. It is a non-
lysosomal protein degradation pathway for unwanted intracellular proteins, including misfolded, 
mutated, mislocated or damaged proteins, and is therefore important in maintaining cell 
homeostasis (Wang & Maldonado, 2006). It is involved in the regulation of many cellular 
processes such as cell cycle and division, development and differentiation, apoptosis, cell 
trafficking and morphogenesis of neuronal networks (Ciechanover, 1998).  
 
The degradation pathway involves “tagging” the protein by covalent attachment to multiple 
ubiquitin molecules forming polyubiquitin-protein conjugates through a series of enzyme-
mediated reactions by ubiquitin ligases (Glickman & Ciechanover, 2002). This marks it for 
degradation by the 26S proteasome complex, which consists of a proteolytic core complex (20S 
proteasome) capped at one or both ends with 19S regulatory complexes (Voges et al., 1999), for 
non-lysosomal protein degradation (Ciechanover, 1998). Once the tagged proteins attach to the 
ubiquitin receptors in the proteasome, deubiquitinating enzymes recycle the ubiquitin molecules 
prior to protein degradation (Ciechanover, 1998). A defect in this system results in an 
accumulation of unwanted proteins (tagged and untagged) which form aggregates in the cells 
and become toxic to neurones. This was confirmed by in vitro studies which showed that 
proteasomal inhibition in neuronal cells resulted in an accumulation of ubiquitinated proteins, in 
addition to a pro-inflammatory response, with an increase in inflammatory markers 
cyclooxygenase-2 (COX-2) and prostaglandin PGE(2) (Rockwell et al., 2000), and subsequently 
neurodegeneration (McNaught et al., 2002a). 
 
Studies on post mortem brain have observed structural and functional deficits of the 
proteasome by 33 – 42 % in the SN of idiopathic PD patients (McNaught & Jenner, 2001; 
McNaught et al., 2003). Particularly, the α-subunits of the 20/26S proteasomes are lost within 
dopaminergic neurones and the enzymatic activities of the 20S are reduced in the SN (McNaught 
et al., 2003; Bukhatwa et al., 2010). Additionally, administration of the proteasomal inhibitors N-
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benzyloxy-carbonyl-Ile-Glu(O-t-butyl)-Ala-leucinal (PSI) and epoxomicin to rodents caused 
nigrostriatal degeneration and the formation of LB inclusions consisting of ubiquitin and α-
synuclein (McNaught et al., 2004; Zeng et al., 2006; Bukhatwa et al., 2009).  
 
Failure of the UPS has been supported by the identification of ubiquitinated proteins in Lewy 
bodies. These include oxidised (Dexter et al., 1989a; Castellani et al., 2002), nitrated (Good et al., 
1998), and phosphorylated proteins (Fujiwara et al., 2002). Additionally, ubiquitin associated 
with protein processing, and mutated proteins such as parkin, α-synuclein and UCH-L1, linked 
with the degradation system (Section 1.1.3) (McNaught et al., 2002b; Olanow et al., 2004) are 
also present. 
 
In conclusion, supporting evidence, such as the discovery of mutated parkin and UCH-L1 
proteins, suggests that the impairment of the UPS plays a critical role in the pathogenesis of PD. 
This impairment promotes the accumulation of misfolded or damaged proteins and the 
formation of LBs, which may be the initiator or result of a cascade of events such as oxidative 
stress, nitrative stress and/ or inflammation.  
 
1.1.4.1 Autophagy 
Similar to the UPS system, autophagy is also a protein degradation mechanism but involves 
degradation by lysosomes. These include aggregate-prone proteins, damaged organelles as well 
as invasive pathogens (Clarke, 1990). Increasing evidence suggests dysregulation of this process 
results in the accumulation of these proteins in PD, especially as autophagosomal proteins are 
present in LBs (Banerjee et al., 2010; Tanji et al., 2011). There are three types of autophagy, 
namely, macroautophagy, where proteins are sequestered into autophagosome which fuses 
with the lysosomal membrane; microautophagy, where proteins are taken directly into 
lysosomes; and chaperone-mediated autophagy (CMA), which involves the binding of proteins to 
chaperone proteins, for example heat-shock cognate 70 (HSC70), to translocate proteins across 
the lysosomal membrane (Yang & Klionsky, 2010). The expression of CMA proteins, Lysosomal-
associated membrane protein 2A (LAMP2A) and HSC70, were reported to be significantly 
reduced in the SNpc and amygdala of PD brains (Alvarez-Erviti et al., 2010). This evidence 
confirms the involvement of autophagy impairment in the pathogenesis of PD. 
 
Numerous studies have shown that native α-synuclein is degraded by CMA, and inhibition of 
autophagy has resulted in accumulation and aggregtion of mono-ubiquitinated α-synuclein 
(Cuervo et al., 2004; Rott et al., 2008). Cell culture studies have also shown that A53T and A30P 
mutant α-synuclein, inhibit autophagy and fail to translocate across the lysosomal membrane 
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for degradation (Martinez-Vicente et al., 2008). In addition, two PD-associated proteins, PINK1 
and Parkin have been shown to mediate autophagy. PINK1, which is a mitochondrially targeted 
serine/threonine kinase, accumulates on the outer membrane of the mitochondrion when there 
is a loss of membrane potential (Vincow et al., 2013). This triggers the recruitment of Parkin, a 
cytosolic E3 ubiquitin ligase, to the impaired mitochondria to ubiquitinate the proteins on the 
outer membrane and facilitate their degradation by autophagy (Narendra et al., 2008; Poole et 
al., 2010). Mutations in PINK1 as in PD patients and inhibition of PINK1 kinase activity, fails to 
recruit Parkin to the mitochondria resulting in accumulation of damaged mitochondria (Geisler 
et al., 2010). Interestingly, deletion of PINK1 gene induces autophagy of the mitochondria 
through elevation of mitochondrial superoxide; and Parkin overexpression rescues the PINK1-
deficient phenotype, by translocating to the depolarized mitochondria to also induce autophagy 
(Narendra et al., 2008; Dagda et al., 2009). This suggests that the 2 genes may work via different 
mechanisms to maintain mitochondrial homeostasis. Furthermore, loss of either LRRK2 or DJ-1 
also results in impairment of autophagy (Alegre-Abarrategui et al., 2009; Tong et al., 2010; Hao 
et al., 2010). This indicates that the PD-associated proteins function together, and mutations in 
one protein can result in an impairment of the lysosomal degradation system which contributes 
to cell death via accumulation of unwanted protein and mitochondria. They also provide a link 
between familial PD and autophagy. 
 
More recently, mutations in the gene encoding for glucocerebrosidase (GBA), a lysososmal 
enzyme that catalyses the hydrolysis of the membrane glycolipid, glucocerebroside to ceramide 
and glucose, has been linked to increase the risk of PD (Velayati et al., 2010). Deficient 
glucocerebrosidase activity is implicated in the lysosomal storage disorder, Gaucher’s disease 
(GD). Investigations on the mutations of GBA has been linked to PD through lysososmal 
insufficiency and autophagic dysfunction, which reduces α-synuclein degradation and 
contributes to the accumulation of unwanted proteins, resulting in further disruption of the 
autophagic system (Velayati et al., 2010). Interestingly, heterozygous GBA mutations lead to 
Gaucher’s disease, but both homozygous and heterozygous mutations lead to an increased risk 
of PD, and the severity of PD is linked to the degree of GBA activity. GBA mutations increase the 
risk of developing PD by 20- to 30- fold and about 5 – 10 % of PD patients have a GBA mutation 
(Velayati et al., 2010; Dexter & Jenner, 2013). 
 
Similar to the UPS, autophagy plays a significant role in the clearance of damaged, mutated, 
misfolded or unwanted proteins. Disruption of this system contributes significantly to the 
progression of dopaminergic cell loss through the accumulation of proteins and LB formation. 
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1.1.4.2 Mitochondrial dysfunction 
Several reports have documented abnormalities of the mitochondrial respiratory chain in PD. 
Mitochondria are the primary energy producers of the cells, which regulate cell survival through 
the production of ATP. This involves the transport of electrons via complexes I-IV in the inner 
mitochondrial membrane through a series of oxidative phosphorylation reactions. Impairment in 
this system results in energy deficiency and oxidative stress (Figure 1-2), and renders cells more 
susceptible to toxins and eventually cell death (Keane et al., 2011).  
 
The most direct evidence for mitochondrial dysfunction comes from studies on autopsy tissue of 
PD patients, where complex I activity was reported to be decreased in the SN (Schapira et al., 
1990) and frontal cortex (Parker, Jr. et al., 2008). However, impairment of complex I is not 
confined to the brain as platelet mitochondria purified from PD patients also showed a reduction 
in activity (Parker, Jr. et al., 1989). This is supported by in vitro investigations on cybrid cell lines, 
which contain mitochondria from the platelets of PD patients. It was found that they are more 
sensitive to MPP+-induced cell loss than control, and produce an increase in reactive oxygen 
species (Swerdlow et al., 1996; Gu et al., 1998). This suggests that mitochondrial deficiency may 
be widespread in PD and is probably due to genetic factors. Indeed, increased levels of 
mitochondrial DNA (mtDNA) deletions in the striatum of PD patients have been reported (Ikebe 
et al., 1990). But, there is limited evidence of mtDNA defects in PD, and the link needs to be 
further investigated. 
 
However, increasing evidence for mitochondrial dysfunction comes from genetic mutations. 
Particularly the PINK1 gene, which encodes for the mitochondrial membrane kinase and its 
mutation, is associated with autosomal recessive forms of PD (Gandhi et al., 2006). Preliminary 
studies in G309D PINK1 transfected neuroblastoma SH-SY5Y cell lines, reported wild-type PINK1 
to protect neurones from stress-induced mitochondrial dysfunction and apoptosis, following 
proteasome inhibitor exposure (Valente et al., 2004). Functionally, PINK1 knock-out mice exhibit 
dopamine release impairment (Kitada et al., 2007), and impaired mitochondrial respiration, as 
well as increased sensitivity to oxidative stress (Gautier et al., 2008). Similarly, PINK1 mutant flies 
showed increased sensitivity to apoptotic stimuli and loss of synaptic function (Morais et al., 
2009). Furthermore, mutations in other genes responsible for familial forms of PD such as 
parkin, DJ-1 and LRRK2 have also been associated with altered mitochondrial function (Yao & 
Wood, 2009). In particular, loss of function of DJ-1, parkin and PINK1 decreased mitochondrial 
protection against oxidative stress and subsequently increased its disruption (Dexter & Jenner, 
2013). The evidence of mutated proteins linked to the impaired mitochondrial function confirms 
the genetic links of mitochondrial deficiency in PD pathogenesis.  
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 Environmental factors associated with sporadic PD are also linked to mitochondrial inhibitors 
and pesticides. In fact, initial evidence for mitochondrial defects comes from investigations of 
four young drug-users who developed parkinsonism after unintentional exposure to 
mitochondrial inhibitor MPTP (Langston et al., 1983a). Once this lipophilic toxin crosses the 
blood brain barrier, it is oxidised to its metabolite MPP+ in glial cells. MPP+ has a high affinity for 
dopamine transporters (DAT) and enters dopaminergic neurones to cause selective 
degeneration  by inhibiting complex I of the mitochondrial respiratory chain and/ or interacting 
with cytosolic enzymes (Dauer & Przedborski, 2003). In addition, evidence have been obtained 
from studies where exposure to the pesticide rotenone, a complex I inhibitior (Betarbet et al., 
2000), and paraquat, an indirect mitochondrial inhibitor through redox cycling (Richardson et al., 
2005; Miller, 2007); and the fungicide maneb, a complex III inhibitor (Meco et al., 1994) induced 
parkinsonism. 
 
There is no doubt that mitochondrial dysfunction and its association with oxidative stress plays 
an important role in both familial and sporadic PD progression. However, whether this 
impairment is a primary or secondary event is still unknown and requires further investigation. 
 
1.1.4.3 Oxidative stress  
Oxidative stress, a major implicator of nigral degeneration, is defined as the imbalance between 
reactive oxygen species (ROS) production and antioxidant defence system (Betteridge, 2000). It 
is linked to other components of the degenerative process including, UPS dysfunction and 
inflammation (Jenner, 2003a), but is particularly linked to mitochondrial dysfunction (Figure 1-2).  
 
ROS are produced in the mitochondria as by-products of the electron-transport chain, in the 
form of superoxide anion (O2
-) and hydrogen peroxide (H2O2) (Pitkanen & Robinson, 1996). A 
defence mechanism consisting of enzymes such as superoxide dismutase (SOD), catalase, 
glutathione (GSH) and ascorbate convert these radicals into harmless molecules (Turrens, 2003). 
Oxidative stress occurs when the radicals are generated at increased levels which overwhelm the 
antioxidant capacity  (Giasson et al., 2002). Post mortem studies have shown that there are 
increased levels of SOD in the SN which protects against the production of superoxide (Marttila 
et al., 1988; Saggu et al., 1989). By contrast, reduced levels of GSH are found specifically in the 
SNpc (Perry & Yong, 1986; Sofic et al., 1992; Sian et al., 1994), resulting in reduced clearance of 
H2O2 (Jenner & Olanow, 1996). Studies in incidental Lewy body disease (ILBD: considered to be 
pre-clinical PD (DelleDonne et al., 2008)) observed decreased GSH levels, similar to those seen in 
advanced PD, thus suggesting oxidative stress is an early event in PD pathogenesis (Dexter et al., 
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1994). This reduction in GSH levels is linked to increased ROS production, which inhibits complex 
I leading to subsequent mitochondrial dysfunction resulting in neuronal death (Jha et al., 2000).  
 
Furthermore, in dopaminergic neurones, dopamine metabolism also yields oxidative by-products 
by auto-oxidation, such as superoxide ion (.O2
-), hydrogen peroxide (H2O2) and reactive quinones. 
Enzymatic metabolism of dopamine by monoamine-oxidase B (MAO-B) not only generates 
deaminated, metabolites homovanilic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC), 
but also H2O2, which is converted to the highly reactive form hydroxyl radical (OH
.) by the Fenton 
reaction in the presence of iron (Olanow, 1990; Jenner & Olanow, 1996). Increased levels of free 
iron have been reported to be found in the SN, which probably drives the generation of ROS 
(Dexter et al., 1989b; Sofic et al., 1991), as well as low levels of ferritin, the protein that stores 
iron in the brain (Dexter et al., 1991). Thus, the environment in the PD brain is pro-oxidant. 
 
ROS readily oxidises cellular macromolecules such as proteins, DNA and lipids, thereby resulting 
in their damage and eventually their clearance mechanisms. ROS are normally generated, and 
generally increases with age, as there is evidence of marked increases of oxidised proteins and 
DNA in ageing brains (Mariani et al., 2005). Direct evidence from post-mortem PD brain tissue 
revealed elevated levels of lipid peroxidation markers 4-hydroxynonenal (4-HNE) and 
malondialdehyde (MDA) in dopaminergic cells in the substantia nigra (Dexter et al., 1989a; 
Dexter et al., 1994; Yoritaka et al., 1996). Moreover, a marked increase in 8-Hydroxy-2-
guanosine (8-OHG), an oxidative DNA damage product, is increased in the SN (Sanchez-Ramos et 
al., 1994; Alam et al., 1997b). Increases of protein carbonyls, indicative of oxidative protein 
damage has been found in the SN, caudate nucleus and putamen of PD brain tissue, and even in 
other areas not affected in PD, but may be contributors to the non-motor symptoms of the 
disorder (Alam et al., 1997a). Therfore indicating that oxidative damage is widespread and not 
specifically restricted to the nigrostriatal pathway. 
 
1.1.4.4 Nitrative stress 
Similarly to oxidative stress, nitrative stress is the imbalance between the reactive nitrogen 
species (RNS) and the antioxidant defence system, involving nitric oxide (NO), an important 
signalling molecule in many biological processes (Mayer & Hemmens, 1997). In response to 
cellular damage, including oxidative stress, there is an increase in the expression of the gene 
involved in NO production, called nitric oxide synthase (NOS), which exists in 3 major isoforms; 
endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS) (Marletta et al., 1998; 
McNaught & Jenner, 1999). Excessive production of NO interacts with superoxide anion (.O2
-) to 
form an unstable reactive free radical species peroxynitrite (ONOO-), which forms nitrogen 
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dioxide, carbonate and hydroxyl radicals, as by-products (Szabo et al., 2007). These 
peroxynitrate radicals result in nitration of tyrosine and nitrosylation of cysteine molecules 
within both proteins and enzymes leading to a loss of function (Jenner, 2003a). For example, 
nitration of striatal tyrosine hydroxylase (TH), the enzyme involved in dopamine synthesis, 
resulted in loss of enzyme activity and subsequent decrease in dopamine synthesis (Ara et al., 
1998). 
  
Evidence from post-mortem PD patients showed increased levels of 3-nitrotyrosine (3-NT), 
which is used as a biological marker of ONOO- formation, in Lewy bodies (Gatto et al., 2000; 
Greenacre & Ischiropoulos, 2001). Similarly, the increase in 3-NT was also detected in the SN of 
primates (Ferrante et al., 1999) and in the SN and striatum of mice following MPTP treatment 
(Pennathur et al., 1999; Riobo et al., 2001). Additional studies found 3-NT-positive α-synuclein in 
Lewy bodies in post mortem tissue (Giasson et al., 2000), and in the SN and ventral midbrain of 
MPTP-treated mice (Ferrante et al., 1999), implicating that α-synuclein is a target for nitration.  
 
Some evidence have shown that tyrosine nitration of mitochondrial complex I contributes to its 
inhibition (Bolanos et al., 1996; Heales & Bolanos, 2002). But it is not clear if this nitration of 
complex I is related to the mitochondrial dysfunction observed in PD pathology. However, 
reduced levels of GSH observed following NO-mediated mitochondrial damage (Bolanos et al., 
1996) is presumed to be due to the direct nitration of GSH reductase resulting in its inhibition 
(Ara et al., 1998) and increased oxidative stress. 
 
Moreover, numerous proteins in PD have been found to be modified by the nitrosylation of 
cysteine residues. This includes enzymes involved in gene transcription, receptor mediated 
signal transduction, apoptosis (Tsang & Chung, 2009) and importantly, dopamine synthesis 
(Chung et al., 2004). In addition, genes implicated in familial PD, like Parkin, were detected to be 
nitrosylated in post mortem PD brain tissue and in mice following MPTP treatment, resulting in 
loss of activity and subsequently contributing to proteasomal inhibition (Moncada & Bolanos, 
2006).  
 
The evidence depicts oxidative and nitrative stress to be involved in neuronal degeneration. 
They seem to contribute to the cascade resulting in dopaminergic neuronal death through their 
close associations to other mechanisms of the degenerative process, such as mitochondria 
dysfunction, protein clearance impairment and inflammation (Figure 1-2). But it is unclear 
whether they are initiators of these mechanisms or consequences.  
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 1.1.4.5 Inflammation 
There is a number of evidence supporting the role of inflammatory changes in the pathogenesis 
of PD. This is primarily due to the effects of active microglia and to a lesser extent, active 
astrocytes. Initial evidence comes from post mortem studies on PD patients showing active 
microglia and T-lymphocytes in the SNpc (McGeer et al., 1988b). In addition, there is an 
increased number of active microglia in other regions such as the hippocampus, entorhinal 
cortex, cingulated and temporal cortex (Sawada et al., 2006; Imamura et al., 2003). Moreover, 
pro-inflammatory cytokines, tumour necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-2 and IL-
6 have been found to be expressed at high levels in the SN as well as cerebrospinal fluid (CSF) of 
PD patients (Mogi et al., 1994a; Mogi et al., 1994b; Dobbs et al., 1999; Nagatsu et al., 2000). 
Furthermore, RANTES, a chemokine produced by activated microglia, is significantly increased in 
PD patients compared to control, and significantly correlated with Unified Parkinson’s Disease 
Rating Scale scores (UPDRS) (Rentzos et al., 2007). 
 
Glia cell populations in the CNS are composed of macroglia that includes astrocytes and 
oligodendrocytes (Teismann et al., 2003a), and microglia which constitutes approximately 20% 
of the glia population (Tremblay et al., 2011). These microglia are regarded as typical resident 
immune-competent cells of the CNS and key players in fighting disease and neuronal stress 
(Tremblay et al., 2011). In the ‘resting’ state, they are characterised by a ramified morphology 
with small bodies, long slender processes with secondary branching and lamellipodia 
(Kreutzberg, 1996; Xiang et al., 2006). In response to CNS tissue damage or pathogen insult, the 
processes of the microglia retract and become amoeboid-like to form the ‘active’ phenotype 
(Aloisi, 2001). There is an up-regulation of MHC antigens and their complementary receptors 
(such as macrophage antigen-complex I (MAC-I)) on the surface of microglia to enable them to 
act by phagocytosing debris, and promote tissue repair through the secretion of neurotrophic 
factors, such as brain-derived neurotrophic factors (BDNF) (Graeber & Kreutzberg, 1994; 
Nakamura, 2002; Banati, 2003). However, if injury is sustained, microglia become cytotoxic and 
secrete immunomodulatory molecules such as pro-inflammatory cytokines (TNF-α, IL-1β, IL-2 
and IL-6), proteinases, eicosanoids and NO to the site of infection to promote persistent 
degeneration (Knott et al., 2000; Czlonkowska et al., 2002; Beal, 2003; Zhang et al., 2005; Long-
Smith et al., 2009). A vast array of evidence supports the toxic role of microglia over their 
protective role in PD. However, the exact mechanism by which microglia promote dopaminergic 
cell death via an inflammatory response in PD is unknown, but it is assumed to be linked to the 
generation of pro-inflammatory factors, ROS and RNS which are deleterious to oxidatively 
damaged-nigral neurones (Dutta et al., 2008). 
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 Studies in in vivo models of PD, have also confirmed inflammation-mediated neuronal 
degeneration. Elevated levels of active microglia has been reported in the SN of MPTP-treated 
mice (Breidert et al., 2002), primates (McGeer et al., 2003), and 6-OHDA-treated rodents (Crotty 
et al., 2008; He et al., 2001; Akiyama & McGeer, 1989). Particularly, studies with 
lipopolysaccharide (LPS) in animal models of PD, has provided further supporting evidence for 
inflammation-mediated neurodegeneration. LPS, an endotoxin found on the outside of gram 
negative bacteria, is a potent stimulator of peripheral immune cells and CNS microglia and 
astrocytes (Lehnardt et al., 2003; Dutta et al., 2008). LPS acts via the transmembrane protein 
Toll-like receptor-4 (TLR-4) on glial cells to upregulate gene transcription for a variety of pro-
inflammatory factors and free-radical generating enzymes (Lu et al., 2008). Additionally, post 
mortem studies also reported elevated levels of inflammatory mediators’, iNOS and 
cyclooxygenase-2 (COX-2) in PD patients (Knott et al., 2000), and this was confirmed in vivo 
following LPS treatment (Hunter et al., 2007). Injection of LPS into the SNpc induced a loss of 
dopaminergic cells (Castano et al., 1998; Herrera et al., 2000), but as neurones lack TLR-4 
proteins, LPS does not act directly on dopaminergic neurones but via glial cells involving NO-
mediated toxicity, which can be attenuated by iNOS inhibitors (Iravani et al., 2002; Arimoto & 
Bing, 2003; Iravani et al., 2005; Dutta et al., 2008). Despite the extensive evidence, it is unknown 
whether inflammation occurs as a primary event or secondary event in PD pathogenesis. 
However, the presence of microglia activation detected in PD patients and primates years after 
MPTP exposure (Langston et al., 1999; Barcia et al., 2004) suggest it may be a secondary event 
and a consequence of dopaminergic neuronal loss. 
 
In conjunction with active microglia, astrocytes are activated and implicated in the inflammatory 
response observed in PD. Not surprisingly, the density of astrocytes is also elevated in the SN of 
PD post mortem tissue (Damier et al., 1993) as well as individuals exposed to MPTP (Langston et 
al., 1999). This is confirmed by reports of increased astrocytic activation in the striatum and SN 
of 6-OHDA-treated rodents (He et al., 2001), MPTP-treated mice (Breidert et al., 2002; 
Liberatore et al., 1999) and LPS injected rats (Castano et al., 1998; Herrera et al., 2000). 
 
Typically, astrocytes protect neurones from cell death by releasing neurotrophic factors, namely, 
glial cell line-derived neurotrophic factor (GDNF) and BDNF, and/ or increasing the activity of 
glutathione reductase (GSH) (Knott et al., 2002; Chen et al., 2006; Ishida et al., 2006). However, 
once active, they contribute to neuronal death by releasing neurotoxic factors NO, glutamate 
and H2O2 in primary mesencephalic cultures (McNaught & Jenner, 1999), which promote 
oxidative and nitrative stress. 
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 In summary, a bulk of post mortem and animal studies support the detrimental role of glial cell-
mediated inflammation in PD pathology, and anti-inflammatory therapies could be sought to 
prevent or halt further degeneration. Pre-clinical data of anti-inflammatory agents have shown 
them to be protective, however, long-term use of non-steroidal anti-inflammatory drugs 
(NSAIDs) have been associated with adverse side-effects such as gastrointestinal lesions, and this 
limits their use in clinic (Hirsch & Hunot, 2009). From the evidence listed here, it can therefore 
be concluded that inflammation is a mechanism that needs to be closely regulated as it has 
beneficial components such as, releasing neurotrophic factors and clearing debris which 
promotes cell survival, but can also be very detrimental resulting in neuronal death. 
 
1.1.4.6 Mode of cell death 
Neurones undergo two cell death mechanisms when under stress, namely apoptosis and 
necrosis. Apoptosis is a genetically regulated cell death mode by which cells undergo self-
destruction once apoptotic genes are activated (Hacker, 2000). Morphologically cells undergo 
shrinkage, chromatin and cytoplasmic condensation, nuclear fragmentation and blebbing of the 
plasma membrane, and there is no accompanying inflammatory reaction (Majno & Joris, 1995). 
Conversely, necrosis is a passive form of cell death and occurs in response to toxic insults or 
spontaneous insults such as stroke or trauma, and results in loss of ATP, cytoplasmic vacuolation 
and eventually cell bursting triggering an inflammatory response and damage to surrounding 
tissue (Ziegler & Groscurth, 2004). 
 
Evidence supporting apoptosis come from in vitro studies, where neurotoxins selective for 
dopaminergic neurones, 6-Hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-pyridinium 
(MPP+) were found to induce morphological and biochemical hallmarks of apoptosis in rat 
phaeochromocytoma PC-12 cell lines and primary dopaminergic cells (Walkinshaw & Waters, 
1994; Blum et al., 1997; Lotharius et al., 1999; Viswanath et al., 2001). Overexpressing anti-
apoptotic protein Bcl-2 and pre-treatment with caspase inhibitors protected PC-12 cells from 6-
OHDA-induced apoptosis (Offen et al., 1997; Takai et al., 1998). Even though there is evidence to 
support the contribution of apoptosis in PD, necrosis is suggested as a possible mechanism of 
cell death, although there has not been sufficient supporting evidence (Jellinger, 2000). 
 
Evidence from post-mortem studies on Parkinsonian brain tissue, have reported apoptotic 
morphological characteristics including chromatin condensation, cell shrinkage and DNA 
fragmentation in dying neurones (Mochizuki et al., 1996; Anglade et al., 1997; Tatton et al., 
1998). Increased expression of pro-apoptotic markers Bax and caspase-3 have been reported 
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(Anglade et al., 1997; Hartmann et al., 2000; Tatton, 2000), in addition to an increased 
expression of anti-apoptotic marker Bcl-2 (Mogi et al., 1996). Despite these findings, some 
investigations have failed to show evidence of apoptotic cell death in the SN of post mortem PD 
brain tissue, and this may be due to the sensitivity and specificity of the techniques used 
(Jellinger, 2000). 
 
Finally, data from in vivo studies also support the involvement of apoptosis in dopaminergic cell 
death. In particular, mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyidine (MPTP), 
showed DNA fragmentation in the SN (Tatton & Kish, 1997) and neuroprotection of 
dopaminergic cells was achieved following the inhibiton of Poly (ADP-ribose) polymerase (PARP) 
(Cosi et al., 1996), or ablation of the pro-apoptotic Bax gene as well as overexpression of Bcl-2 
protein (Offen et al., 1997; Yang et al., 1998; Vila et al., 2001). Moreover, cell shrinkage and 
nuclear chromatin condensation of apoptotic cells in the SN were identified as dopaminergic 
using terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL) staining 
and silver staining in 6-OHDA lesioned rats (He et al., 2000; Marti et al., 2002). 
 
In conclusion, these in vitro and in vivo evidences support programmed cell death to be involved 
in neuronal degeneration of PD, despite the limited evidence of necrosis. However, the cause of 
apoptosis still remains uncertain, but it seems to be the consequence of the other events of the 
degenerative process, such as mitochondrial and UPS dysfunction, inflammation and oxidative 
and nitrative stress (Figure 1-2). If this is true, then neuroprotective therapies that prevent these 
degenerating mechanisms are urgently needed to halt or slow down neuronal demise and 
subsequent disease progression. 
 
1.1.5 Neuroprotective therapies 
As discussed in the previous sections, in order to prevent or reduce the onset of motor 
symptoms of PD, drugs which prevent neuronal degeneration needs to be sought.  With this in 
mind, many pharmacological compounds have been and are still being investigated for their 
neuroprotective properties. This includes anti-apoptotic agents, antioxidants, dopamine 
agonists, MAO-B inhibitors and neurotrophic factors (Table 1-3). Once promising results have 
been achieved in vitro, the neuroprotective effects of the compounds are measured in humans. 
Clinical trials employ surrogate outcome measures including the time needed for dopaminergic 
therapy, changes over time in the Unified Parkinson’s Disease Rating Scale (UPDRS) clinical 
score, mortality rates and radio-ligand binding in neuroimaging studies (Lohle & Reichmann, 
2010; Lang et al., 2013).  
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There have been many ambitious efforts in the search for disease-modifying therapies in PD, but 
many clinical trials have so far failed to identify any compound with neuroprotective properties 
(Lohle & Reichmann, 2010). This is due to inconsistencies between pre-clinical data in animal 
models and clinical trials, which questions the validity of the animal models as reflecting the true 
underlying neurodegenerative processes of PD. As of yet, there is currently no neuroprotective 
agent that has been successfully developed to date, however, there are many candidates in the 
pipeline which are showing promising pre-clinical results such as exendin (Aviles-Olmos et al., 
2013), osteopontin (Ailane, 2011, personal communication; Broom, 2012, personal 
communication) and most recently, histone deacetylase inhibitors involved in epigenetic 
modifications. 
 
Therefore, due to the multi-factorial origins of PD development and progression, an effective 
treatment approach that would not only protect neurones but also limit inflammation by 
inhibiting microglial over-activation, while maintaining a ‘stress-free’ environment favourable to 
health and repair is needed. These multi-targeted demands have resulted in manipulation of 





Table 1-3 Overview of neuroprotection clinical trials in PD.  
(Adapted and modified from Lohle and Reichmann, 2010; Lang et al., 2012)  
Class Drug Aim Primary 
outcome(s) 
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6 months Negative (Lang et al., 2006) 
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early PD 
Change in 
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Change in total 
UPDRS 
5 years lower scores at 
5 yrs than 
baseline at 
'OFF' periods 
(Schneider et al., 
2010) 
Abbreviations: UPDRS - Unified Parkinson’s Disease Rating Scale; 123I-β-CIT - 2β-carbomethoxy-3β-[4-
iodophenyl]tropane; 18F-DOPA - L-3,4-dihydroxyphenylalanin; ICV - Intracerebroventricular; Ipu - Intraputamenal 
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1.2 Epigenetic modification 
The genetic code and material inherited amongst all cells is the same, but the changes and 
regulations of these genes enables each cell to retain its specific physical characteristic and 
biological function in line with the tissue or organ it resides (Bernstein et al., 2007). These 
changes in gene expression that does not involve any alterations in the DNA is termed as 
epigenetic modification. It is a crucial physiological mechanism essential for cellular 
differentiation, development and behaviour (Abel & Zukin, 2008; Portela & Esteller, 2010). 
Dysregulation of this mechanism has been a premise in disorders of synaptic plasticity and 
cognition including neurodegenerative disorders, mood disorders and neurodevelopmental 
disorders (such as Rett syndrome and Fragile X syndrome) (Abel & Zukin, 2008) in addition to 
cancer and metabolic diseases (Portela & Esteller, 2010). 
 
Eukaryotic DNA is compacted through its association with an octamer of 4 histone core particles- 
H3/H4 tetramer and H2A/H2B dimer, to form nucleosomes. Together with a linker DNA of 10 – 
60 base pairs, they assemble into a dynamic structure known as a chromatin (Stein, 1980) 
(Figure 1-3). This tight wrapping is due to electrostatic interactions between the negatively 
charged DNA and positively charged octamer (Stein, 1980). The amino terminal ‘tails’ of the 
histone proteins are sites for post-translational modifications, which include acetylation, 
methylation, phosphorylation, ubiquitination and SUMOlyation. These modifications alter the 
chromatin structure and make specific regions of the genome more or less accessible for 
transcription (Peterson & Laniel, 2004). Post translational histone modifications and DNA 
methylation are the two main categories of epigenetic modifications (Bernstein et al., 2007). 
 






Figure 1-3 Nucleosome and 
chromatin structure.  
DNA wrapped around core 
histones form a nucleosome. 
They are connected by linker 
DNA strands. These structures 
compacted together forms a 
chromatin. (Adapted and 
modified from Schlissel, 2003; 
Kouzarides, 2007).  
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DNA methylation occurs at the highest level in the brain and exclusively at CpG dinucleotide sites 
in mammals (Ehrlich et al., 1982). It plays a role in long-term transcription silencing and 
heterochromatin organisation (Miranda & Jones, 2007). This process is regulated by the DNA 
methyltransferases (DNMT1, DMNT3a and DMNT3b) and that transfer a methyl group from S-
adenosyl methionine (SAM) to the fifth carbon of a cytosine residue to form 5-methylcytosine 
(5-mC) (Miranda & Jones, 2007). S-adenosyl methionine is a compound which results from one-
carbon metabolism of B vitamins including folic acid, B6 and B12 (Rottach et al., 2009). 
Alterations of this metabolic cycle leads to aberrant DNA methylation processes where 
hypermethylation of CCG repeats causes Fragile X mental retardation-1 (FMR1) gene repression 
is associated with Fragile X syndrome (Rottach et al., 2009). In addition, mutation in genes for 
proteins involved in DNA methylation homeostasis such as methyl-CpG binding domain (MBD) 
protein (MECP2) results in Rett syndrome (Kumar, 2000; Rottach et al., 2009).  
 
Post-translational histone methylation of either arginine or lysine residues occurs on the N-
terminal tails of histone H3 or H4 proteins (Kouzarides, 2007). This process is facilitated by 
histone methyl-transferases (HMTs) specific to arginine or lysine. Similar to DNA methylation, 
HMTs use SAM as a methyl donor (Arrowsmith et al., 2012). The addition of a methyl group does 
not affect the chromatin structure directly as it does not change the charged state of the 
arginine or lysine resides. Methylation therefore acts as a binding site for other proteins that 
promote chromatin condensation or transcriptionally regulating proteins (Nielsen et al., 2001; 
Trojer et al., 2007). The effect of methylation on transcription activation or repression is 
determined by the site of the residue on the histone tail and the degree of methylation 
(Kouzarides, 2007; Arrowsmith et al., 2012). It has important roles in many biological processes, 
including cell-cycle regulation, DNA damage and stress response, development and 
differentiation (Kouzarides, 2007). Mutations in or altered expression of histone methyl 
modifiers and methyl-binding proteins correlate with increased incidence of various different 
cancers such as leukaemia, breast cancer and lymphoma among others (Albert & Helin, 2010; 
Greer & Shi, 2012). 
 
Histone acetylation is the most investigated post-translational process. It is regulated by the 
activities of two antagonistic enzymes: Histone Acetylases (HATs) and Histone Deacetylases 
(HDACs). HATs covalently bind acetyl moieties to ε-amino groups of lysine residues within the N-
terminal tail of histones on nucleosomes (Yang & Seto, 2007). This neutralises the basic charge 
of the lysine and promotes a more relaxed chromatin structure, allowing transcription 
activation. In addition to transcription, acetylation regulates microtubule dynamics and 
intracellular transport, repair, replication and chromatin remodelling (Kouzarides, 2007; 
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Kazantsev, 2007). HDACs on the other hand act as transcription repressors, by removing the 
acetyl groups and promoting chromatin condensation and transcription silencing (Hanen et al., 
2008).  
 
Under physiological conditions, the equilibrium between HATs and HDACs is maintained to 
achieve normal cellular function and survival. It is now believed that this balance is disturbed in 
pathological circumstances, where HAT activity is greatly reduced in neurodegenerative diseases 
(Saha & Pahan, 2006). In other words, there is a relative HDAC over-activity in degenerating 
neurones, which results in not only hypoacetylation, but reduced expression of cell survival 
genes and increased expression of apoptotic genes (Saha & Pahan, 2006). In fact, Rouaux et al. 
(2003) reported that the HAT and transcription factor, cAMP response element-binding (CREB)-
binding protein (CBP) which is neuroprotective, specifically looses activity during apoptotic 
conditions following potassium deprivation, and results in hypoacetylation and subsequent 
activation of caspases  (Rouaux et al., 2003).  Therefore, as the imbalance towards HDAC 
dominance is assumed to be a contributor to the development and progression of 
neurodegenerative diseases, inhibiting the activity of these enzymes would be an obvious 
therapeutic approach to rescue degenerating neurones. 
 
Transcriptome-wide studies on neoplastic cells have shown that the substrates of HATs and 
HDACs are not only histones, as HDAC inhibitors affected the transcription levels of only 7 – 10 % 
of all genes (Xu & Marks, 2007). Some of the non-histone protein targets include transcription 
factors and regulators, signal transduction mediators, DNA repair enzymes, nuclear import 
regulators, chaperone proteins, structural proteins and inflammation mediators. This therefore 
implies that HDAC inhibitors possess the ability to induce transcriptional activation of disease-
modifying genes (Lu et al., 2006; Feinberg, 2007; Hanen et al., 2008), which may revive neurones 
undergoing stress or damage during neurodegeneration in diseases such as Parkinson’s disease. 
 
 
1.3 Histone deacetylase (HDAC) 
Eighteen mammalian HDACs have been identified and are grouped into four categories based on 
yeast homology, including structure and localisation (Table 1-4). Class I, II and IV HDACs, are also 
known as classical HDACs, and consist of 11 enzymes which share a zinc catalytic domain (de 
Ruijter et al., 2003). Class III HDACs are known as sirtuins and have 7 members. Their catalytic 
mechanism on the other hand requires nicotinamide adenine dinucleotide (NAD+) as a cofactor 
(Michishita et al., 2005).  
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Classical HDACs 
Class I (HDAC1, 2, 3 and 8) are enzymes closely related to the yeast transcriptional regulator 
Rpd3, with molecular weights between 22 – 55 kDa (de Ruijter et al., 2003). They are 
ubiquitiously expressed and predominantly nuclear proteins, with the exception of HDAC3 which 
migrates between the nucleus and cytoplasm (de Ruijter et al., 2003; Longworth & Laimins, 
2006). Class IIa (HDAC4, 5, 7 and 9) and Class IIb (HDAC6 and 10) are homologous to the yeast 
Hda1, with molecular weights between 120 – 135 kDa (Witt et al., 2008). They are found in both 
nucleus and cytoplasm (Witt et al., 2008). Grozinger et al., (2000) showed that HDACs 4 and 5 
interact with 14-3-3 proteins to shuttle to the cytoplasm; whereas loss of the interaction 
resulted in their translocation to the nucleus (Grozinger & Schreiber, 2000). Unlike Class I, Class 
IIa HDACs display tissue-specific expression and are highly expressed in the heart, skeletal 
muscle and brain (Lucio-Eterovic et al., 2008). HDAC6 and 10 differ from Class IIa HDACs through 
the possession of a second catalytic domain which function together and site-directed 
mutagenesis results in loss of enzymatic function (Guardiola & Yao, 2002; Verdin et al., 2003). 
Class IV, consists solely of nuclear HDAC 11, which displays characteristics of both Classes I and 
II, and is highly expressed in kidney, heart, brain, skeletal muscle and testis (Gao et al., 2002b), 
but has distinct physiological roles (Broide et al., 2007).  
  
Sirtuins 
Class III HDACs, referred to as sirtuins are highly homologous to the yeast Sir2 (Michan & Sinclair, 
2007). All 7 enzymes show different cellular localisation, where SIRT 1, 6 and 7 localise to the 
nucleus, SIRT 3, 4 and 5 to the mitochondria and SIRT 2 to the cytoplasm (Frye, 1999; Michishita 
et al., 2005).  
 
The widespread expression of these HDACs shows their importance in cell survival processes. 
But the existence of this many isoforms raises the question about whether they have specific 
functions in gene expression and development, and this has resulted in recent analyses of the 
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Table 1-4 Summary of HDAC classes.  
Including, expression pattern and cellular localisation. (Adapated from McKinsey et al., 2002; 














HDAC1 482 1p34.1 Nucleus Ubiquitous 
HDAC2 488 6q21 Nucleus Ubiquitous 
HDAC3 428 5q31.3 Nucleus/Cytoplasm Ubiquitous 
















HDAC7 855 12q13.1 Nucleus/Cytoplasm 
Heart, Skeletal 
muscle, Lung 









 HDAC6 1215 1p34.1 Nucleus/Cytoplasm 
Heart, Kidney, 
Pancreas 
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1.3.1 Role of HDACs  
The physiological role of each HDAC is not clearly defined, however, evidence shows that HDACs 
are involved in the development of the nervous system, and play a key role in cognition and 
neuronal death (Shen et al., 2005; Cunliffe & Casaccia-Bonnefil, 2006). This is due to their effects 
not only on histone proteins, but also on transcriptional factors such as E2F and Sp1, and tumour 
suppressor proteins such as p53 (Morrison et al., 2007). Through isoform-specific knockdown 
analyses and treatment with HDAC inhibitors, it has been suggested that the consequences of 
HDAC inhibition depends on the cell-type. Therefore, Class I HDACs, which are ubiquitous, are 
involved in cell proliferation and survival, whereas Class II HDACs seem to have tissue-specific 
roles (de Ruijter et al., 2003; Dietz & Casaccia, 2010). 
 
Table 1-5 Functions of HDACs in CNS and Periphery. 
Class I 
HDAC CNS Role Peripheral role 
1 • Deletion results in early embryonic lethality in mice 
(Lagger et al., 2002). 
• Promote generation and differentiation of neurones in 
the retina and spinal cord of zebrafish (Yamaguchi et 
al., 2005; Cunliffe, 2004). 
• Over-expression in in vitro and in vivo ischemia models 
rescued neurones from p25 toxicity whereas HDAC1 
inhibition resulted in p25-induced DNA damage and 
aberrant cell cycle activity, and subsequently neuronal 
loss (Kim et al., 2008). 
 
2 • Reduction in HDAC2 levels in mature neurones 
attenuated basal excitatory neurotransmission without 
a significant change in the nerve terminal numbers, 
however, over-expression of HDAC2 increased 
excitatory synapses in mature neurones (Akhtar et al., 
2009). 
• Negatively regulates memory facilitation in transgenic 
mice which was overcome by chronic HDAC inhibition 
with Suberoylanilide hydroxamic acid (SAHA) (Guan et 
al., 2009). 
 
3 • Homozygous HDAC3 deletions, as well as treatments 
with HDAC3 specific inhibitor, RGFP136 significantly 
improved long-term memory (McQuown et al., 2011). 
• HDAC3 over-expression proved to be cytotoxic to 
cortical neurones, and in hippocampally derived HT22 
cell line it exacerbated toxic effects of the toxin homo-
cysteic acid (HCA), an oxidative stress inducer (Bardai & 
D'Mello, 2011). 
 
8 • Implicated in the negative regulation of CREB-
dependent gene expression (Fischer et al., 2010), which 
is critical for various cellular processes including 
glucose metabolism, cell survival and neuronal 
plasticity, which are essential for learning and memory 




Continues on next page 
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Class IIa 
HDAC CNS role Peripheral role 
4 • HDAC4 mediates neuronal death in normal cells 
through intracellular shuttling from the cytoplasm 
to the nucleus in response to stress, however, 
neuronal death is suppressed when HDAC4 is 
inhibited by Trichostatin A (TSA) or Trapoxin A 
(TPX), or inactivated by SiRNA in cultured 
cerebellar granules (Bolger & Yao, 2005). 
• Decline in HDAC4 expression during normal retina 
development has resulted in apoptosis of rod 
photoreceptors and bipolar (BP) interneurones, 
however, over-expression of HDAC4 in a mouse 
model of retinal degeneration prolonged 
photoreceptor survival and reduced the naturally 
occurring cell death of the BP cells (Chen & Cepko, 
2009), 
• Deletion of HDAC4 has an inhibitory effect in 
regulating memory, and enhances learning and 
LTM formation (Wang et al., 2011). 
• HDAC4 is a critical modulator of 
the muscle transcription factor 
myocyte enhancer factor-2 
(MEF2)-dependent structural 
and contractile gene expression 
in response to neural activity. In 
chronically reduced neural 
activity, HDAC4 binds and 
suppresses MEF2-dependent 
gene expression and contributes 
to the progressive muscle 
dysfunction observed in 
neuromuscular diseases such as 
ALS (Cohen et al., 2007; Cohen 
et al., 2009). 
5 • HDAC5 appears to act as a regulator of adaptive 
responses to chronic stress and cocaine 
consumption, where there is decreases of HDAC5 
function in the nucleus accumbens (NAc), a major 
brain reward region (Renthal et al., 2007) 
• Mouse models of depression lacking HDAC5 
exhibited hypersensitive responses to chronic 
stress and the anti-depressant effect of imipramine 
was linked to down-regulation of HDAC5 in the 
hippocampus, which is implicated in the 
pathophysiology of depression (Tsankova et al., 
2006). 
 
7 • Remains to be investigated • Specifically expressed in the 
vascular endothelium where it 
maintains vascular integrity by 
repressing the expression of 
matrix metalloproteinase 10. 
• Lack of HDAC7 results in 
embryonic lethality due to 
impaired endothelial cell–cell 
adhesion and disrupted integrity 
of blood vessels (Chang et al., 
2006).  
• Controls endothelial cell growth 
via modulation of β-catenin, 
which is important as defects in 
signaling of Wnt/β-catenin has 
been implicated in AD, autism 
and schizophrenia (Margariti et 
al., 2010; Freese et al., 2010). 
9 • Nucleocytoplasmic tanslocation of HDAC9, induced 
by spontaneous neural activity, regulates the 
expression of immediate-early genes (such as c-
fos) and dendritic growth in developing cortical 
neurons. (Sugo et al., 2010). 
• Roles overlap with HDAC5 in 
cardiac development, as loss of 
either gene sensitizes the heart 
to stress signals, but knockout of 
both result in lethal ventricular 
septal defects (Chang et al., 
2004). 
 Continues on next page 
- 49 - 
Class IIb 
HDAC CNS role Peripheral role 
6 • Implicated in cellular processes such as neuronal 
transport, where it is a regulator of the cytoskeletal 
network (Gao et al., 2007); co-ordinates the cell 
response to stress via the regulation of heat-shock 
protein (HSP)-90 (Kovacs et al., 2005);  a component of 
aggresome which recruits misfolded protein to dynein 
motors for transport to aggresome (Kawaguchi et al., 
2003). 
• HDAC6 interacted with polyubiquitinated proteins 
when the UPS was impaired for degradation via 
autophagy in Drosophila melangaster (Pandey et al., 
2007). 
• Recruited by Parkin to aid the clearance of impaired 
mitochondria via autophagy (Lee et al., 2010b). 
• Contrary, inhibition of HDAC6 has been suggested to be 
neuroprotective, as HDAC6 is involved in the 
deacetylation of antioxidant enzymes, peroxiredoxin-1 
and peroxiredoxin-2, to enable reduction of peroxides 
which contribute to ROS production and oxidative 
stress (Parmigiani et al., 2008).  
• Loss of HDAC6 has been shown to be neuroprotective 
in primary neurons over-expressing mutant Huntington 
protein, where this loss significantly facilitated the 
axonal transport of neurotrophic factors such as BDNF 
(Dompierre et al., 2007) 
 
10 • Remains to be investigated. • In SNU-human gastric cells, 
HDAC10 knockdown 
increased the expression 
levels of thioredoxin-
interacting protein, an 
endogenous inhibitor of 
thioredoxin which acts as a 
cellular antioxidant, and 
caused an accumulation of 
ROS (Lee et al., 2010a).  
 
Class IV 
HDAC CNS role Peripheral role 
11 • Acts as a regulator of the gene encoding interleukin 10 
(IL-10), where overexpression of HDAC11 inhibited IL-
10 expression and induced inflammatory bone marrow-
derived antigen-presenting cells (APC) to prime naive T 
cells and restore  the responsiveness of tolerant CD4+ T 
cells (Villagra et al., 2009).  
• HDAC11 has also been demonstrated to regulate 
oligodendrocyte-specific protein gene expression and 
cell development in OL-1 Oligodendroglia cells, non-
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These functions show that these classical HDACs have specific and extensive roles in memory 
formation, synaptic plasticity, neuronal growth and differentiation, which are essential for 
neuronal survival. In PD, preventing dopaminergic neuronal loss is the ultimate goal as 
highlighted earlier, and the tabulated evidence show that inhibition of Class I HDAC3, and Class II 
HADC4 and 6 would be particularly beneficial in PD therapeutics, as they are proteins identified 
with neurotoxic activity (Bolger & Yao, 2005; Dompierre et al., 2007; Bardai & D'Mello, 2011) 
(Table 1-5). However, it seems that inhibition of some HDAC isoforms may have more damaging 
effects than beneficial ones on neurones. For example, overexpression rather than inhibition of 
HDAC1, protects neurones from p25 toxicity (Kim et al., 2008); and inhibition of HDAC5, which 
controls behavioural adaptations to chronic emotional stimuli such as stress and addiction 
(Renthal et al., 2007), would augment and contribute to this non-motor symptom of PD (Dagher 
& Robbins, 2009). Irrespective of this issue, the bigger picture of PD pathology needs to be taken 
into consideration, where neuroprotective agents for dopaminergic neurones are urgently 
sought after, as this would alleviate the onset of motor symptoms and improve the quality of life 
for patients. 
 
1.4 Histone deacetylase Inhibitors (HDAC-I) 
As the search for potential disease-modifying agents for PD increases, small molecules which are 
able to cross the blood-brain barrier are required. In this case, the efficacy of HDAC-Is have been 
observed in an array of disorders from immune disorders, diabetes, sickle-cell anaemia, and 
importantly stroke to neurodegenerative disorders (Kazantsev & Thompson, 2008). Interestingly, 
they are most commonly used as anti-cancer agents. Their ability to induce cell growth arrest, 
differentiation and/ or apoptotic cell death by selectively altering the transcription of 
approximately 2 % of genes expressed in tumour cells make them ideal candidates (Marks et al., 
2001). Not surprisingly, various HDAC-Is are in clinical trials for numerous of cancers including 
leukaemia, T-cell lymphoma, non-small cell cancer, solid tumour and haematological 
malignancies (Wagner et al., 2010). The idea that drugs used in cancer therapeutics to reduce 
proliferation and induce apoptosis, could be beneficial in neurodegenerative disorders, where 
cells die prematurely is conflicting. Yet, recent genetic studies have shown that there are 
overlapping pathways involved in the progression of both diseases, such as, mitochondrial 
dysfunction, oxidative stress and inflammation (Devine et al., 2011a). This therefore makes 
agents that have an array of targets and functions, such as HDAC-Is, seem like ideal candidates 
for PD treatment. 
 
HDAC-Is, which differ in classical HDAC isoenzyme selectivity are classed into four main chemical 
families. These are the short-chain fatty acids, hydroxamates, cyclic pepetides and benzamides 
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(Table 1-6). Majority of the inhibitors currently available non-selectively influence all eleven 
HDAC isoforms (Bieliauskas & Pflum, 2008).  
 
Short chain fatty acids are relatively small and simple structured. The most common examples 
are sodium butyrate (Nab), valproic acid (VPA; valproate) and phenylbutyrate, which mainly 
inhibit Class  I HDACs in the range of millimoles (Khan et al., 2008). Sodium butyrate has been 
shown to exert anti-depressant properties in the mouse brain and stimulate neurogenesis in the 
rat brain following cerebral ischemia (Schroeder et al., 2007; Kim et al., 2009). VPA is an 
established central nervous system (CNS) drug used as an anti-convulsant, mood stabiliser and 
adjuvant treatment for schizophrenia (Grayson et al., 2010). Both sodium butyrate and VPA have 
exhibited anti-inflammatory properties and have shown to be neuroprotective in rat ischemia 
models (Kim et al., 2007), suggesting an anti-inflammatory role of this class of HDAC-Is in PD 
pathogenesis. 
 
Hydroxamates bind to the zinc ion in the catalytic domain of HDAC to inactivate the enzyme 
(Marks et al., 2004). For this reason, they act as pan-HDAC-Is and are selective for Class I and II 
HDACs without showing isoform selectivity with high nanomolar potency (Grayson et al., 2010). 
Examples include, Trichostatin A (TSA), Suberoylanilide hydroxamic acid (SAHA; vorinostat), 
Oxamflatin, Panobinostat, Givinostat, Belinostat. Most of these compounds are undergoing 
clinical trials for cancer (Wagner et al., 2010), but  SAHA  is the most clinically advanced as it has 
obtained US Food and Drug Administration (FDA) approval for T-cell lymphoma (Grant et al., 
2007). Its ability to cross the brain blood barrier (BBB) makes it an ideal agent for neurological 
disorders (Chuang et al., 2009). 
 
Cyclic peptides induce inhibition of HDACs by binding to the zinc ion site, and show selectivity for 
Class I HDAC isoforms (Grayson et al., 2010; Furumai et al., 2002; Grayson et al., 2010). Two 
common examples of this class are romidepsin (FK-228; desipeptide) and apicidin. Romidepsin 
shows potent efficacy for HDAC1 and 2, whereas apicidin is selective for HDAC2, 3 and 8 
(Furumai et al., 2002; Khan et al., 2008). Romidepsin has also recently obtained FDA approval for 
T-cell lymphoma (VanderMolen et al., 2011). The HDAC isoform selectivity of these inhibitors 
make them ideal agents for multi-factorial disorders such as PD, as their treatment would limit 
possible side effects. 
 
Benzamides are relatively new HDAC-Is which also exhibit isoform selectivity. Examples currently 
in clinical trials include MS-275 and CI-994 (Grayson et al., 2010). They are both selective for 
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HDAC1. Similar to the cyclic peptides, the isoform selectivity of these inhibitors could limit toxic 
side effects which are exerted by pan-HDAC-Is and class selective HDAC-Is. 
 
The extensive use of HDAC-Is in cancer therapeutics, has expanded the portfolio of the 
inhibitors. For this reason, it would be relatively quick to get HDAC-Is prescribed once they have 
successfully passed trials for PD. The overlap between cancer and PD progression instills some 
optimism that these agents may exert beneficial effects in PD. However, the contradicting 
effects that HDAC-Is have on the HDAC isoforms, enhances the crucial need for isoform-selective 
HDAC-Is. 
 
Table 1-6 Structure and inhibitory profile of some inhibitors.  
(Modified from Blanchard & Chipoy, 2005; Bolden et al., 2006; Witt et al., 2008; Khan et al., 
2008). 
Class Structure Class Inhibited 
Short-chain fatty 
acid 
Butyrate             
Valproic Acid      
Class I 
Hydroxamate 
Suberoylanilide Hydroxamic Acid (SAHA) 
 
Trichostatin A   
Class I and II 
Benzamide 








Apicidin                                             
 
Romidepsin   
Class I 
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1.4.1 Evidence of HDAC-I therapeutic role in neurodegenerative diseases  
Despite the vast use of HDAC-I’s in cancer therapy, there has recently been an explosion of 
interest in the potential therapeutic role of HDAC-Is in neurodegenerative disorders. In fact a 
beneficial role for HDAC-Is was first discovered in Huntington’s disease (HD) when HDAC-Is 
attenuated cell death and improved motor function and survival in Drosophila (Steffan et al., 
2001). Additional studies showed SAHA ameliorated the cognitive and motor deficit 
characteristics of the disorder in transgenic mouse models through increased histone acetylation  
(Hockly et al., 2003). Sodium butyrate also protected R6/2 transgenic mice models from the 
lethality of the CAG expansion disorder in the coding region for the protein huntingtin, and 
caused less brain atrophy in transgenic mice compared to vehicle treated mice (Ferrante et al., 
2003). Further studies found phenylbutyrate exerted neuroprotective effects in the N171-82Q 
transgenic mouse models of HD (Gardian et al., 2005). 
 
Moreover, investigations in mouse models of spinal muscular atrophy (SMA), with low levels of 
survival motor neurone (SMN) protein involved in motor neurone degeneration, had increased 
levels of SMN protein and less regions exhibiting muscle atrophy, following sodium butyrate 
treatment (Chang et al., 2001; Brichta et al., 2003). Further studies, also reported that VPA-
treated SMA mice displayed elevated levels of SMN protein, which resulted in improved motor 
function, reduced motor neurone degeneration and decreased muscle atrophy compared to the 
control group, through activation of the survival motor neurone gene (SMN2) (Tsai et al., 2008).  
 
Furthermore, VPA and phenylbutyrate administration ameliorated histone hypoacetylation in 
G86R and G93A transgenic amyotrophic lateral sclerosis (ALS) mice, and prevented motor 
neurone death in the rodents (Ryu et al., 2005; Rouaux et al., 2007). Finally, treatment of 
ischemic brain tissue with SAHA prevented histone deacetylation, thus increasing histone H3 
acteylated levels. This was accompanied by increased expression of the neuroprotective proteins 
heat-shock protein 70 (Hsp70) and Bcl-2 (Faraco et al., 2006). 
 
So far, these promising evidences confirm the theory that epigenetic modifications could 
potentially be disease-modifying. This has led to the assumption that such beneficial effects 
could also be achieved in PD models, and has therefore increased the recent interest of HDAC 
inhibition in PD.  
 
1.4.2 Therapeutic role for HDAC-I in PD 
There is very limited evidence of the role of HDAC-Is in PD. However, the findings that have been 
reported so far implies that HDAC-Is may have the potential to be promising neuroprotective 
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agents in the disorder. Pionneering work from Beal and colleagues (2004) reported that 
phenylbutyrate administration significantly reduced striatal depletion of dopamine and 
dopaminergic cell death in mice following MPTP treatment (Gardian et al., 2004).  
 
Other studies also reported that mutant α-synuclein (A30P and A53T) present in Lewy bodies 
and associated with familial forms of PD, acted in the nucleus to bind to histones and reduce 
levels of acetylated histone H3, by inactivating HATs CBP, p300 and P/CAF (Kontopoulos et al., 
2006). This resulted in hypoacetylation, inhibited transcription, and promotion of apoptosis and 
neurotoxicity in human neuroblastoma cell lines. These cells were rescued from α-synuclein 
neurotoxicity and apoptosis by HDAC-Is, suberoylanilide hydroxamic acid (SAHA) and sodium 
butyrate (Kontopoulos et al., 2006).  
 
In summary, even though these findings are limited, they are positive and provide optimistic 
evidence that HDAC inhibition in PD could potentially protect dopaminergic cells from toxin- or 
stress-induced cell death and subsequently be useful as a treatment of PD. However, the effects 
of these drugs on the survival of dopaminergic neurones remain uncertain and will be addressed 
in these studies.  
 
1.5 Thesis hypothesis 
The identification of neuroprotective approaches that can delay or halt disease progression is 
the primary goal in PD research.  Despite promising results from a number of compounds 
including cogane in animal studies (Table 1-3), all of the putative agents have failed to 
demonstrate unequivocal neuroprotection in clinical trials. As there is increasing evidence 
suggesting the potential neuroprotective effect of HDAC inhibitors in neurodegenerative 
diseases, it was hypothesised that HDAC inhibitors will protect dopaminergic neurones from 
oxidative stress- and inflammation-induced cell death in PD. 
 
1.6 Thesis aims 
In order to test this hypothesis, the studies described in this thesis aimed to investigate the role 
of HDAC-Is, VPA and SAHA, as potential neuroprotective agents against dopaminergic cell death 
in models of PD. Specifically, the thesis aimed to: 
1. Model dopaminergic cell death in PD using in vitro and in vivo models with toxins H2O2 
MPP+, LPS and 6-OHDA. 
2. Determine the effect of HDAC-Is on toxin-induced neuronal cell death in in vitro and in 
vivo models. 
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3. Determine the effect of HDAC-Is on inflammation associated with cell death in vitro and 
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2.1 Introduction 
The aim of the studies described in this thesis was to investigate the neuroprotective effect of 
HDAC inhibitors on dopaminergic neurone cell death in in vitro and in vivo models of PD.  The 
following studies were performed: 
1. Neuroprotection studies in cell lines. 
Neuroblastoma cell lines N1E-115 and SH-SY5Y were treated with HDAC inhibitors in the 
presence and absence of hydrogen peroxide (H2O2) and 1-methyl-4-phenylpyridinium (MPP
+). 
These act through reactive oxygen species (ROS) generation and inhibition of mitochondrial 
complex I respectively. The effect of the HDAC inhibitors on cell survival was determined by 
measuring the release of lactate dehydrogenase (LDH) and differentiating between the viable 
and non-viable cells by trypan blue exclusion. 
2. Neuroprotection studies in rat primary ventral mesencephalic cultures. 
Primary ventral mesencephalic cell cultures were prepared from 14 day old rat embryos. The 
cells were treated with HDAC inhibitors in the presence and absence of MPP+ and 
lipopolysaccharide (LPS). The effects of the inhibitors were assessed by immunocytochemical 
staining for tyrosine hydroxylase (TH), astrocytes (GFAP) and microglia (OX-42). 
3. Neuroprotection studies in 6-hydroxydopamine and LPS- lesioned mice. 
Mice were lesioned with 6-hydroxydopamine (6-OHDA) and LPS to induce a partial lesion of the 
nigro-striatal pathway. HDAC inhibitors were administered to the animals before, during and 
after lesioning, and their effects were observed by immunohistochemistry with antibodies 
against TH, GFAP and OX-42.  
 
This chapter describes the general materials and methods, common between the in vitro and in 
vivo models, used in these studies. Methods specific to each model is detailed in the individual 
results chapters. 
 
2.1.1 Toxin-induced models of PD 
Toxin-induced models are widely used in vitro and in vivo as tools to increase the understanding 
of the pathological process of PD, however, it is important that they are biologically relevant to 
the human disease reflecting the pathological processes involved. For this reason, in this study, 
MPP+- and H2O2-induced toxicity was used to cause dopaminergic cell death in vitro, and 6-
OHDA- and LPS-lesioned mice in vivo. Partial destruction of the nigro-striatal pathway was 
induced following unilateral stereotaxic injection of 6-OHDA or LPS into the striatum. These 
models produce irreversible dopaminergic cell death and the mechanism by which this occurs is 
described below. 
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2.1.1.1 MPP+  
MPP+ is the toxic active metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). In 1982, MPTP was found to induce parkinsonism in man when 
young drug addicts accidentally injected this drug (Langston et al., 1983b). Subsequent 
investigations of MPTP in rodent and primate models have shown it induces selective 
destruction of the dopaminergic neurones of the nigro-striatal tract as well as the observation of 
motor deficits (Langston et al., 1984; Jenner et al., 1984).  
 
When MPP+ is administered to culture media, it is taken up into dopaminergic neurones via the 
dopamine transporter (DAT) (Javitch et al., 1985; Gainetdinov et al., 1997). Once in the 
neurones, MPP+ accumulates in the mitochondria where it inhibits complex I of the electron 
transport chain. This impairs mitochondrial respiration by inhibiting aerobic glycolysis and 
increasing lactate production, resulting in reduced ATP production and increased ROS release 
such as superoxides (Nicklas et al., 1987). This dual effect of decreased ATP and increased ROS 
increases NO-dependent increase in pro-apoptotic protein bax  (Dennis & Bennett, 2003), as well 
as initiating other cell death-related pathways such as p38 mitogen-activated kinase 
(Karunakaran et al., 2008) and c-jun N-terminal kinase (JNK) (Saporito et al., 2000) which all 
contribute to apoptotic cell death (Tatton & Kish, 1997). MPP+ is also stored in the vesicles 
through uptake by the vesicular monoamine transporter (VMAT2) (Gainetdinov et al., 1998). In 
the vesicles, MPP+ displaces stored dopamine into the extracellular space where it is oxidised by 
MAO into metabolites such as 3,4-dihydroxyphenylacetaldehyde (DOPAL) which is toxic to 
dopaminergic neurones (Burke et al., 2008b; Panneton et al., 2010), dopamine quinones and 
free radicals (LaVoie & Hastings, 1999).  
 
2.1.1.2 H2O2 
Unlike MPP+, H2O2 is not selective for the mitochondria, but it is commonly used to induce 
oxidative stress in culture. H2O2 is a ubiquitous molecule to living organisms (Halliwell et al., 
2000). At cellular levels, oxygenated species such as H2O2 is generated normally and detoxified 
by antioxidant enzymes such as catalase and glutathione to produce oxygen and water (Makino 
et al., 1994; Hashida et al., 2002). For this reason, H2O2 is added as a bolus to culture medium 
(Gille & Joenje, 1992). The oxygenated species become hazardous when the balance between 
radical formation and removal is disturbed.  H2O2 is an unreactive species, but its deleterious 
effects are due to its ability to stimulate the super hydroxyl radical formation by the Fenton and 
Haber-Weiss reactions, both mediated by iron, to subsequently induce lipid peroxidation and 
DNA damage (Mello Filho & Meneghini, 1984; Starke & Farber, 1985).  
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When H2O2 is administered to culture medium, it readily penetrates the cellular envelope where 
it causes a reduction in the activity of antioxidant enzymes. This results in the formation of 
hydroxyls close to the chromatin which initiate DNA single-strand breaks (Mello Filho & 
Meneghini, 1984). This in turn activates poly(ADP-ribose) polymerase to deplete the levels of the 
coenzyme nicotinamide adenine dinucleotide (NAD) (Schraufstatter et al., 1986), which is 
needed for electron transfer during redox reactions. H2O2 induces ATP depletion by inactivating 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which catalyses glycolysis (Hinshaw et al., 
1990), and this in turn results in mitochondrial impairment. Furthermore, H2O2 increases 
intracellular free calcium, which has been implicated to be associated with cell death 
(Whittemore et al., 1995). These effects of H2O2 combined, results in the induction of apoptotic 
neuronal death (Whittemore et al., 1995).  
 
MPP+ and H2O2 are ideal candidates to investigate HDAC-Is potential antioxidant characteristic. 
This is due to the fact that both of the toxins induce oxidative stress, mitochondria impairment 
and apoptosis, which are implicated in the pathogenesis of PD. 
 
2.1.1.3 6-OHDA 
 Since it was first reported to lesion the nigro-striatal dopaminergic pathway over 50 years ago 
(Ungerstedt, 1968), 6-OHDA has become the most routinely utilised and characterised toxin-
based model of PD. It is commonly used in rats but other species, for example mice, monkeys, 
cats and dogs, are also sensitive to this toxin (Thomas et al., 1991). The structure of 6-OHDA 
resembles that of dopamine but has an additional hydroxyl group thereby making it toxic to 
neurones (Kostrzewa & Jacobowitz, 1974). 6-OHDA does not cross the BBB so it is directly 
injected into the SNpc, medial forebrain bundle (MFB) or striatum (Carvey et al., 2005) where it 
initiates dopaminergic cell death.  
 
Although the exact mechanism of 6-OHDA toxicity is unclear, the current understanding is that, 
following injection, it enters neurones via the plasma membrane DAT into the cytoplasm (Choi et 
al., 1999), where 6-OHDA destroys catecholaminergic neurones by a combination of cellular 
oxidative stress and mitochondrial dysfunction (Hanrott et al., 2006). 6-OHDA oxidises to form 
ROS including H2O2 (Mazzio et al., 2004) which is induced by MAO (Karoum et al., 1993), and 
quinones (Saner & Thoenen, 1971) to directly damage neurones. It elevates the levels of iron in 
the SN (Oestreicher et al., 1994) which drives the generation of ROS as well as damaging the 
electron transport system through membrane lipid peroxidation (Glinka & Youdim, 1995). It 
decreases the levels of striatal anti-oxidant enzymes including superoxide dismutase (SOD) and 
glutathione (GSH) (Perumal et al., 1992) promoting ROS accumulation. Furthermore, 6-OHDA 
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potently inhibits complexes I and IV of the mitochondrial respiratory chain, particularly NADH 
dehydrogenase (complex I) and cytochrome c oxidase (complex IV) (Glinka & Youdim, 1995; 
Glinka et al., 1997). This consequently causes ATP depletion, further oxidative stress and 
decrease in cell protective mechanism which results in cellular degeneration (Glinka & Youdim, 
1995). Moreover, dopamine depletion, nigral dopamine cell loss, and neurobehavioral deficits 
have been successfully achieved using this model (Ungerstedt, 1968). Furthermore, this toxin 
induces neuro-inflammation in the brain (Cicchetti et al., 2002), which is ongoing and implicated 
in the pathogenesis and progression of PD. Many of the effects of 6-OHDA mirrors the events 
occurring in PD, thus making it a good model to investigate the effects of HDAC-Is. 
 
2.1.1.4 LPS 
The use of the gram-negative bacteria endotoxin LPS has been a useful tool to demonstrate and 
study neuro-inflammation in the pathogenesis of PD and anti-inflammatory agents for PD 
therapy. LPS-induced inflammation replicates some characteristics of PD, such as glia activation 
and loss of dopaminergic neurones (Iravani et al., 2005). LPS is not directly toxic to neurones, but 
can become more toxic to neurones in the presence of glial cells than 6-OHDA (Bronstein et al., 
1995). LPS is commonly used in rodents and can be administered systemically or injected into 
the striatum or SN (Hunter et al., 2009). 
 
Following injection into the brain, LPS initially binds to the LPS-binding protein (LBP) to transfer 
LPS to the CD14/Toll-like receptor (TLR) 4 complex expressed on glia cells to induce their 
activation and a cellular response (Ulevitch & Tobias, 1995; Castano et al., 1998; Herrera et al., 
2000; Palsson-McDermott & O'Neill, 2004). This activation of glial cells induces the expression of 
iNOS which in turn up-regulates NO and 3-nitrotyrosine (3-NT) generation release to mediate 
toxicity (Iravani et al., 2002; Arimoto & Bing, 2003). The activation of glial cells also induces the 
release of inflammatory cytokines, IL-1α, IL-1β, IL-6 and TNF-α, which are thought to be 
responsible for increased iNOS expression (Arimoto & Bing, 2003; Lehnardt et al., 2003). NO 
interacts with metals, thiols and oxides leading to the increased generation of oxidative and 
nitrative stress which are deleterious to neurones (Dawson & Dawson, 1996). This stress is 
promoted by the increased levels of iron in the SN following intrastriatal injection of LPS (Hunter 
et al., 2008). Similar to the 6-OHDA model, the LPS model also exhibits features of PD such as 
progressive degeneration of dopaminergic cell bodies in the SN and their striatal terminals, 
depletion dopamine content in the striatum, in addition to mitochondrial impairment (Hunter et 
al., 2007; Hunter et al., 2009).  
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Even though no model exists to completely and accurately portray the pathology of PD, the toxic 
models of 6-OHDA and LPS have been useful for understanding PD pathogenesis as well as 
testing new potential agents such as HDAC-Is in this study. 
 
2.1.2 HDACs and HDAC-Is 
This study focussed exclusively on the activities of the classical HDACs. This is because this class 
of enzymes have been widely investigated in cancer, and more recently in neurodegenerative 
disorders, such as HD and AD. In particular Class I HDAC3, Class II HDAC4 and 5, and Class IV 
HDAC11 were shown by gene expression mapping of the rat brain to have the highest expression 
in nigro-striatal pathway, particularly, the substantia nigra pars compacta (Broide et al., 2007) 
which is affected in PD (Ehringer & Hornykiewicz, 1998).  
 
The two chosen inhibitors utilised in this present study are VPA and SAHA, as they have been 
thoroughly examined in terms of toxicology, side effects and dose; and are already in clinical use 
for mood disorders and T cell lymphoma, respectively. In addition, they have already been 
shown to have positive effects in the neurodegenerative disorders HD and AD (Chapter 1). VPA 
shows selectivity for class I isoforms in millimolar range  but has been confirmed by biochemical 
assays to have very little effect on Class II HDAC isoforms (Khan et al., 2008). It is widely 
prescribed as an anti-convulsant and mood-stabilising drug commonly used to treat epilepsy and 
bipolar disorder and has been on the market for over 3 decades (Phiel et al., 2001; Brichta et al., 
2003). SAHA, on the other hand, is a pan inhibitor which is selective for both class I and II HDAC 
isoforms (Bieliauskas & Pflum, 2008). It has been FDA approved for cutaneous T cell lymphoma, 
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2.2 Animals for biochemical analysis 
Male C57BL/6J mice (Harlan, Bicester, UK), weighing 25-30 g, were singly housed in a 
temperature controlled room of 23oC (King’s College London Biological Services Unit) with a 12 
hour light-dark cycle and free access to pelleted food and water. All experimental procedures 
were carried out in accordance with the Animals (Scientific Procedures) Act 1986 under the UK 
Home Office licence number 70/6898. 
 
2.3 Preparation of mouse brains 
2.3.1 Transcardial Perfusion and dissection for western blot and immunohistochemistry 
Mice were terminally-anaesthetised with sodium pentobarbital solution (20 %; 100 mg/kg ip). 
The thoracic cavity was cut open and transcardially perfused with 0.1 M PBS pH 7.4, containing 
sodium chloride (NaCl; 137 mM), diSodium hydrogen orthophosphate anhydrous (Na2HPO4; 8 
mM), Potassium dihydrogen orthophosphate (KH2PO4; 1.5 mM). The brains were removed and 
cut at the level of the optic chiasm forming a rostral and a caudal compartment of the brain. The 
rostral part of the brain was flash-frozen in liquid nitrogen, followed by storage -70oC, until used 
for western blot (Section 2.4). The caudal part was post-fixed in PFA (4 %) in 0.1 M PBS for 7 days 
at 4oC, followed by storage in cryoprotective solution composed 0.1 M PBS containing sucrose 
(30 %) and sodium azide (0.05 %) also at 4oC, until used for immunohistochemistry (Section 
2.6.6.2). 
 
2.4 Western blotting 
This is an analytical technique to detect proteins according to their molecular weights in brain 
homogenates or cell lysates.  
 
2.4.1 Preparation of cell lysates 
Cell lines were grown in a 175 cm2 flask to confluence, and washed with 0.1 M PBS as described 
in Chapter 3.  Using a sterile cell scraper the cells were released from the flask, collected and 
centrifuged at 1000 g. The pellet was resuspended in lysis buffer (250 µl) containing sodium 
dodecyl sulphate (SDS; 1%) and Tris (hydroxymethyl) aminomethane hydrochloride (Tris-HCL; 50 
mM) (pH 7.4); heated at 98oC for 10 minutes followed by centrifugation at 1000 g. The 
supernatant (150 µl) was transferred to a new eppendorf and stored at -80oC until analysis. 
 
2.4.2 Preparation of brain tissue homogenates 
Brain tissue stored at -80oC was weighed and homogenised (1:5 w/v) in  Tris-base lysis buffer (50 
mM; pH 8.0) containing Triton-X-100 (1 %), sodium chloride (150 mM), ethylenediamine-
tetraacetic acid (EDTA; 5 mM), phenylmethylsulphonyl fluoride (PMSF; 2 mM) and protease 
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inhibitor cocktail set III (5 %). Homogenates were centrifuged (Biofuge Fresco, Heraeus) at 13000 
g for 30 minutes at 4oC.The supernatant was collected and stored at -80oC.  
 
2.4.3 Gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to detect 
proteins in tissue homogenates and cell lysates. The components of the gel comprised of a 
resolving and stacking gel (Table 2-1). Sample protein concentrations were determined using the 
NanoDrop® detailed in Section 2.5. They were mixed with an equal amount of loading buffer, 
boiled for 3 minutes at 95oC, and then each sample (15 µl) was loaded onto the gel.  The ladder 
marker (precision plus protein standard) (10 µl) was also loaded onto the gel. Protein separation 
by electrophoresis was performed in running buffer (Table 2-1) at a constant current of 30 mA 
for 90 minutes. 
 
2.4.4 Immunoblotting 
On completion of electrophoresis, polyvinylidene difluoride (PVDF) membranes were rinsed in 
methanol (100 %) and deionised water and then soaked in blot buffer (Table 2-1). The gel and 
PVDF membrane were sandwiched between 2 layers each consisting of 4 filter papers, soaked in 
blot buffer. Protein transfer onto the membrane was performed at 20 V for 20 minutes using a 
Bio-Rad transblotter.  
 
Following transfer, the membranes were blocked in milk (5 %) in 1 X Tris-buffered saline (TBS) 
and Tween-20 (0.1 %) (TBS-T) at room temperature, with gentle agitation on a shaker (DS-500E 
Orbital shaker, VWR International, UK). After 1 hour, the membranes were incubated with the 
primary antibody (at the appropriate dilution listed in Table 2-2) in albumin bovine serum (5 %)/ 
TBS-T at 4oC overnight on a shaker. Membranes were washed 3 times for 5 minutes with TBST-T, 
and followed by 1 hour incubation at room temperature with the polyclonal goat anti-rabbit 
horseradish peroxidise (HRP) - conjugated secondary antibody (Table 2-3) diluted in milk (5 %)/ 
TBS-T. 
 
Membranes were washed with TBS-T (3 X 5 minutes) and protein bands were detected by 
enhanced chemiluminescence (ECL) western blot detection kit (Table 2-4). Following 
manufacturer’s instructions, the reagents were mixed and pipette over the membranes and 
incubated in the dark for 5 minutes. The membranes were sandwiched in clear acetate sheets, 
placed in an X-ray film cassette and exposed to Kodak® Hyperfilm at different time points (5 
seconds to 3 minutes). The films were developed by a fully automated X-ray film processor 
(Compact X4, Xograph healthcare, UK). 
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 To recognise differences in protein loading, the membrane was stripped with antibodies by 
incubating with stripping buffer (Table 2-1) for 30 minutes at 5oC. Following washes with TBS-T 
(3 X 10 minutes), the membrane was blocked with milk (5 %)/ TBS-T, reprobed with β-actin 
primary antibody (Table 2-2) followed by mouse HRP secondary antibody (Table 2-3), 1 hour 










Figure 2-1 Protein expression of HDAC isoforms by western blot.  
PC12 cell line was screened for the expression of HDAC3, 4, 5 and 11. β-Actin was used as a 
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Table 2-1 List of buffers used for western blot. 
Buffer Components Source 
4X Resolving Gel 
Buffer (RGB), pH 8.8 
1.5 M Tris-base 
Adjust pH with HCl 
Sigma-Aldrich, Dorset, UK 
4X Stacking Gel 
Buffer (SGB), pH 6.8 
0.5 M Tris-base 
Adjust pH with HCl 
Sigma-Aldrich, Dorset, UK 
10X Running buffer 
(RB) 
25 mM Tris 
200 mM Glycine 
10 % Sodium dodecyl 
sulphate (SDS) 
Sigma-Aldrich, Dorset, UK 
BDH, VWR International, Lutterworth, UK 
Sigma-Aldrich, Dorset, UK 
10X TBS 50 mM Tris-base 
150 mM NaCl 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Blot Buffer 48 mM Tris 
39 mM Glycine 
20 % Methanol 
Sigma-Aldrich, Dorset, UK 
BDH, VWR International, Lutterworth, UK 
 
Loading Buffer 5 mM Tris, pH 6.8 
2 % SDS 
10 % Glycerol 
0.1 % Bromophenol blue 
5 % β-mercaptoethanol 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Alfa Aesar, Lancashire, UK 
Stripping Buffer 62.5 mM Tris, pH 6.8 
100 mM 
β-mercaptoethanol 
2 % SDS 
Sigma-Aldrich, Dorset, UK 
 
 
Sigma-Aldrich, Dorset, UK 
 
 
2.5 Measurement of Protein Content 
2.5.1 Protein concentration 
Protein concentration of cell lysates and tissue homogenates prepared as described in Sections 
2.4.1 and 2.4.2, was determined using the NanoDrop® ND-10000 spectrophotometer (Labtech 
international Ltd., East Sussex, UK).  Using the module ‘Protein A280’ on the ND-1000 3.5.1 
software, an aliquot of the sample (2 µl) was loaded onto the measurement pedestal and the 
protein absorbance at 280 nm wavelength was measured (Figure 2-2). Protein measurements 
for each sample were determined in triplicate, and the mean was used as final concentration. 
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 Figure 2-2 An example of an absorbent spectrum using the NanoDrop spectrophotometer.  
The protein content of a mouse brain striatum homogenate (1:10 w/v) was measured in 
triplicate using the NanoDrop ND-1000 Spectrophotometer. The protein absorbance of all three 
runs (red, green and blue) at 280 nm wavelength (arrow) was compared to an internal Bovine 
serum albumin (BSA) protein standard. The protein concentration is recorded as mg/ml.  
 
 
To assess the accuracy and linearity of the Nanodrop, a series of Bovine serum albumin (BSA) 
dilutions ranging from 0.4 - 25 mg/ml were measured and compared to actual concentrations. 
The concentrations obtained for cell lysates and tissue homogenates examined in this thesis 
were 1 – 12 mg/ml, which lies within the most accurate range of the Nanodrop (Figure 2-3) 
therefore no correction was made. The BSA standard was linear (r2= 0.9971), but deviated from 
the expected measurements at concentrations above 10 mg/ml. 
 
 
Figure 2-3 Comparison of protein concentration of BSA standard curve using Nanodrop.  
BSA (0.4 - 25 mg/ml) was measured using the internal standard (blue) and to compared the 
actual concentrations (red).  Measurements were repeated in triplicate. Data are expressed as 
mean ± SEM. 
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2.6 Immunochemical Staining 
2.6.1 Plate preparation 
Glass coverslips (13 mm diameter; Scientific Laboratories supplies, UK) were washed three times 
with ethanol (70 %) followed by three washes with sterile distilled water. They were then 
sterilised in an autoclave (Dixons Surgical Ltd, Wickford, Essex, UK) at 121oC for 30 minutes and 
air-dried under a safety cabinet. They were soaked in poly-D-lysine solution (0.01 % in sterile 
distilled water) for 30 minutes at room temperature. The coverslips were then rinsed twice with 
sterile distilled water to wash off any unbound material, and left to dry overnight under a safety 
cabinet.  
 
2.6.2 Preparation of cell culture 
Cell lines were seeded onto poly-D-Lysine (0.05 %; Sigma-Aldrich, Dorset, UK) coated coverslips 
in 24 well plates at a density of 1x105. They were grown and maintained at 37oC (described in 
detail in Chapter 3) for 2 days. The media was aspirated and the cells were washed with 0.1 M 
PBS, followed by paraformaldehyde (PFA) (4 %; 500 µl) at room temperature for 30 minutes. The 
PFA was then discarded, and the wells were rinsed three times with sterile PBS (0.1 M; pH 7.4; 
500 µl) and stored in sterile PBS (1 ml) at 4oC, until immunolabelling (Section 2.6.3). 
 
A similar process was followed for primary culture; however, the cells were grown for 7 days in 
an incubator (detailed in Chapter 4). The cells were processed in a similar manner to cell lines 
and stored in PBS (0.1 M; 1ml) at 4oC, until processed for staining (Sections 2.6.3, 2.6.5 and 
2.6.6.1). 
 
2.6.3 Single immunoflourescence staining 
Cell lines and primary culture cells fixed on coverslips detailed in Section 2.6.2, were labelled by 
single immunoflourescence in 24 well plates (500 µl per well), and were agitated using a plate 
shaker (VXR basic Vibrax ®, IKA, Germany). The cells were first washed 3 X 5 minutes with 0.1 M 
PBS and blocked with goat serum (10 %) in 0.1 M PBS at room temperature for 1 hour. Primary 
antibodies were prepared in goat serum (GS; 1 %) in 0.1 M PBS at dilutions detailed in Table 2-2, 
and the cells were incubated at 4oC overnight. On the next day, the cells were washed 3 X 5 
minutes with Triton-X 100 (0.05 %)/ 0.1 M PBS (PBS-T), followed by 2 hours incubation with the 
secondary antibody (Table 2-3) at room temperature in the dark. Following 3 X 5 minutes 
washes, the cells were mounted with Vectashield® Hard set mounting medium containing 4, 6-
diamidino-2-phenylindole (DAPI; Vector Laboratories, Peterborough, UK) and left to dry at 4oC 
for 24 hours. Cells were examined using an immunofluorescence microscope (Zeiss Axioskop, 
Carl Zeiss, Hertfordshire, UK) (Figure 2-4). 
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Figure 2-4 Single immunoflourescence labelling of primary culture cells.  
Ventral mesencephalic (VM) cultures were stained with antibodies against tyrosine hydroxylase 
(TH) (green). DAPI was used as counter stain for nucleus staining (blue). Scale bar = 100 µm 
 
 
2.6.4 Preparation of mouse brain tissue 
Coronal sections (30 µm) of mouse brains were cut using a freezing microtome (Leica SM 
2000R). Substantia nigra pars compacta (SNpc) was sectioned at the level of the third nerve 
(Paxinos G. & Franklin F., 2004). Free floating sections were collected into 96 well plates (1 
section/ well) filled with 0.1 M PBS and NaN3 (0.05 %), and processed for double 
immunofluorescence (Section 2.6.5) or immunohistochemical staining (Section 2.6.6.2). 
 
2.6.5 Double immunoflourescence staining 
Primary VM cultures fixed on coverlips (Section 2.6.2) and free floating mouse brain sections 
(Section 2.6.4) were labelled in 24 well plates of 0.1 M PBS (pH 7.4) (500 µl per well) on a plate 
shaker providing constant gentle agitation. First, both cell cultures and brain sections were 
washed with 0.1 M PBS 3 X 5 minutes. Subsequently, they were incubated with blocking solution 
(10 %) containing GS and donkey serum (DS), in PBS-T for 1 hour at room temperature. They 
were then incubated with two different primary antibodies (Table 2-2) diluted in blocking 
solution (1 %) at 4oC overnight. Following 3 X 5 minutes washes in PBS-T, the samples were 
subjected to incubation with the two respective secondary antibodies in PBS-T (Table 2-3), for 2 
hours at room temperature. After 3 X 5 minutes washes in 0.1 M PBS, the labelled cells and 
sections were mounted with Vectashield® Hard set mounting medium containing DAPI, or 
Vectashield® Hard set mounting medium for fluorescence, respectively. They were then 
examined as previously mentioned in Section 2.6.3 (Figure 2-5). 
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 Figure 2-5 Double immunoflourescence labelling of primary culture cells.  
Fixed VM cultures were double stained for histone deacetylase 3 (HDAC3) (red) and glial 
fibrilliary acidic protein (GFAP) (green). The nucleus was counter stained with DAPI (blue). Scale 
bar = 100 µm 
 
 
2.6.6 Immunoperoxidase staining 
2.6.6.1 Immunocytochemical staining of fixed cells 
Fixed VM cells on coverslips underwent immunocytochemistry in 24 well plates of 0.1 M PBS (pH 
7.4) (500 µl per well). The cells were first washed for 10 minutes with 0.1 M PBS and then 
incubated with methanol (70 %)/ hydrogen peroxide (H2O2; 0.3 %) in deionised water (DI H2O) 
for 30 minutes to quench the endogenous peroxidase activity. The cells were washed 3 x 10 
minutes with 0.1 M PBS followed by incubation with blocking solution (20 %) containing GS in  
0.1 M PBS for 1 hour at room temperature. Next the cells were washed rinsed with GS (1 %) in 
PBS-T to permeabilise the membrane, and incubated overnight in the desired primary antibody 
dilution (Table 2-2) in GS (1 %)/ PBS-T overnight at room temperature. On the next day, the 
antibody was removed and the coverslips washed with GS (1 %)/ 0.1 M PBS, and subsequently 
incubated with biotinylated secondary antibody (Table 2-3) in 0.1 M PBS for 1 hour at room 
temperature. On completion, the cells were washed with 0.1 M PBS and incubated for 1 hour at 
room temperature with avidin-biotin peroxidise complex (ABC-kit; Vector laboratories, 
Peterborough, UK). They were then washed with 0.1 M Tris-HCl 3 X 10 minutes. To visualise the 
staining, the cells were incubated with 3, 3’-diaminobenzidine tetrahydrochloride (DAB; 0.05 %)/ 
0.1 M Trisl-HCl (500 µl) for 1 minute. The reaction was initiated on addition of H2O2 (30 %, 1 µl). 
The reaction was then terminated by rinsing the coverslips with 0.1 M Tris-HCl followed by a 
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final DI H2O wash. The cell containing coverslips were hydrated in ethanol baths (100 %, 98 %, 
and 70 %) for 1 second each, followed by a DI H2O rinse and counterstained with cresyl violet for 
1 minute. The cells were then rinsed once with DI H2O and dehydrated in ethanol (70 %, 98 %, 
and 100 %) for 5 seconds each and delipidated in Histoclear for 2 minutes. The coverslips were 
mounted onto superfrost slides with DePeX mounting medium and left overnight to dry. Cells 





Figure 2-6 A typical GFAP staining in rat primary cultures.  
Rat VM cell cultures were stained with antibodies against GFAP (brown) and counterstained with 
cresyl violet (violet). Scale bar = 100 µm (A) and 50 µm (B). 
 
 
2.6.6.2 Immunohistochemical staining of free floating sections 
Free floating mouse brain sections were first washed in 0.1 M PBS (500 µl) for 10 minutes and 
transferred into methanol (70 %)/H2O2 (0.3 %) in DI H2O for 20 minutes. The sections were 
washed 3 x 10 minutes in PBS-T and then blocked with GS (20 %) in PBS-T for 1 hour at room 
temperature. Following this, the sections were incubated with the primary antibody (Table 2-2) 
at the desired dilution in GS (1 %)/ PBS-T overnight at room temperature. On day 2, the sections 
were rinsed with PBS-T and incubated with the appropriate biotinylated secondary antibody 
(Table 2-3) diluted in GS (1 %)/ PBS-T for 1 hour at room temperature. Following 3 x 10 minutes 
washes with PBS-T, sections were incubated in ABC solution for 1 hour at room temperature. 
The sections were once again washed in 0.1 M Tris-HCl, and then incubated in DAB (0.05 %)/ 
Tris-HCl for 1 minute for visualisation of the cells. H2O2 (30 %, 1 µl) was added to initiate the 
reaction. Termination of the reaction occurred when the cells were washed in Tris-HCl 3 X 10 
minutes, and then mounted on polysine coated microscope slides and left to dry overnight. On 
day 3, the sections were hydrated through a series of ethanol dilutions (100 %, 98 %, and 70 %) 
and DI H2O for 5 minutes each. They were counterstained in cresyl violet for 2 minutes 
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dehydrated in the order of DI H2O, 70 %, 98 % and 100 % for 5 minutes each and delipidated in 
Histoclear for 15 minutes. The slides were then cover slipped using DePeX mounting medium 
(VWR International, Lutterworth, UK) and allowed to dry overnight. Sections were examined as 









Figure 2-7 Typical TH immunoperoxidase staining in the mouse SN.  
Mouse brain sections (30 µm) were stained with an antibody against TH (brown) and 
counterstained with cresyl violet (violet) at the level of the substantia nigra. Abbreviations: VTA, 
ventral tegmental area; SNpc, Substantia nigra pars compacta; SNpr, Substantia nigra pars 
reticulate; TH+, Tyrosine hydroxylase positive. Scale bars = 200 µm (A) and 100 µm (B). 
 
 
2.6.7 Quantification of positive staining in cell culture 
Positively labelled mounted VM cells were counted on 3 coverslips per culture at X20 
magnification under a light/ fluorescence microscope (Zeiss Axioskop, Carl Zeiss, Hertfordshire, 
UK), using the Axio vision software, powered by the Zeiss Axiocam camera. Immunoreactive cells 
were counted in 8 random areas on each coverslip using an eye piece reticule, where total area 
was equivalent to 8 mm2. The total number of cells counted was calculated and expressed as 
‘the number of positively stained cells per 8 mm2’ or a ‘percentage of immunoreactive cells’ 
(n=3). 
 
2.6.8 Quantification of positive staining in mouse tissue 
Positively stained cells on mounted brains sections was counted bilaterally on 3 sections per 
animal at X10 magnification using an eye piece grid, where total area was equal to 1 mm2. Slides 
were examined in a blind manner using the equipment and software detailed in Section 2.6.7. 
The number of positively labelled cells was expressed as the mean of the counts obtained from 
representative sections (n=3). 
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IHC IF WB 
Polyclonal rabbit anti-rat tyrosine 
hydroxylase (TH) 
1:500 1:200 - 
Pel-Freeze Biologicals, USA 
Monoclonal mouse anti-tyrosine 
hydroxylase (TH) 
1:500 1:200 - 
Sigma-Aldrich, Dorset, UK 
Polyclonal rabbit anti-glial fibrillary 
acidic protein (GFAP) 
1:500 1:200 - 
Dako UK Ltd., Cambridgeshire, 
UK 
Polyclonal rabbit anti-glutamic acid 
decarboxylase (GAD) 
1:500 - - 
Sigma-Aldrich, Dorset, UK 
Monoclonal rat anti-mouse CDIIb 
(OX-42) 
1:100 1:200 - 
AbD Serotec, Oxon, UK 
Monoclonal mouse anti-rat CDIIb 
(OX-42) 
1:100 1:200 - 
AbD Serotec, Oxon, UK 
Polyclonal rabbit anti-HDAC3 - 1:500 1:1000 Abcam Ltd., Cambridge, UK 
Polyclonal rabbit anti-HDAC4 - 1:500 1:1000 Abcam Ltd., Cambridge, UK 
Polyclonal rabbit anti-Histone 
deacetylase (HDAC5) 
- 1:200 1:1000 
New England Biolabs Ltd., 
Hertfordshire, UK 
Polyclonal rabbit anti-HDAC11 - 1:500 1:1000 Abcam Ltd., Cambridge, UK 
Polyclonal rabbit anti-acetyl-Histone 
H4 
- - 1:2000 
Millipore UK Ltd., Watford, UK 
Monoclonal mouse anti β-actin 
- - 1:5000 
Insight Biotechnology Ltd., 
Middlesex, UK  
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IF IHC WB 
Alexa Fluor® 488 donkey anti-
mouse IgG (H+L) 
1:500 - - 
Invitrogen life technologies, 
Paisley, UK 
Alexa Fluor® 594 goat anti-rabbit 
IgG (H+L) 
1:500 - - 
Invitrogen life technologies, 
Paisley, UK 
Biotinylated goat anti-mouse IgG  
- 1:250 - 
Vector laboratories, 
Peterborough, UK 
Biotinylated goat anti-rabbit IgG  
- 1:250 - 
Vector laboratories, 
Peterborough, UK 
Polyclonal goat anti-rabbit HRP 
conjugate 
- - 1:1000 
Dako UK Ltd., Cambridgeshire, 
UK 
Polyclonal goat anti-mouse HRP 
conjugate. 
- - 1:1000 
Dako UK Ltd., Cambridgeshire, 
UK 
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Table 2-4 List of reagents and compounds. 
Name Supplier 
30% Acrylamide/bis solution, 37.5:1 Bio-Rad, Hertfordshire, UK 
Boc-Lys(Ac)-7-Amino-4-Methylcoumarin  MP Biomedicals Europe, Cambridge, UK 
CytoTox-ONETM Homogenous membrane 
integrity assay 
Promega, Southampton, UK 
DePeX mounting medium VWR international, Lutterworth, UK 
Dulbecco’s modified eagle medium (DMEM) Invitrogen, Paisley, UK 
Emla cream BSU, KCL, UK 
Enhanced Chemiluminescence (ECL) plus 
blotting detection system 
Amersham Biosciences, Buckinghamshire, UK 
Foetal bovine serum (FBS) Invitrogen, Paisley, UK 
HDAC developer Cambridge Bioscience, Cambridge, UK 
HDAC deacetylated standard Cambridge Bioscience, Cambridge, UK 
Histoclear  Fisher scientific, Leicestershire, UK 
Isofluorane  BSU, KCL, UK 
Lipopolysaccaride E. Coli O55:B5 Merck chemicals Ltd., Nottingham,UK 
Marcain BSU, KCL, UK 
Methanol  BDH, VWR international, Lutterworth, UK 
Penicillin-Streptomycin-Neomycin (PSN)  Invitrogen, Paisley, UK 
Precision Plus protein standard Bio-Rad, Hertfordshire, UK 
Protease inhibitor cocktail set III Merck chemicals Ltd., Nottingham, UK 
PVDF membrane Bio-Rad, Hertfordshire, UK 
Sodium pentobarbitone (Euthatal®) Merial, Dundee, UK 
Standard Avidin biotin complex (ABC) Vector laboratories, Peterborough, UK 
Sterile distilled water PAA laboratories Ltd., Yeovil, UK 
Suberoylanilide Hydroxamic Acid (SAHA) Cambridge Bioscience, Cambridge, UK 
Tris-(hydroxymethyl) methylamonium chloride 
(Tis-HCl) 
BDH, VWR international, Lutterworth, UK 
Trypsin (1x) Invitrogen, Paisley, UK 
Vectashield® Hard set mounting medium 
(with DAPI) 
Vector laboratories, Peterborough, UK 
Vectashield® Hard set mounting medium for 
fluorescence 
Vector laboratories, Peterborough, UK 
Chemicals and reagents which are not listed were obtained from Sigma-Aldrich, Dorset, UK 
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Table 2-5 List of equipments and consumables. 
Name Supplier 
16 mm coated Vicryl Ethicon, Berkshire, UK 
26s Hamilton needle Essex scientific laboratory supplies Ltd., Essex, 
UK 
70IRN Hamilton syringe Essex scientific laboratory supplies Ltd., Essex. 
UK 
Acetate sheets KCL stores, UK 
Autoclave  Meadowrose scientific Ltd., Oxfordshire, UK 
Bisafety cabinet II Walker safety cabinets Ltd., Derbyshire, UK 
Centrifuge  Meadowrose scientific Ltd., Oxfordshire, UK 
Cryospray  Bright instrument company Ltd., 
Cambridgeshire, UK 
CO2 incubator SANYO E&E Europe BV, Leicestershire, UK 
Compact X4, Xograph  Imaging system, Gloucestershire, UK 
Cover slips (22 x 50 mm) VWR international Ltd., Lutterworth, UK 
Cover slips round (13 mm) VWR international Ltd., Lutterworth, UK 
Dissecting Microscope Vickers Instruments, Croydon, UK 
Kodak hyperfilm GE Healthcare Ltd., Buckinghamshire, UK 
Light/ Fluorescence Microscope Carl Zeiss Ltd, Hertfordshire, UK 
Multidish 24 well plates VWR international Ltd., Lutterworth, UK 
Microplate Corning 96 well plate Fisher scientific, Leicestershire, UK 
The Nanodrop® ND-10000 
Spectrophotometer 
Labtech international Ltd., East Sussex, UK 
Microplate reader, GeminiXS Molecular devices, Cambridgeshire, UK 
Microplate reader, Vmax Molecular devices, Cambridgeshire, UK 
Microscope slide, polysine coated VWR international Ltd., Lutterworth, UK 




















Chapter 3 The effect of HDAC inhibitors on toxin-induced cell death on 
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3.1 Introduction 
Aberrant recruitment of HDACs to repress transcription and silence gene expression of possible 
disease-modifying genes has been associated with a wide number of neurodegenerative 
disorders such as Huntington’s (HD), Parkinson’s (PD) and Alzheimer’s (AD) disease, spinal 
muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).  
 
The most prominent evidence for the protective effects of HDAC inhibitors comes from in vivo 
models of HD, where photoreceptor neurodegeneration was retarded in a Drosophila model of 
polyglutamine-repeat disease (Steffan et al., 2001). The pan HDAC-I, suberoylanilide Hydroxamic 
acid (SAHA), also slowed neurodegeneration and improved motor impairments in R6/2 genetic 
mouse models (Hockly et al., 2003). These are mice generated to express exon 1 of human HD 
carrying (CAG)115–(CAG)150 repeat expansions. They develop the progressive neurological 
symptoms exhibited in HD such as deficits of motor skills, altered locomotor activity, seizures 
and impaired cognitive performance (Mangiarini et al., 1996; Davies et al., 1997). SAHA did not 
inhibit the polyglutamine aggregation associated with HD pathogenesis, but increased histone 
acetylation, indicating that it probably acts by redressing transcriptional repression. 
 
In PD, accumulation of mutated neuronal protein α-synuclein has been implicated in disease 
progression. Kontopoulos et al., (2006) showed that α-synuclein bound to histones in the 
nucleus to inhibit acetylation of histone H3 and contribute to neurotoxicity (Kontopoulos et al., 
2006). This cellular toxicity was ameliorated by HDAC inhibitors in SH-SY5Y cultured cells 
transfected with A30P and A53T α-synuclein and α-synuclein transgenic Drosophila, similarly to 
that observed in HD. Evidence from a small molecule inhibitor of sirtuin 2, a Class III histone 
deacetylase, was also found to protect dopaminergic cells transfected with A53T α-synuclein and 
transgenic Drosophila (elav-GAL4/+) from toxicity (Outeiro et al., 2007). However, very little is 
known about the ability of HDAC-Is to protect dopaminergic cells from oxidative stress 
implicated in the pathogenesis of idiopathic PD (detailed in Chapter 1). One of the possible 
major causes of degeneration in PD progression as previously described is oxidative stress, which 
is linked to other components of the degenerative process including mitochondrial dysfunction, 
excitotoxicty, nitric oxide toxicity and inflammation (Jenner, 2003b). 
 
Despite the limitations, there are indications that HDAC-Is may have the potential to arrest 
oxidative stress exerted during disease progression. Such as, evidence from Ryu and colleagues 
(2003), which showed that transcription factor Specific protein-1 (Sp1) is acetylated in response 
to oxidative stress in neurones, but is suppressed by HDACs. HDAC-Is augment Sp1 acetylation, 
Sp1 DNA binding and Sp1 gene expression, which confers resistance to oxidative stress-induced 
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death in vitro and in vivo (Ryu et al., 2003). Langley et al., (2008) also showed that pulse 
exposure of cortical neurones to HDAC-Is resulted in resistance to oxidative stress toxicity 
associated with transcriptional up-regulation of the cell cycle inhibitor p21waf1/cip1 (Langley et al., 
2008).  
 
3.1.1   Hypothesis 
It was hypothesised that the HDAC inhibitors would protect dopaminergic cells against H2O2- and 
MPP+-induced cell death. 
 
3.1.2 Aims 
To test the hypotheses, the susceptibility of dopaminergic cell lines which expressed HDAC to 
the toxins H2O2 and MPP
+ was assessed. The effect of HDAC inhibitors on toxin-induced cell 
death was measured. Specifically, the main aims were to: 
1. Determine the dopaminergic phenotype of mouse adrenergic N1E-115 and human 
catecholaminergic SH-SY5Y cell lines and their expression of HDAC3, 4, 5 and 11. 
2. Investigate the effect of neurotoxins, H2O2 and MPP+, which induce oxidative stress in 
N1E-115 and SH-SY5Y cell lines. 
3. Determine the neuroprotective effect of HDAC inhibitors, SAHA and valproic acid (VPA), 
on H2O2- and MPP
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3.2 Material and Methods 
3.2.1 Cell culture 
Human neuroblastoma SH-SY5Y and mouse neuroblastoma N1E-115 cells were purchased from 
American Type Culture Collection (Manassas, USA) and maintained in high glucose Dulbecco’s 
Modified Eagle’s medium (DMEM) supplemented with heat-inactivated Foetal Bovine Serum 
(FBS) (10 %) and penicillin (5 mg/ml), streptomycin (5 mg/ml) and neomycin (10 mg/ml) in 0.85 
% saline (PSN 1 %). The medium was changed every 2-3 days. The cells were grown in T75 cm2 
flasks at 37oC incubator (MCO-18AIC, Sanyo), with atmosphere of CO2 (5 %) and relative 
humidity (95 %). 
 
3.2.2 Trypsinisation of cells 
Confluent cultured cells were passaged by discarding the culture media and washing twice with 
sterile phosphate buffered saline (PBS; 0.1 M). Trypsin-EDTA (0.25 %) was added to the flasks 
and incubated at 37oC for 2 minutes. Flasks were tapped gently to detach the cells, followed by 
the addition of culture medium (prepared in Section 3.2.1) to inhibit the trypsin activity. The 
detached cells were collected and centrifuged (Jouan centrifuge cr3i, Meadowrose Scientific Ltd) 
at 1000 g for 5 minutes. The pellet was re-suspended in culture medium (5 ml) and the 
suspension was re-plated at half the original density into 75 cm2 culture flasks or utilised for 
subsequent experiments. 
 
3.2.3 Cell counting 
The cell density was determined using a haemocytometer (improved Neubauer). Cell suspension 
(50 µl) was first diluted (1:1 v/v) with trypan blue solution (0.4 %). The haemocytometer was 
covered with a cover slip, and cell/ trypan blue solution (50 µl) gently filled by resting the pipette 
tip on the edge of the chambers allowing it to be filled by capillary action. Non-viable cells were 
stained blue, while viable cells remained unstained. Viable cells were counted in four sets of 16 
corner squares (highlighted in red in Figure 3-1) using an inverted microscope (Nikon TMS) with 
a magnification of x 0.25. Each set of 16 corner squares represents the number of cells x 104 per 
ml. The following equation was therefore employed to calculate the cell density per ml:  
 
Average count of cells per 16 corner square x dilution factor x 104 
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Figure 3-1 Diagram of haemocytometer gridlines. 
Image shows the 16 corner square that are counted, highlighted in red. Adapted and modified 
from www.deltaenvironmental.com.au. 
 
3.2.4 Characterisation of dopaminergic and HDAC phenotype 
3.2.4.1 Immunofluorescence 
Immunofluorescence was used to detect the presence of tyrosine hydroxylase (TH), and HDAC3, 
4, 5 and 11 in SH-SY5Y and N1E-15 cell lines, as described in Section 2.6. In summary, the cell 
lines were seeded at a density of 1 x 105 in 24 well plates on 0.05 % poly-D-lysine coated cover 
slips. Once grown, they were fixed with paraformaldehyde (PFA) (4 %), blocked with goat serum 
(20 %) and incubated at 4oC overnight with primary antibodies raised in rabbit against TH 
(1:200), HDAC3 (1:500), HDAC4 (1:500), HDAC5 (1:200) and HDAC11 (1:500) (Table 2-2). On the 
subsequent day, the cells were incubated with Alexa Fluor 594 IgG secondary antibody (1:500) 
(Table 2-3) for 2 hours at room temperature. The cells were processed as in Section 2.6.3 and 
visualised using an immunofluorescence microscope (Zeiss Axioskop, Carl Zeiss). 
 
3.2.4.2 Western blot analysis 
Western blot technique was used to detect the expression of HDAC3, 4, 5 and 11 proteins in SH-
SY5Y and N1E-115 cells. The technique is described in detail in Section 2.4. Cell lysates, prepared 
as described in Section 2.4.1, were resolved onto a SDS-PAGE gel (8-10 %) and transferred onto a 
PVDF membrane. The membrane was blocked with milk (5 %) in TBS-T for 1 hour, and incubated 
with primary antibodies against HDAC3, 4, 5, 11 (1:1000) and β-actin (1:5000) (Table 2-2), as 
loading control overnight at 4oC. After incubation with anti-rabbit or anti-mouse IgG-horseradish 
peroxidise (HRP)-conjugated secondary antibody (1:2000) (Table 2-3) for 1 hour, bands were 
visualised by the enhanced chemiluminescence system detailed in Section 2.4.4.  
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3.2.5 Neuroprotection study 
3.2.5.1 Induction of toxin-induced cell death 
SH-SY5Y and N1E-115 cell lines were plated at 2 x 104 and 1 x 104, respectively into 96 well 
plates, and grown in growth medium for 24 hours at 37oC in an incubator as described in Section 
3.2.1. On day 2, the cells were incubated with heat-inactivated foetal bovine serum free media 
(Serum-free media) for 2 hours, prior to 24 hours incubation with serum-free media containing 
hydrogen peroxide (H2O2) (10
-6 to 10-3 M) or 1-methyl-4-phenylpyridinium (MPP+) (10-1.5 to 10-3.5 
M). Cells treated with serum-free media served as controls. Lactate dehydrogenase (LDH) 
release, a marker for damaged cells, was determined by a commercially available LDH assay 
(Section 3.2.6.1), and viability of cells was determined trypan blue assay as described in Section 
3.2.6.2. EC50 values for the effect of H2O2 and MPP
+ on LDH release and trypan blue were 
determined by using non-linear regression as described in Section 3.2.7. The rationale for using 
these EC50 concentrations was to generate 50 % cell death in the cultures, a difference which is 
substantial enough to allow any changes measured in the cultures to be attributed to the effects 
of the HDAC-Is following their treatment in the Neuroprotection experiments. 
 
3.2.5.2 Effect of HDAC inhibitors on toxin-induced cell death 
To assess the effect of HDAC inhibitors on toxic insult, cells were grown in 96 well plates for 24 
hours. VPA (10-9 to 10-3 M) and SAHA (10-9 to 10-3 M) were diluted in serum-free media and 
applied to the cells for a 2 hour incubation period. On completion, the media was removed and 
the cells were incubated for further 24 hours with a mixture of HDAC inhibitors and EC50 
concentrations of H2O2 and MPP
+ in serum-free media, similar to Section 3.2.5.1. Control cells 
were incubated with HDAC inhibitors or toxin alone in serum-free media for 24 hours. Untreated 
control cells were treated with serum-free medium only. LDH release and cell viability was 
assessed as described in Section 3.2.6. Figure 3-2 summarises the experimental timeline. 
 
    

















LDH or trypan 
blue assay
0 Hr 24 Hr 26 Hr 50 Hr  
Figure 3-2 Experimental outline. 
SH-SY5Y and N1E-115 cell lines were plated at 0 hour and grown 24 hours in serum-containing 
medium. At 24 hours, the medium was aspirated and changed to serum-free medium (SFM), 
VPA (0.3, 0.6, 1.2 mM) or SAHA (0.01, 0.1, 1 µM) for 2 hours followed by the same 
concentrations with or without EC50 concentrations of H2O2 or MPP
+. Twenty-four hours later cell 
viability assays were performed. 
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3.2.6 Determination of cell death 
The effect of the toxins and HDAC inhibitors were assessed either through the release of lactate 
dehydrogenase (LDH) of damaged cells or by counting viable cells which were not stained by the 
trypan blue dye. 
 
3.2.6.1 Lactate dehydrogenase (LDH) assay 
Lactate dehydrogenase (LDH) is released from cells with damaged membranes. It is measured by 
supplying lactate, NAD+ and resazurin as substrates in the presence of diaphorase. Diaphorase 
catalyses the conversion of resazurin to resorufin and produces a red fluorescent compound. 
The CytoTox-ONETM homogeneous membrane integrity assay was performed according to the 
manufacturer’s instructions (Promega, Southampton, UK). Briefly, the Cyto-Tox-ONE reagent 
(100 µl) was added to the cell culture media of each treated well, and incubated for 10 minutes 
at 22oC. Stop solution (50 µl) was added to each well to end the reaction. A fluorescent signal 
was measured using a spectrophotometer (SpectraMax Gemini XS, Molecular Devices) with an 
excitation wavelength of 560 nm and an emission wavelength of 590 nm. Experiments were 
performed in triplicate on three separate occasions. A lysis solution (9 % w/v, Triton®-X-100 in 
water) supplied in the kit generated maximum LDH release, served as a positive control, and 
culture media only wells were used as background readings. The data was displayed as average 
percent cytotoxicity employing the following equation: 
 
Percent cytotoxicity = 100   x 
(Experimental – Culture Medium Background) 
(Maximum LDH Release – Culture Medium Background) 
  
 
3.2.6.2 Trypan blue exclusion assay 
The trypan blue exclusion test estimates the proportion of viable cells in a cell suspension. It 
works on the notion that viable cells have intact membranes, so prevents penetration of the dye, 
however dead cells have damaged membranes, so allows the nuclei to be stained. In this assay, 
cells were collected from 12 well plates using a cell scraper and resuspended in 500 µl PBS. Cell 
suspension in PBS (100 μl) was combined with 0.4 % trypan blue (100 μl). Cells were counted 
using a haemocytometer. The number of blue stained cells (Figure 3-3) was subtracted from the 
total cell number which was then divided by the total number of cells counted to estimate 
percent viability as follows: 
Percent viability = 100   x 
Viable cell  
Total cells (viable and non-viable cells) 
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Figure 3-3 An example of trypan blue exclusion in N1E-115 cells.  
Cells grown in a 12 well plate were incubated with 0.4 % trypan blue solution. Viable cells 
remained unstained (black arrow) and nonviable cells were stained blue (red arrow) with trypan 
blue. Scale bar = 200µm. 
 
 
3.2.7 Statistical Analysis 
All experiments were performed in duplicate (trypan blue exclusion assay) or in triplicate (LDH 
assay) on three separate occasions (n=3). To analyse toxin-induced effects, data from each 
experiment were plotted as logarithmic values and a sigmoidal concentration-response curve 
was established using non-linear regression (Graph Pad Prism 5 software, USA). The software 
also determined the half maximal effective concentration (EC50). For HDAC inhibitor effect, data 
were analysed using one-way or two-way ANOVA followed by Newman Keuls post-hoc multiple 
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3.3 Results 
3.3.1 Characterisation of dopaminergic phenotype in cell lines 
N1E-115 and SH-SY5Y cell lines were characterised for tyrosine hydroxylase (TH) by 
immunoflourescence. Both cell lines showed positive TH immunostaining which is mainly 
present in the cytoplasm (Figure 3-4). 
 
 
Figure 3-4 Expression of dopaminergic marker in N1E-115 and SH-SY5Y cell lines.  
Cell lines (A) N1E-115 and (B) SH-SY5Y were stained with antibodies against tyrosine hydroxylase 
(TH) (red). The nuclei were counterstained with DAPI (blue). Photomicrographs are typical of 
duplicate analyses.  Scale bar = 100 µm. 
 
 
3.3.2 Determination of HDAC expression in cell lines 
N1E-115 and SH-SY5Y cells were characterised for the presence and localisation of the HDAC 
isoforms, 3, 4, 5 and 11. For all isoforms stronger immunoreactive fluorescence signals was 
visualised for the enzymes in N1E-115 than in SH-SY5Y (Figure 3-5).   
HDAC3 was mainly localised in the nucleus and HDAC4 and 5 was localised mainly in the 
cytoplasm of N1E-115 cells. Diffused HDAC11 staining was visualised in both the cytoplasm and 
nucleus of N1E-115 cells (Figure 3-5A).  
Similarly, HDAC3 was localised in the nucleus of SH-SY5Y cells. HDAC4, HDAC5 and HDAC11 were 
found in nucleus and cytoplasm of SH-SY5Y cells (Figure 3-5B). 
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Figure 3-5 Expression of HDAC phenotype in cell lines.  
(A) N1E-115 and (B) SH-SY5Y cell lines were stained with antibodies against HDAC3, 4, 5 and 11 (red). Dapi (blue) was used to counterstain the nucleus. 
Photomicrographs are typical of duplicate analyses. Scale bar = 100 µm. 
(A) N1E-115 (B) SH-SY5Y 
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 Western blotting was also used to confirm the protein expression of the HDAC isoforms 3, 4, 5 
and 11 in N1E-115 and SH-SY5Y cell lines. In both cell lines, HDAC3 was detected as a band at 50 
kDa, HDAC4 at 140 kDa, HDAC5 at 124 kDa and HDAC11 at 39 kDa (Figure 3-6). 
 
 
Figure 3-6 Protein expression of HDAC isoforms by western blotting.  
N1E-115 and SH-SY5Y cell lines were screened for the expression of HDAC3, 4, 5 and 11. β-Actin 
was used as a loading control. Images are typical of duplicate analyses. 
 
 
3.3.3 Effect of H2O2 and MPP+ on cell survival 
To assess the effect of HDAC inhibitors on toxin-induced cell death, N1E-115 and SH-SY5Y cell 
lines were treated with H2O2 (10
-6 – 10-3 M) and MPP+ (10-3.5 – 10-1.5 M) for 24 hours and cell 
death was measured by the LDH assay. Both toxins produced a concentration-related cell death 
in N1E-115 and SH-SY5Y cell lines. The EC50 values for H2O2-induced cytotoxicity was calculated 
for N1E-115 (60.0 ± 0.4 µM) and SH-SY5Y (350.0 ± 0.5 µM) (Figure 3-7A-B). Following MPP+-
induced cytotoxicity, EC50 values were calculated for N1E-115 (3.0 ± 0.2 mM) and SH-SY5Y (3.0 ± 
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Figure 3-7 Cell death in N1E-115 and SH-SY5Y cells following H2O2 and MPP
+ treatment.  
N1E-115 and SH-SY5Y cells were subjected to (A-B) H2O2 (10
-6-10-3M) and (C-D) MPP+ (10-3.5-10-1.5 
M) for 24 hours. Cell loss was assessed by the LDH assay, where maximum LDH released was 
recorded at 100%. Non-linear regression curve was fitted to calculate EC50. Data are expressed as 




Similarly to LDH assay, N1E-115 and SH-SY5Y cell lines were incubated with H2O2 and MPP
+ (10-9 
– 10-1 M) for 24 hours and cell viability was assessed by trypan blue dye exclusion assay. Viable 
cells were counted and the EC50 values for H2O2-induced cell death were calculated for N1E-115 
(96.0 ± 4.0 µM) and SH-SY5Y (935.0 ± 6.0 µM) (Figure 3-8A-B). Subsequently, the EC50 values for 
MPP+-induced cell death was also determined for N1E-115 (62.0 ± 5.0 µM) and SH-SY5Y (82.0 ± 
 5.0 µM) cell lines (Figure 3-8C-D). 
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Figure 3-8 Viable N1E-115 and SH-SY5Y cells following H2O2 treatment and MPP
+ treatment. 
N1E-115 and SH-SY5Y cells were exposed to (A-B) H2O2 (10
-9-10-1 M) and (C-D) MPP+ (10-9-10-1 M)   
for 24 hours. Cell viability was assessed by the trypan blue exclusion assay. Non-linear regression 
curve was fitted to calculate EC50. Data are expressed as mean ± SEM (n=3); **p<0.01, *p<0.05 
compared to control cells (one-way ANOVA followed by Newman-Keuls test). 
 
 
3.3.4 Involvement of HDAC inhibitors in toxin-induced LDH release 
3.3.4.1 Effect of HDAC inhibitors on cell survival following H2O2 treatment. 
N1E-115 and SH-SY5Y cell lines were treated with EC50 concentrations of H2O2 (60 µM and 350 
µM for LDH assay; 96 µM and 935 µM for trypan blue assay, respectively) in the presence and 
absence of a range of SAHA and VPA (10-9 – 10-3 M) concentrations. Control cells were treated 
with serum-free medium only or toxin in serum-free medium.  
 
SAHA Treatments 
In N1E-115, there was 73 % cell survival in the control culture (Figure 3-9A) treated with serum-
free medium only. SAHA alone only affected the degree of cell loss at 10-4 M and 10-3 M, where 
cell survival decreased to 45 % and 30 %, respectively. Although this was only significantly 
different to control at 10-3 M. H2O2 (60 µM) alone induced 36 % cell survival which was 
significant to the serum-free only culture. SAHA (10-9 - 10-3 M) added 2 hours before and during 
H2O2 incubation had no effect on H2O2–induced cell death, except at the highest concentration, 
10-3 M, where the cell survival tended to be increased to 53 % although this was not significantly 
different to H2O2 alone. 
A B 
C D 
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 In SH-SY5Y cells, 83 % cell survival was observed in untreated cultures. Treatment with SAHA did 
not alter the degree of cell viability, except at the high concentrations, 10-4 and 10-3 M, where 
cell survival significantly decreased to 73 % and 58 % respectively (Figure 3-9B). H2O2 (350 µM) 
alone induced 40 % cell survival. SAHA (10-9 - 10-3 M) incubation had effects on H2O2-induced cell 
death, at 10-8, 10-7 and 10-3 M where cell continued existence decreased to 26 %, 30 % and 71 %, 
respectively. 
 
In untreated N1E-115 cultures, 78 % viable cells were counted. SAHA alone treatments 
decreased the number of surviving cells to a range of 59 % and 39 %, which were statistically 
significant to the control (Figure 3-9C). H2O2 (96 µM) generated 45 % surviving cells. SAHA 
administration for 2 hours prior to H2O2 had no effect on cell survival, except at the highest 
concentration (10-3 M) where 29 % of viable cells was recorded. 
 
In SH-SY5Y untreated cultures, 85 % cells survived serum-free treatments (Figure 3-9D). SAHA 
alone caused a statistically significant decline in the number of viable cells to approximately 60 % 
across all the concentrations. H2O2 (935 µM) alone produced 46 % viable cells, and SAHA 
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Figure 3-9 Effect of H2O2 on cell survival following SAHA pre-treatment.  
N1E-115 (A & C) and SH-SY5Y (B & D) cell survival was assessed by LDH assay (A & B) and trypan 
blue exclusion assay (C & D). The cells were exposed to SAHA (10-9 - 10-3 M) pre-treatment for 2 
hours, followed by 24 hours co-treatment with H2O2 (60 µM and 350 µM for the LDH assay; 96 
µM and 935 µM for the trypan blue assay, respectively). Cell death was measured by the LDH 
assay, where maximum LDH release was recorded at 100 %. Viable cells for the trypan blue assay 
were counted and percentages were calculated from total cell counts of dead and surviving cells. 
Data are expressed as mean ± SEM (n=3); **p<0.01, *p<0.05 comparison between H2O2-free 
treatments; ++p<0.01 compared to serum-free control; ##p<0.01, #p<0.05 compared to H2O2 




Approximately 74 % viable cells were observed in untreated N1E-115 cultures. VPA alone 
treatments had no effect on the cell viability (Figure 3-10A). As expected, H2O2 (60 µM) alone 
treatment induced 57 % cell survival. VPA administration for 2 hours prior to H2O2 significantly 
increased H2O2-induced cell loss to approximately 68 % at all concentrations, although this was 
not dose dependent. 
 
In SH-SY5Y cells, 81 % viable cells were observed in untreated cultures (Figure 3-10B). As for 
N1E-115 cultures, VPA treatments did not alter the cell viability at any of the concentrations 
tested, and H2O2 (350 µM) alone induced approximately 43 % cell viability. VPA (10-9 – 10-3 M) 
administration prior to H2O2 had no significant effect on H2O2-induced cell death, although there 





    
 
B N1E-115 SH-SY5Y 
C D 
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Figure 3-10 Effect of H2O2 on cell survival following VPA pre-treatment.  
N1E-115 (A & C) and SH-SY5Y (B & D) cell survival was assessed by LDH assay (A & B) and trypan 
blue exclusion assay (C & D). The cells were exposed to VPA (10-9 - 10-3 M) pre-treatment for 2 
hours, followed by 24 hours co-treatment with H2O2 (60 µM and 350 µM for the LDH assay; 96 
µM and 935 µM for the trypan blue assay, respectively). Cell death was measured by the LDH 
assay, where maximum LDH release was recorded at 100 %. Viable cells for the trypan blue assay 
were counted and percentages were calculated from total cell counts of dead and surviving cells. 
Data are expressed as mean ± SEM (n=3); **p<0.01, *p<0.05 comparison between H2O2-free 
treatments; ++p<0.01 compared to serum-free control; ##p<0.01 compared to H2O2 only treated 
control cells (two-way ANOVA followed by Newman-Keuls test). 
 
 
In N1E-115 untreated cultures 79 % of viable cells was counted (Figure 3-10C). VPA alone 
significantly declined the number of viable cells by approximately 18 % across all the 
concentrations. H2O2 alone treatment had 51 % surviving cells. VPA administration had no 
significant effect on cell survival. 
 
In untreated SH-SY5Y cultures, 86 % of viable cells were represented. VPA administration 
statistically decreased the percentage of viable cells to approximately 59 % across the 
treatments (Figure 3-10D). H2O2 alone induced 42 % of viable cells.  VPA administration for 2 
hours prior to H2O2 administration had no significant effect on cell viability. 
 
 
A B N1E-115 SH-SY5Y 
C D 
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3.3.4.2 Effect of HDAC inhibitors on cell viability following MPP+ administration 
N1E-115 and SH-SY5Y cell lines were treated with EC50 concentrations of MPP
+ (3 mM and 3 mM 
for LDH assay; 62 µM and 82 µM for trypan blue assay, respectively) in the presence and 
absence of a range of SAHA and VPA (10-9 – 10-3 M) concentrations. Control cultures were 
treated with serum-free medium only or toxin in serum-free medium.  
 
SAHA Treatments 
In untreated N1E-115 cultures, approximately 76 % cell viability was observed (Figure 3-11A). 
SAHA decreased cell survival in a bell shaped concentration-dependent manner, with significant 
decrease to 40 % and 31 % at 10-5 and 10-4 M, respectively. MPP+ (3 mM) alone induced 53 % cell 
viability, however, although SAHA (10-9 – 10-3 M) administration had no significant effect on 
MPP+-induced cell survival, cell loss tended to be greater than for MPP+ alone control at all 
concentrations.  
 
In untreated SH-SY5Y cultures, approximately 83 % cell survival was observed. Treatment with 
SAHA did not alter the degree of cell loss except at the highest concentration (10-3 M) where 36 
% cell viability was observed (Figure 3-11B). MPP+ (3 mM) alone induced 57 % cell survival in the 
control condition. SAHA had no effect on MPP+-induced cell death, except at the highest 
concentration where cell viability of 8 % was measured, which was significantly greater than that 
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 Figure 3-11 Effect of MPP+ on cell survival following SAHA pre-treatment.  
N1E-115 (A & C) and SH-SY5Y (B & D) cell survival was assessed by LDH assay (A & B) and trypan 
blue exclusion assay (C & D). The cells were exposed to SAHA (10-9 - 10-3 M) pre-treatment for 2 
hours, followed by 24 hours co-treatment with MPP+ (3 mM and 3 mM for the LDH assay; 62 µM 
and 82 µM for the trypan blue assay, respectively). Cell death was measured by the LDH assay, 
where maximum LDH release was recorded at 100 %. Viable cells for the trypan blue assay were 
counted and percentages were calculated from total cell counts of dead and surviving cells. Data 
are expressed as mean ± SEM (n=3); **p<0.01, *p<0.05 comparison between MPP+-free 
treatments; ++p<0.01, +p<0.05 compared to serum-free control; ##p<0.01 compared to MPP+ 
only treated control cells (two-way ANOVA followed by Newman-Keuls test). 
 
 
In untreated N1E-115 cultures 80 % cell viability was observed. SAHA alone caused a decrease 
across the concentrations, but was only statistically significant at 10-3 M, where 37 % viable cells 
were counted (Figure 3-11C). MPP+ (62 µM) alone had 40 % cell viability. SAHA administration 
for 2 hrs prior to MPP+ administration had no significant effect on the cells, even at 10-3 M, 
where the lowest cell count was recorded at 22 %. 
 
In SH-SY5Y control cultures, 81 % cell survival was recorded (Figure 3-11D). SAHA alone 
statistically decreased the cell survival gradually from 70 % at 10-9 M to 56 % at 10-3 M. MPP+ (82 
µM) alone induced 48 % cell viability, and SAHA administration caused a gradual decline in cell 




A B N1E-115 SH-SY5Y 
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VPA Treatments 
In N1E-115 cultures, 70 % cell viability was measured in untreated cells. VPA alone did not alter 
the degree of cell death at any concentration tested (Figure 3-12A). MPP+ (3 mM) alone 
significantly decreased cell survival to 38 %. VPA administration (10-9 – 10-3 M) had no significant 
effect on the degree of MPP+-induced cell loss at any concentration tested.  
 
In untreated SH-SY5Y cultures, 78 % cell viability was observed. Treatment with VPA alone did 
not significantly affect cell loss at any concentration tested (Figure 3-12B). MPP+ (3 mM) alone 
induced 58 % cell survival. VPA administration prior to MPP+ addition had no effect on MPP+-
induced cell loss, except at the highest concentrations 10-4 M and 10-3 M, where cell loss was 





Figure 3-12 Effect of MPP+ on cell survival following VPA pre-treatment.  
N1E-115 (A & C) and SH-SY5Y (B & D) cell survival was assessed by LDH assay (A & B) and trypan 
blue exclusion assay (C & D). The cells were exposed to VPA (10-9 - 10-3 M) pre-treatment for 2 
hours, followed by 24 hours co-treatment with MPP+ (3 mM and 3 mM for the LDH assay; 62 µM 
and 82 µM for the trypan blue assay, respectively). Cell death was measured by the LDH assay, 
where maximum LDH release was recorded at 100 %. Viable cells for the trypan blue assay were 
counted and percentages were calculated from total cell counts of dead and surviving cells. Data 
are expressed as mean ± SEM (n=3); **p<0.01, *p<0.05 comparison between MPP+-free 
treatments; ++p<0.01 compared to serum-free control; ##p<0.01, #p<0.05 compared to MPP+ 
only treated control cells (two-way ANOVA followed by Newman-Keuls test). 
 
A B N1E-115 SH-SY5Y 
C D 
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In N1E-115 untreated cells, 80 % cell viability was observed (Figure 3-12C). VPA alone 
significantly decreased viability by approximately 18 % across all the concentrations tested. 
MPP+ (62 µM) alone induced 45 % cell viability. Administration of VPA 2 hours prior to MPP+ 
incubation induced further significant decline to 35 % at 10-9 and 10-8 M, and then a gradual 
increase to 49 % at 10-3 M, which was not significant.  
 
SH-SY5Y untreated cells generated 78 % cell survival (Figure 3-12D). VPA alone did not have an 
effect on cell viability across all the concentrations tested. MPP+ (82 µM) alone induced 48 % cell 
survival, and administration of VPA prior to MPP+ incubation did not have any effect on cell 
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3.4 Discussion 
The hypothesis that the HDAC inhibitors would protect dopaminergic cells against toxin-induced 
cell death in cell lines, due to the presence of HDAC isoforms, was first tested by characterising 
the cell lines for dopaminergic and HDAC phenotype. The susceptibility of the cell lines to toxin-
induced toxicity was then compared. 
 
3.4.1 Characterisation of cell lines 
Positive staining for TH in both mouse adrenergic N1E-115 and human catecholaminergic SH-
SY5Y confirms they have dopaminergic phenotype. This is in agreement with previous evidence, 
where both cell lines were shown to possess dopaminergic characteristics by staining positive for 
TH (Amano et al., 1972; Richelson, 1973; Biedler et al., 1978). 
 
Immunofluorescence staining of SH-SY5Y and N1E-115 cells for the HDAC isoforms showed that 
HDAC3 is localised mainly in the nucleus, whereas HDAC5 is primarily localised in the cytoplasm. 
HDAC4 and HDAC11 are present in both the nucleus and cytoplasm but stronger stains in the 
cytoplasm may indicate greater levels of protein outside the nucleus. These results are in 
agreement with previous reports where Class I (HDAC3) are predominantly nuclear and Class II 
(HDAC4 and 5) shuttle between the nucleus and cytoplasm (Verdin et al., 2003; Lucio-Eterovic et 
al., 2008). HDAC4 and 5 remain mainly in the cytoplasm due to their association with 14-3-3 
protein which excludes them from the nucleus. In addition, a conserved nuclear import signal 
mapped to their N-terminal and binding to 14-3-3, has been suggested to mask their nuclear 
localisation (Wang & Yang, 2001; Sengupta & Seto, 2004). 
 
HDAC11, which has previously been demonstrated to be localised mainly in the nucleus (Gao et 
al., 2002b; Liu et al., 2008) was found in both nucleus and cytoplasm in this study. This agrees 
with reports that this isoform has the characteristics of both Classes I and II HDACs (Broide et al., 
2007). If this is the case, it suggests that HDAC11 may also interact with 14-3-3 protein to localise 
predominantly in the cytoplasm, although this has not been confirmed. 
 
Analysis by Western blot (Figure 3-6) confirmed the expression of the HDAC isoforms 3, 4, 5 and 
11 in the two cell lines. In summary, positive staining of the two cell lines for dopaminergic 
phenotype and HDAC phenotype makes them a good in vitro model for this study.   
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3.4.2 The effect of H2O2 and MPP+ on cell viability 
The main aim of the study was to investigate the effect of HDAC-I in in vitro models of PD in 
these cell lines. Initial studies investigated the concentration-response relationship of 
neurotoxins H2O2 and MPP
+, which results in the inhibition of mitochondrial complex I and 
induces oxidative stress in N1E-115 and SH-SY5Y cell lines.  
 
H2O2 was chosen as it induces the oxidative stress as observed in PD. It exerts its effects via ROS 
generation which inhibits mitochondrial complex I and causes lipid peroxidation and DNA and 
protein damage in cells (Halliwell & Aruoma, 1991). It has also been reported to activate 
caspase-3 (Jeon et al., 1999), and stimulate cytochrome c release from mitochondria (Li et al., 
1997), both involved in cell death.  
 
The second toxin, MPP+, a metabolite of MPTP, on the other hand acts via inhibiting complex I 
(nicotinamide adenine dinucleotide coenzyme Q reductase) of the mitochondrial respiratory 
system (Chiba et al., 1985). This leads to energy depletion and generation of ROS, similar to 
H2O2, resulting in oxidative stress and cell death (Mizuno et al., 1987).  
 
Both toxins induced concentration-dependent cell loss in N1E-115 and SH-SY5Y cell lines, 
indicating their vulnerability towards the toxins. Induction of LDH leakage and trypan blue stain 
of non-viable cells after toxin treatment confirms cell death by loss of membrane integrity which 
is probably the result of mitochondrial complex I activity impairment. Previous evidence have 
shown that MPP+ induced the production of ROS in SH-SY5Y neuroblastoma cells, resulting in the 
initiation of apoptosis (Fall & Bennett, 1999). Even though this was not tested, caspase-3 assay 
could have been employed to test this notion and confirm that the cell loss observed in the 
cultures was probably due to apoptosis. In fact, H2O2 and MPP
+ used in previous studies have 
been shown to induce apoptosis in dopaminergic cells (Sheehan et al., 1997; Gomez et al., 2001; 
Uberti et al., 2002; Dennis & Bennett, 2003; King & Jope, 2005; Wang et al., 2009a). EC50 
concentrations reported in these studies are comparable to the concentrations reported in here: 
H2O2 (100 – 935 µM) and MPP+ (3 mM). The low concentrations reported in this study for MPP+ 
(100 – 200 µM) assessed by trypan blue exclusion assays however does not correlate to previous 
findings. This variation is because the trypan blue dye is able to stain all dead cells as well as 
those with cell membrane damages, whereas the LDH assay only measures the leakage of LDH 
from cells with damaged membranes (Lappalainen et al., 1994), therefore requiring higher toxin 
concentrations.  
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The cell death was determined and expressed as percentage cytotoxicity in both assays. The LDH 
assay, which measures LDH leakage from cells with disrupted membranes is indicative of 
necrotic cell death (Lobner, 2000). The trypan blue exclusion assay on the other hand stains all 
dead cells indicating that it measures both apoptotic and necrotic cell loss. Therefore, caspase-3 
assay which measures apoptosis would have been an appropriate test to determine whether 
HDAC-Is were inducing apoptotic or necrotic neuronal loss in the cultures. Assays such as MTT 
and ATP were considered, however as both toxins inhibit mitochondrial function, they were 
concluded to be inappropriate.  
 
3.4.3 HDAC-I’s do not protect dopaminergic cell lines against toxin induced cell death 
To investigate the effects of HDAC-Is in the presence of H2O2 and MPP
+, N1E-115 and SH-SY5Y 
cells were subjected to 2 hours pre-treatment prior to toxin exposure for 24 hours. LDH assay 
results, showed SAHA alone treatments had the tendency to increase cell death only at high 
concentrations (10-4 and 10-3 M) in both cell lines. This result was similar for trypan blue 
exclusion assay where absolute cell numbers were counted. Concomitant treatment of the 
HDAC-I and both toxins, showed SAHA to exacerbate to effects of the toxins at all concentrations 
tested in both assays, except for N1E-115 cells where SAHA proved to be potentially protective 
at the highest concentration (10-3 M) which was not significant (Figure 3-9A&C; Figure 3-11C). 
 
VPA, on the other hand, had little or no effect on cells when they were treated with VPA alone 
or concomitantly with the toxins. Similarly to SAHA, VPA also exacerbated the effects of the 
toxins H2O2 and MPP
+ in both LDH and trypan blue exclusion assay.  
 
The toxic  effects of the HDAC-Is observed here contradicts previous reports where inhibition of 
HDAC with sodium butyrate (Nab) reduced cell death at millimolar concentrations (Candido et 
al., 1978) and also recently confirmed by Kidd & Schneider (2010) where VPA and Nab (both 1 
mM) protected against MPP+-induced apoptotic cell loss in dopaminergic cell lines (Kidd & 
Schneider, 2010). The protective effect implicated by these studies was achieved at 
concentrations which are not physiologically plausible as they are too high, and would hinder the 
use of these inhibitors as a therapeutic approach. In addition, due to the nature of cell lines to 
withstand harsh conditions, this cannot be a true representation of a neuroprotective effect, and 
other models will have to be investigated. Moreover, it is unlikely that such high levels can be 
translated and sustained in in vivo models due to the pharmacotoxicity effects of these HDAC-Is 
even at low concentrations. A contributory factor to their toxicity could be due to the fact that 
their mechanisms of action are highly non-specific and non-targeted. 
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Treating the cells with serum-free media, also contributed to the decline in cell viability. Serum 
deprivation has been shown to be toxic to cells (Takeshima et al., 1994a; Bar-Am et al., 2005). 
Despite this finding, serum deprivation was still encouraged as it helps to synchronise the 
development stage of the cancer cell lines, by enabling cells to exit from cell cycle into the non-
dividing state termed G0 characterised by low metabolic activity (Kues et al., 2000). This also 
makes the cells less resistant to toxin insults, because serum enriches the media and promotes 
growth. Therefore, higher toxin concentrations were required to observe maximum cell loss, 
especially when generating the concentration-response curves.  
 
More recently, it has also been reported that serum deprivation induces autophagy by starvation 
(Steiger-Barraissoul & Rami, 2009). To some extent, this may have contributed to the degree of 
cell death assessed, but as the DMEM used in the study contains a variety of amino acids and 
vitamins, it seems unlikely that a major proportion of the cell death measured can be attributed 
to the induction of autophagy. This concept therefore needs to be examined further for 
confirmation. However, if this hypothesised view is false, then it would result in an over-
exaggeration of the toxic effects of the HDAC-Is and toxins, as the cell death measured would be 
attributed to their toxicity. In this case, to overcome the problem of autophagy induction, the 
concentration of FBS could be reduced from 10 %, in the serum-containing media, to 1 %, to 
prevent a complete starvation, and minimise the onset of autophagy. 
 
Treatment with SAHA and VPA resulted in exacerbated neurotoxic damage to the cell lines 
induced by H2O2 and MPP
+. A similar effect in SH-SY5Y cells when treated with Trichostatin A 
(TSA) and rotenone was previously reported (Wang et al., 2009b) . Confirmation of these results 
are by Subramanian and group who reported HDAC-Is induced apoptosis in neuronal 
neuroblastoma cells, via Ku70 hyperacetylation which led to Bax activation and translocation to 
the mitochondria to result in the release of cytochrome c and caspase dependent apoptosis in 
the cytoplasm (Subramanian et al., 2005a; Subramanian et al., 2005b). This indicates that the 
inhibitors may be exerting their anti-cancer effects in the assays as both N1E-115 and SH-SY5Y 
cells are mouse and human neuroblastoma-derived, respectively. This is confirmed by Marks et 
al. (2000) who suggested that small molecule Class I and II HDAC-Is, such as VPA and SAHA, 
produce responses in a wide variety of cultured transformed cells including neuroblastoma cells 
associated with anti-tumour agents, which triggers apoptosis, cell cycle arrest and differentiation 
(Marks et al., 2000).  
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3.4.4 Conclusion 
In conclusion, this study showed that N1E-115 and SH-SY5Y possess dopaminergic and HDAC 
phenotype. In addition to expressing their vulnerability to neurotoxins to enable the effects of 
HDAC-Is to be investigated. Inhibition of HDACs showed the inhibitors are toxic to the cell lines 
and exacerbate the effects of H2O2 and MPP
+, except at high concentrations where they tend to 
be protective. As the cell lines are immortalised, they are able to withstand such high 
concentrations which are not pharmacologically possible to translate into in vivo models. 
Secondly, the cell lines were not induced to differentiate into neuronal-like morphology with 
retinoic acid, where they resembled functionally mature neurones. Therefore the effects of the 
HDAC-Is observed in the cell lines is not a true representation of the effects they would have on 
mature neurones. Thirdly, they are of neuronal origin and lack the complexity of the ‘real 
picture’, where different cell types such as glial cells are present. This therefore only allowed the 
effects of HDAC-Is on oxidative stress to be investigated and not inflammation. For this reason, 
further investigation performed in primary mesencephalic cultures as an in vitro cell death 
model of PD is reported in the next chapter. 
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4.1 Introduction 
In the preceding chapter, it was reported that HDAC-Is did not protect dopaminergic neuronal 
cell lines against toxin-induced cell death despite the presence of multiple HDAC isoforms. 
Indeed, at higher concentrations the inhibitors were toxic to the cell lines and exacerbated the 
toxic effects of both H2O2 and MPP
+, resulting in increased cell loss. Although this suggests that 
HDAC-Is may not be useful as neuroprotective agents mediated by a direct action on neuronal 
cells, it does not preclude other mechanisms of action which may have a beneficial protective 
effect. 
 
HDAC-Is have been shown to have anti-inflammatory properties in models of autoimmune and 
inflammatory diseases (Leoni et al., 2002; Leoni et al., 2005; Camelo et al., 2005; Lin et al., 2007). 
This may be relevant to PD as glial cell toxicity plays a major role in the pathogenesis of the 
disease (see Chapter 1). Investigations in post mortem PD brains have shown increased numbers 
of activated microglia, phagocytes and astrocytes in the substantia nigra. These cells are 
activated in response to cellular damage, including oxidative stress and the increased expression 
of genes involved in nitric oxide (NO) and cytokine synthesis (McNaught & Jenner, 1999). Thus 
HDAC-Is may have an anti-inflammatory role that would result in protection against cell death in 
PD, however, this has not been investigated. 
 
In order to study this anti-inflammatory role of HDAC-Is, it is important to use a cell system that 
is composed of a mixed population of neurones and glial cells. Primary rat cultures derived from 
foetal ventral mesencephalon are the best suited option, as they have been extensively used to 
investigate dopaminergic cell death in in vitro studies (Chung et al., 2005; Ono et al., 2007; 
Pruszak et al., 2009). In addition, primary cultures closely mimic the in vivo state, and generate a 
more physiologically relevant effect as opposed to cell lines. 
 
In the present study, primary cultures were used to investigate and compare the effects of 
HDAC-Is in MPP+-induced oxidative stress and LPS-induced inflammation on dopaminergic 
neurones. The two toxins were chosen because they both exert their effects in different 
pathways in cultures and exert different levels of gliosis (Block et al., 2007; MCNaught & Jenner, 
2000; Gao et al., 2003). 
 
 Even though HDAC-Is did not protect dopaminergic neurones from MPP+-induced toxicity as 
shown in the previous chapter, their effects on cultures with mixed cell populations including 
glial cells is of particular interest. This is because besides the harmful effects of glial cells detailed 
in Chapter 1, they do have beneficial effects such as: 1) promoting neuronal survival through the 
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release of endogenous neuroprotective proteins termed neurotrophic factors, such as GDNF 
(Hou et al., 1996; Burke et al., 1998); 2) scavenging toxic compounds released by dying neurones 
(Rosenberg, 1991; Aloisi, 2001); and 3) protecting neurones against oxidative stress by up-
regulating the synthesis of the antioxidant glutathione (Iwata-Ichikawa et al., 1999). These 
properties may in turn protect neurones from toxin-induced damage. 
 
4.1.1 Hypothesis 
It was hypothesised that HDAC inhibition will protect dopaminergic neurones from the 
biochemical and pathological changes linked to cell death in the substantia nigra induced by 
MPP+ and LPS by reducing the inflammatory response. 
 
4.1.2 Aims 
To test this hypothesis, the effect of HDAC inhibition on MPP+ and LPS-induced cell death was 
investigated in the rat primary VM cell cultures. The main aims were to: 
1. Characterise VM cultures for constituent cell types. 
2. Determine the expression of HDACs in VM cultures. 
3. Assess the effect of HDAC inhibitors on dopaminergic cell death following MPP+ and LPS 
treatment. 
4. Investigate the effect of HDAC inhibitors on the inflammatory changes induced by MPP+ 
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4.2 Materials and methods 
4.2.1 Primary cell culture 
Pregnant female Wistar rats (Charles River, Margate, UK), were housed in a temperature-
controlled room (23oC) (King’s College London Biological Services Unit) with a 12 hour light-dark 
cycle and ad libitum access to pelleted diet and water. Experiments were conducted according to 
guidelines set out in the UK Animals (Scientific Procedures) Act, 1986. 
 
4.2.2 Dissection of ventral mesencephalon 
Pregnant rats were killed by an overdose of carbon dioxide (CO2) followed by cervical 
dislocation. The uterine horn was removed by caesarean section, cleared of blood and 
membranes, and placed into a petri dish containing ice-cold sterile PBS (0.1 M). The foetal 
ventral mesencephalon (VM) (Figure 4-1) was dissected under a microscope (Vickers 
Instruments, Croydon) and collected into a falcon tube containing ice-cold sterile PBS (0.1 M), 
using micro-dissection scissors and micro-forceps (World Precision Instuments, Hertfordshire). 
 
 
Figure 4-1 Outline of VM dissection.  
(A) An E14 old rat embryo. Black circle shows the mesencephalon that develops into the ventral 
tegmental area and substantia nigra. (B & C) depicts the top of the head (neural tube) with the 
VM highlighted with white arrow. (D) The neural tube is isolated and cut open (at white line) to 
reveal a butterfly image with the VM in the middle (E). Adapted and Modified from Studer, 2001; 
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4.2.3 Preparation of mesencephalic primary culture 
Using aseptic technique, cell preparation was performed in a class II safety cabinet (Walker 
Safety Cabinets, Derbyshire) following tissue dissection. The collected mesencephalon was 
washed three times with ice-cold PBS and enzymatically digested with Trypsin-EDTA solution 
(2.5 %; 2 ml) at 37oC for 2 minutes. Trypsin was inactivated by addition of high glucose 
Dulbecco’s Modified Eagle Medium (DMEM) (10 ml) supplemented with heat-inactivated foetal 
bovine serum (10 %) and PSN (1 %; 100 IU/ml) and centrifuged at 1000 g for 90 seconds. The 
tissue pellet was resuspended in DMEM (1 ml) and dissociated with p1000 Gilson pipette 
followed by a fire-polished glass Pasteur pipette. The cell density was determined as described in 
Section 3.2.3 and the cells were plated at 2 x 105 cells per well into a 24 well plate containing 
poly-D-lysine coated 13 mm coverslips (Section 2.6.1). Cells were grown at 37oC in an incubator 
(MCO-18AIC, Sanyo), with CO2 (5 %) and humidity (95 %) in atmospheric air. Following 7 days in 
vitro (DIV7), the cells were processed for immunochemical staining (Section 4.2.6). 
 
4.2.4 Characterisation of VM cultures 
Primary culture cells were characterised for TH; glutamic acid decarboxylase (GAD), a GABA-ergic 
neurone marker; GFAP, a marker for astrocytes; and OX-42, for microglia. At DIV7 after 
dissection, the medium was aspirated and the cells were washed with cold sterile PBS followed 
by 15 minutes fixation with PFA (4 % in PBS). Immunoperoxidase staining was performed as 
described in Section 4.2.6.1. 
 
4.2.5 Neuroprotection study 
4.2.5.1 Effect of MPP+ and LPS on VM cultures 
Neuronal cell death was induced in VM cultures (DIV7) using MPP+ (1 to 100 µM) or LPS (1 to 200 
µg/ml) in serum-free medium for 24 hours. Control cells were grown in serum-free medium only 
for 24 hours. The media was aspirated and the cells were fixed with PFA (4 %) as described in 
Section 2.6.2. The cells were then stained for TH cell number by immunocytochemistry and 
counted as described in Section 4.2.7. EC50 calculation of MPP
+ and LPS were determined in 
Section 4.2.8. 
 
4.2.5.2 Neuroprotection assays on MPP+ and LPS induced toxicity 
To assess and compare the effects of HDAC inhibition on MPP+ and LPS-induced cell death, VM 
cultures (DIV7) were pre-treated with SAHA (0.01, 0.1 and 1 µM) or VPA (0.3, 0.6 and 1.2 mM) 
diluted in serum-free media for 2 hours (Figure 4-2). The media was then replaced with the same 
concentrations of VPA or SAHA with or without EC50 concentrations of MPP
+ or LPS determined 
in Section 4.2.5.1, for a further 24 hours. Control cells were incubated with serum-free medium 
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only, HDAC inhibitor only or toxin only for 24 hours. The cells were fixed as described in Section 
2.6.2, and stained for TH, GFAP and OX-42 by immunocytochemistry as described in Section 
4.2.6. 
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Figure 4-2 Schematic experimental outline.  
VM cultures were plated at day 0, and grown for 7 days. On day 7, the medium was aspirated 
and changed to serum-free medium (SFM), VPA (0.3, 0.6, 1.2 mM) or SAHA (0.01, 0.1, 1 µM) for 
2 hours followed by the same concentrations with or without EC50 concentrations of MPP
+ or 





4.2.6.1 Immunoperoxidase staining of fixed VM cells 
Immunoperoxidase staining was used to identify the expression of TH, GAD, GFAP and OX-42 in 
VM cultures. This is described in detail in Section 2.6.6. To summarise, VM cell cultures attached 
to poly-D-lysine (0.05 %; Sigma-Aldrich, Dorset, UK) coated coverslips, were fixed with PFA (4 % 
in 0.1 M PBS) and incubated in 24 well plates with primary antibodies against TH (1:500), GAD 
(1:500), GFAP (1:500) and OX-42 (1:100) overnight at room temperature (Table 2-2). The 
following day, the cells were incubated with biotinylated secondary antibody (1:250) (Table 2-3) 
and ABC solution for 1 hour each at room temperature. Cells were visualised by exposing to DAB 
for 1 minute. The cells were hydrated in ethanol (100 %, 98 % and 70 %), counterstained with 
cresyl violet, dehydrated in ethanol (70 %, 98 % and 100 %) and mounted onto superfrost 
microscope slides. 
 
4.2.6.2 Double immunofluorescence of fixed primary cultures 
Double immunofluorescence histochemistry was used to assess the co-expression of TH, GFAP 
and OX-42 with HDAC isoforms 3, 4, 5 and 11 described in detail in Section 2.6.5. In brief, VM 
cultures fixed to poly-D-lysine coated coverslips were first blocked with blocking solution (10 %) 
followed by incubation of primary antibodies against HDAC3, 4, 5, 11 and TH, GFAP and OX-42 
(dilutions in Table 2-2) overnight at 4oC. On the next day, the cells were incubated with the two 
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respective secondary antibodies (Table 2-3) for 2 hours at room temperature. The cells were 
mounted with Vectashield® Hard set mounting medium containing DAPI and examined using a 
fluorescence microscope (Zeiss Axioskop, Carl Zeiss, Hertfordshire, UK). 
 
4.2.7 Cell Counting 
Positively stained cells were counted in 8 randomly chosen areas at X20 magnification in one 
cover slip with total area equivalent to 8 mm2, with three coverslips per experiment. For 
characterisation study, the number of TH, GAD and GFAP immunoreactive cells were calculated 
as a percentage of the total number of cells, including the cresyl violet stained cells.  For the 
neuroprotection study, immunoreactive cells were counterstained with cresyl violet and 
expressed as the number of immunoreactive cells per 8 mm2. 
 
4.2.8 Data & Statistical Analysis 
GraphPad Prism 5 software was employed for statistical analysis. Non-linear regression analysis 
was used to determine the EC50 for MPP
+ and LPS. One-way ANOVA followed by Newman Keul’s 
post hoc test was performed on MPP+ and LPS concentration-response data. Neuroprotection 
studies were analysed by two-way ANOVA followed by Newman Keul’s test using toxin and 
HDAC treatment as variables. P<0.05 was considered significant. Data are expressed as mean ± 
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4.3 Results 
4.3.1 Characterisation of VM primary cultures 
VM cultures from E14 embryos were stained at DIV7 for the proportions of dopaminergic, 
GABAergic neurones, astrocytes and microglia by staining for TH, GAD, GFAP and OX-42, 
respectively, using immunoperoxidase and immunofluorescence for the latter (Figure 4-3). The 
majority of cell population were GAD positive cells (55 %), whereas TH positive cells made up 
only 5 % of the culture. Staining for both GAD and TH markers were observed in the cell bodies 
and dendritic processes (Figure 4-3A & B). GFAP-positive cells made up a small proportion of the 
population (8 %), where distinct staining of the cell body and fibrous processes was noted 
(Figure 4-3C), and OX-42-immunoreactive cells made up 0.2 % of the cell population (Figure 
4-3D). 
 
Figure 4-3 Positive immunoperoxidase and 
immunofluorescence staining of VM primary 
cultures for TH, GAD, GFAP and OX-42. 
Representative photomicrographs of VM cell 
cultures (DIV7) stained with antibodies against (A) 
TH, (B) GAD, (C) GFAP, and (D) OX-42. Positively 
stained cells were stained brown (A-C) by 
immunoperoxidase, and green (D) by 
immunofluorescence. Typical stained cell bodies 
are indicated with red arrows. Cultures (A-C) were 
counterstained with cresyl violet and DAPI (D). 
Scale bar = 100 µm (A & B) 200 µm (C & D). (E) Data 
are expressed as percentage of total cell number 
indicated by cresyl violet and DAPI.  
E 
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 4.3.2 Co-expression of HDAC isoforms and dopaminergic cells in VM cultures. 
In order to determine whether HDAC isoforms were co-expressed with dopaminergic cells, VM 
cultures fixed at DIV7 were double-labelled by immunoflourescence for TH and HDAC3, 4, 5 and 
11 (Figure 4-4,). Similar to results observed in Section 3.3.2, HDAC3 was mainly localised in the 
nucleus of the cell body; whereas HDAC4, 5 and 11 were localised mainly in the both cell body 
and dendritic processes.  
 
Double immunoflourescence labelling with anti-TH antibody showed that TH-positive cells 
expressed all four HDAC isoforms (Figure 4-4). These isoforms were also seen to be expressed in 
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 Figure 4-4 Expression of HDAC isoforms in TH immunopositive cells in VM cultures. 
Representative photomicrographs showing (A-D) HDAC3, 4, 5 and 11 positive cells respectively 
(red; solid arrow); (E-H) TH positve cells (green; arrow head) and (I-L) merged images (typical 
cells depicted with broken arrow). DAPI (blue) was used to counterstain nuclei. Scale bar = 100 
µm is representative of all images. 
 
 
4.3.3 Co-expression of HDAC isoforms and inflammatory cells in VM cultures. 
As expected, VM cultures were composed of multiple cell types including inflammatory cells. 
Thus, the expression of HDAC isoforms 3, 4, 5 and 11 was investigated in inflammatory cells, 
including astrocytes and microglial cells. Double-labelling by immunoflourescence with anti-
GFAP (Figure 4-5) and anti-OX-42 (Figure 4-6), also showed that GFAP and OX-42 positive cells 
expressed all four HDAC isoforms. 
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HDAC3 was located primarily in the nucleus of the astrocytes (Figure 4-5-A, E, I), but in some 
cells HDAC3 was found to have some diffused cytoplasmic staining. HDACs 4, 5 and 11 were 
mainly found in the cytoplasm with diffused nucleic staining (Figure 4-5-B-L).  
 
A similar staining pattern was observed in microglia (Figure 4-6). HDACs was primarily localised 
in the nucleus of the cells, whereas HDAC4, 5 and 11 were seen to have both nuclear and 




Figure 4-5 Expression of HDAC isoforms in GFAP immunopositive cells in VM cultures. 
Representative photomicrographs showing (A-D) HDAC3, 4, 5 and 11 positive cells respectively 
(red; solid arrow); (E-H) GFAP positve cells (green; arrow head) and (I-L) merged images (broken 
arrow). DAPI (blue) was used to counterstain nuclei. Scale bar = 100 µm is representative of all 
images. 
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Figure 4-6 Expression of HDAC isoforms in OX42 immunopositive cells in VM cultures. 
Representative photomicrographs showing (A-D) HDAC3, 4, 5 and 11 positive cells respectively 
(red; solid arrow); (E-H) GFAP positve cells (green; arrow head) and (I-L) merged images (broken 




4.3.4 The effect of MPP+ and LPS on TH-positive cells in VM cultures. 
To assess the effect of the toxins MPP+ and LPS on dopaminergic cells in VM cultures, the 
cultures (DIV7) were exposed to MPP+ (1 - 100 µM) and LPS (1 - 200 µg/ml) and cell loss was 
determined by staining for TH-positive cell number by immunocytochemistry. 
 
MPP+ (1 – 100 µM) induced a concentration-related decline in TH positive stained neurones in 
the cultures (Figure 4-7A). The EC50 was calculated to be 3 ± 1.5 µM. Similarly, LPS (1 – 200 
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µg/ml) also induced a concentration-dependent loss of immunoreactive TH cells in VM cultures 
(Figure 4-7B). The EC50 concentration was calculated as 40 ± 0.6 µg/ml. 
 
 
     
Figure 4-7 The effect of MPP+ and LPS on TH-positive cells in VM culture.  
DIV7 embryonic cultures were incubated with serum-free medium for 2 hours prior (A) MPP+ (1 
– 100 µM) and (B) LPS (1 – 200 µg/ml). Positively stained TH cells were counted and displayed as 
percentage TH-positive cells compared to untreated control cells (100 %). Non-linear regression 
curve was fitted to determine EC50. Data are expressed as mean ± SEM (n=3) and analysed by 




4.3.5 The effects of SAHA and VPA on toxin-induced cell loss in rat mesencephalic culture. 
The effects of HDAC-Is, SAHA and VPA, on toxin-induced cell loss in VM primary cultures were 
investigated. Culture cells were subjected to 2 hours pre-treatment with SAHA (0.01, 0.1, and 1 
µM) and VPA (0.3, 0.6, and 1.2 mM) prior to concomitant treatment for a further 24 hours with 
EC50 concentrations of MPP
+ (3 µM) or LPS (40 µg/ml). The number of TH, GFAP or OX-42 cells 
was determined by immunocytochemistry as described in Section 2.6.6. 
 
 
4.3.5.1 The effect of HDAC inhibitors on TH-positive cells following MPP+ and LPS exposure. 
SAHA and MPP+ Treatments 
Control VM cell cultures contained 42 ± 9 TH-positive cells per 8 mm2 with intact cell bodies and 
dendritic processes (Figure 4-8A; Figure 4-9A). Treatment with SAHA alone caused significant 
decreases of TH-positive cells, with the highest percentage loss observed at 1 µM (71 %) which 
caused the loss of the dendritic nodes (Figure 4-9D). MPP+ (3 µM) alone reduced the number of 
TH immunoreactive cells by 45 %. In some instances, some cells were left with intact cell bodies 
with completely disintegrated processes, whereas other cells had both damaged cell bodies and 
processes (Figure 4-9B). Pre-treatment with SAHA for 2 hours prior to MPP+ incubation for 24 
hours had no significant effect on TH cell survival compared to MPP+ alone. However, both 
A B 
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treatments resulted in shortened processes in some surviving cells and complete loss of 
processes in others (Figure 4-9E). 
 
VPA and MPP+ treatments 
Control VM cell cultures contained 36 ± 3 TH-positive cells per 8 mm2 (Figure 4-8B). Similarly to 
SAHA, treatment with VPA alone caused a decline in the number of TH-positive cells where 50 % 
viable cells was observed with 1.2 mM VPA concentration. VPA caused cell processes to 
completely disintegrate leaving the cell bodies intact (Figure 4-9G). MPP+ (3 µM) alone reduced 
the number of TH immunoreactive cells by 47 %.  Pre-incubation of cultures with VPA for 2 hours 
prior to MPP+ had no effect on the number of viable TH immunoreactive cells (Figure 4-9H). 
 
SAHA and LPS treatments 
Control VM cell cultures contained 40 ± 3 TH-positive cells per 8 mm2 (Figure 4-8C).  SAHA alone 
significantly decreased the number of TH-positive cells across the concentrations tested, where 
the lowest number of positive cells (16 ± 2 cells per 8 mm2) was observed at 1 µm. Treatment 
with LPS (40 µg/ml) alone caused 45 % TH immunoreactive cell loss, with remaining cells 
showing loss of cell processes and damage to some cell bodies (Figure 4-9C). Pre-treatment with 
SAHA for 2 hours prior to LPS incubation for 24 hours decreased the number of surviving TH-
positive cells at 0.10 µM to 43 %, causing a loss to both cell bodies and processes (Figure 4-9F).  
 
VPA and LPS treatments 
Control VM cell cultures had 35 ± 3 TH-positive cells per 8 mm2 (Figure 4-8D). VPA alone 
significantly decreased the number of TH-positive cells by 38 % at 0.3 and 0.6 mM and by 55 % at 
1.2 mM. LPS (40 µg/ml) alone declined the positive cells by 52 % to 17 ± 1 TH-positive cells per 8 
mm2. VPA pre-treatment for 2 hours prior to LPS treatment for 24 hours had no effect on the 
number of TH-positive cells across the concentrations tested, but caused a loss to the cell bodies 















Figure 4-8 The effect of SAHA and VPA on the number of TH-positive cells following MPP+ and 
LPS induced toxicity.  
VM cultures (DIV7) were treated with (A-B) MPP+ (3 µM) and (C-D) LPS (40 µg/ml) in the 
presence and absence of (A & C) SAHA (0.01, 0.1 and 1 µM) or (B & D) VPA (0.3, 0.6 and 1.2 
mM). Dopaminergic cell loss was assessed by immunoperoxidase staining for TH. Data are the 
number of TH positive cells per 8 mm2 and are expressed as mean ± SEM (n=3). *p<0.05, 
**p<0.01 compared to untreated control cells. Analysis by two-way ANOVA with Bonferroni test, 
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 Figure 4-9 Immunoperoxidase staining of TH-positive cells in VM cultures following HDAC and 
toxin treatment.  
VM cell cultures showing TH immunoreactivity in (A) untreated cells, and cells treated with: (B) 
MPP+ (3 µM), (C) LPS (40 µg/ml), (D) SAHA (1.0 µM), (E) SAHA (1.0 µM) and MPP+ (3 µM), (F) 
SAHA (1.0 µM) and LPS (40 µg/ml), (G) VPA (1.2 mM), (H) VPA (1.2 mM) and MPP+ (3µM), (I) VPA 
(1.2 mM) and LPS (40 µg/ml). Cells were counterstained with cresyl violet (violet). Morphological 
changes are highlighted with arrows: normal TH-positive cell (solid red arrow), cell losing their 
dendritic nodes (solid green arrow), cell with shortened processes (broken green arrow) and 
complete loss of processes (broken red arrow). Scale bar = 100 µm is representative of all 
images. Photographs are typical of experiments performed in triplicate on 3 separate occasions. 
 
 
4.3.5.2 The effect of HDAC inhibitors on GFAP-positive cells following MPP+ and LPS exposure. 
SAHA and MPP+ treatments 
Control VM cell cultures had 40 ± 10 GFAP-positive cells per 8 mm2. Treatment with SAHA (0.01 - 
1.00 µM) alone tended to increase the number of GFAP-positive cells by approximately 75 % 
(Figure 4-10A). MPP+ (3 µM) alone increased the number of GFAP-positive cells by 185 % 
compared to the untreated cells. Pre-incubation of primary cultures with SAHA for 2 hours prior 
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to MPP+ for 24 hours significantly prevented the MPP+-induced increase in the number of GFAP-
positive cells by 36 – 41 % across the concentrations tested. 
 
VPA and MPP+ treatments 
 Control VM cell cultures contained 40 ± 4 GFAP-positive cells per 8 mm2. VPA (0.3 - 1.2 mM) 
alone tended to increase the number of GFAP-positive cells by approximately 73 % across the 
concentrations tested (Figure 4-10B). MPP+ alone increased the number of GFAP-positive cells by 
185 % compared to the untreated cells. Two hour pre-treatment with VPA prior to  concomitant 
treatment with MPP+ for 24 hours, prevented the MPP+-induced increase in the number of 
GFAP-positive cells by 39 – 46 % across the concentrations tested, although it was only 






   
Figure 4-10 The effect of SAHA and VPA on the number of GFAP cells following MPP+ and LPS 
exposure.  
VM cultures (DIV7) were treated with (A-B) MPP+ (3 µM) and (C-D) LPS (40 µg/ml) in the 
presence and absence of (A & C) SAHA (0.01, 0.1 and 1 µM) or (B & D) VPA (0.3, 0.6 and 1.2 
mM). Astrocytic cell loss was assessed by immunoperoxidase staining for GFAP. Data are the 
number of GFAP positive cells per 8 mm2 and are expressed as mean ± SEM (n=3). **p<0.01 
compared to untreated control cells; #p<0.05, ##p<0.01 compared to MPP+ or LPS alone. 
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 SAHA and LPS treatments 
Control VM cell cultures had 38 ± 7 GFAP-positive cells per 8 mm2. SAHA (0.01 – 1.00 µm) alone 
increased the number of GFAP-positive cells by approximately 20 % (Figure 4-10C). LPS (40 
µg/ml) alone, increased the cells to 88 ± 8 GFAP-positive cells per 8 mm2. Pre-treatment with 
SAHA for 2 hours prior to 24 hours treatment with LPS, prevented the LPS-induced increase in 
GFAP-positive cells in the range of 40 ± 3 - 47 ± 15 per 8 mm2 at all the concentrations tested, 
with a significant effect at 0.10 µm. 
 
VPA and LPS treatments 
Control cultures had 25 ± 8 GFAP-positive cells per 8 mm2 (Figure 4-10D). VPA (0.3 – 1.2 mm) 
alone caused a slight increase of approximately 20 % in the number of GFAP-positive cells. LPS 
(40 µg/ml) increased the number of cells to 89 ± 17 GFAP-positive cells per 8 mm2 compared to 
the control. Two hours pre-treatment with VPA prior to 24 hours concomitant treatment with 
LPS prevented the increase in GFAP-positive cells by 34 ± 5 - 37 ± 5 per 8 mm2 across all the 
concentrations tested compared to LPS alone. 
 
 
The toxins and concentrations tested induced morphological changes of GFAP-positive cells 
(Figure 4-11). In the control sample, the cells looked fibrous with extended cytoskeleton with 
short processes (Figure 4-11A). However, treatment with MPP+ and LPS caused some of the cells 
(approximately 60 - 70 %) to take on an activated morphology, with a re-organised cytoskeleton 
and long processes (Figure 4-11B & C), which is typical of a reactive astrocyte. SAHA and VPA 
alone treatments exhibited approximately 15 - 20 % of the activated morphology (Figure 4-11D 
& G). HDAC-I pre-treatment prior to MPP+ and LPS incubations for 24 hours exhibited 30 – 40 % 
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Figure 4-11 Immunoperoxidase staining of GFAP-positive cells in VM cultures following HDAC 
and toxin treatment.  
VM cell cultures showing GFAP immunoreactivity in (A) untreated cells, and cells treated with: 
(B) MPP+ (3 µM), (C) LPS (40 µg/ml), (D) SAHA (1.0 µM), (E) SAHA (1.0 µM) and MPP+ (3 µM), (F) 
SAHA (1.0 µM) and LPS (40 µg/ml), (G) VPA (1.2 mM), (H) VPA (1.2 mM) and MPP+ (3µM), (I) VPA 
(1.2 mM) and LPS (40 µg/ml). Cells were counterstained with cresyl violet (violet). Morphological 
changes are highlighted with arrows: normal GFAP-positive cell (green arrow), reactive GFAP-
postive cell red arrow). Scale bar = 100 µm is representative of all images. Photographs are 
typical of experiments performed in triplicate on 3 separate occasions. 
 
 
4.3.5.3 The effect of HDAC inhibitors on OX-42-positive cells following MPP+ and LPS exposure. 
SAHA and MPP+ treatments 
Control VM cell cultures contained 10 ± 2 OX-42-positive cells per 8mm2 (Figure 4-12). 
Treatment with SAHA (0.1 – 1 µM) alone induced approximately 36 – 63 % increase in the 
number of OX-42 immunoreactive cells. MPP+ (3µM) alone increased the number of OX-42 cells 
to approximately 26 ± 2 cells/ 8 mm2. Pre-treatment with SAHA for 2 hours prior to MPP+ 
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incubation for 24 hours significantly prevented the increase in the number of OX-42-positive 
cells by 27 – 38 % (Figure 4-12A).  
 
VPA and MPP+ treatments  
Control VM cultures had 9 ± 1 OX-42 immunoreactive cells per 8 mm2. Treatment with VPA (0.3 - 
1.2 mM) alone significantly increased the number of OX-42 cells in a concentration dependent 
manner (Figure 4-12B). Treatment with MPP+ (3 µM) alone significantly increased the number of 
OX-42-positive cells to 28 ± 2 cells per 8 mm2 compared to the control. Pre-incubation with VPA 
for 2 hours prior to MPP+ incubation for 24 hours significantly prevented the increase in the 
number of OX-42-positive cells by 30, 52 and 56 % at 0.3, 0.6 and 1.2 mM, respectively.  
 
SAHA and LPS treatments 
Control VM cultures contained 10 ± 2 OX-42-positive cells per 8mm2 (Figure 4-12A). Treatment 
with SAHA (0.1 – 1 µM) alone increased the number of OX-42-positive cells by approximately 36 
– 63 %. LPS (40 µg/ml) alone increased the number of OX-42 cells to around 26 ± 2 cells/ 8 mm2. 
SAHA also tended to prevent the increase in the number of LPS-induced OX-42-positive cells, 
however, this difference was not statistically significant. 
 
VPA and LPS treatments 
Control VM cultures had 9 ± 1 OX-42-positive cells per 8 mm2 (Figure 4-12B). VPA (0.3 - 1.2 mM) 
alone significantly increased the number of OX-42-positive cells in a concentration dependent 
manner. As expected, treatment with LPS (40 µg/ml) alone significantly increased the number of 
active OX-42-positive cells to 28 ± 2 cells per 8 mm2 compared to the control. A similar effect 
was observed for the LPS treated cultures, where significant decreases by 29, 36 and 39 % were 










- 121 - 
 Figure 4-12 The effect of SAHA and VPA on the number of OX-42-positive cells following MPP+ 
and LPS treatment.  
VM cultures (DIV7) were treated with (A & B) MPP+ (3 µM) and LPS (40 µg/ml) in the presence 
and absence of (A) SAHA (0.01, 0.1 and 1 µM) or (B) VPA (0.3, 0.6 and 1.2 mM). Cell loss was 
assessed by immunoperoxidase staining for OX-42. Data are the number of OX-42 positive cells 
per 8 mm2 and are expressed as mean ± SEM (n=3). *p<0.05, **p<0.01 compared to untreated 
control cells; #p<0.05, ##p<0.01 compared to MPP+ alone; +p<0.05, ++p<0.01 compared to LPS 
alone. Analysis by one-way ANOVA with Newman Keul’s post hoc test. 
 
 
The OX-42 immunoreactive cells were active taking an amoeboid morphology (Figure 4-13A-C). 
Approximately 2 % of partially active OX-42-positive cells were observed in the SAHA and VPA 
only treated conditions in the presence and absence of both MPP+ and LPS (Figure 4-13D, G, F & 
I). In this state, the cells were more ramified and phagocytic, and processes were beginning to 
extend from the amoeboid cell body.  Less than 1 % of OX-42 cells in the resting state were 
A 
B 
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Figure 4-13 Immunofluorescence staining of OX-42 positive cells in VM cultures following 
HDAC and toxin treatment.  
VM cell cultures showing OX-42 immunoreactivity in (A) untreated cells, and cells treated with: 
(B) MPP+ (3 µM), (C) LPS (40 µg/ml), (D) SAHA (1.0 µM), (E) SAHA (1.0 µM) and MPP+ (3 µM), (F) 
SAHA (1.0 µM) and LPS (40 µg/ml), (G) VPA (1.2 mM), (H) VPA (1.2 mM) and MPP+ (3µM), (I) VPA 
(1.2 mM) and LPS (40 µg/ml). Cells were counterstained with cresyl violet (violet). Stages of 
microglial activation indicated with arrows: fully active state (solid arrow), partially active state 
(broken arrow), and resting state (arrow head). Scale bar = 200 µm. Photographs are typical of 
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4.4 Discussion 
This study investigated the role of HDAC-Is in cell death induced by MPP+ and LPS in VM cell 
cultures. It was hypothesised that HDAC inhibition would protect dopaminergic neurones from 
the biochemical and pathological changes linked to cell death in the SN induced by MPP+ and LPS 
by reducing the number of inflammatory cells. In particular, this study aimed to: 1. characterise 
the dopaminergic and HDAC phenotype of the VM cell cultures. 2. determine the dopaminergic 
cell loss following MPP+ and LPS-induced toxicity. 3. assess the role of HDAC inhibition on MPP+ 
and LPS-induced loss of dopaminergic neurones, and 4. evaluate the effects of HDAC inhibition 
on the inflammatory changes induced by MPP+ and LPS treatment. 
 
4.4.1 Characterisation of VM cultures 
The VM cultures (DIV7) showed positive immunolabelling for TH, GFAP and GAD confirming a 
mixed population of cells. The cultures were comprised of approximately 5 % dopaminergic cells, 
55 % GABAergic cells, 8 % astrocytes and 0.2 % microglia. These results are in agreement with 
previous reports of 2-5 % TH, 48 % GAD, 2-17 % GFAP, and 0-0.1 % OX-42 immunopositive cells 
(Takeshima et al., 1994a; Cheung et al., 1997; Pardo et al., 1997; Gilbert et al., 2003; Qian et al., 
2006). ED-1 positive macrophages are also present in VM cultures (Ailane, 2011, personal 
communication), although this was not measured in this study. The characterisation of the 
remaining cell types were not determined in this study and is likely to be accounted for by other 
neuronal cells such as serotonergic, glutamatergic, cholinergic cells and cells that have not 
completely differentiated into dopaminergic neurones (Zurn & Werren, 1994; Spencer et al., 
1995; Rayport, 2001; Ducray et al., 2006). The data however confirms the presence of other cell 
populations other than dopaminergic neurones in primary VM cultures, and importantly allows 
an interaction between cell types, particularly inflammatory cells and neurones to be closely 
investigated. 
 
In order to establish whether HDAC-Is could have an effect on dopaminergic neurones, the 
expression and localisation of HDAC3, 4, 5, and 11 were determined in VM primary cultures. 
Double immunofluorescence staining showed that the four investigated HDACs are expressed in 
the mesencephalic cultures, and this study is the first to describe their localisation in 
dopaminergic neurones, although previous studies by Broide et al. (2007) showed their co-
localisation of HDACs in neurones (anti-NeuN antibody) by double labelling, and Janssen et al. 
(2010) reported HDAC localisation in motor neurones (Broide et al., 2007; Janssen et al., 2010).  
 
Importantly this study also showed that astrocytes and glial cells express HDACs. This is in 
agreement with Faraco et al. (2009) who showed that HDAC transcripts and activity are present 
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in mouse glial cultures, and that inhibition of HDAC with ITF2357 (SAHA structural analogue) 
increased acetylation levels in cultured astrocytes and microglia in vitro (Faraco et al., 2009). The 
localisation of HDACs among these cell types, and the findings reported in this study are 
consistent with the widespread distribution of this enzyme family and specific HDAC expression 
in the brain (MacDonald & Roskams, 2008; Liu et al., 2008; Shen et al., 2008). The presence of 
HDACs suggests a role in cellular biological processes and provides a target for HDAC-Is. 
 
4.4.2 Effect of HDAC-Is on MPP+ and LPS-induced toxicity on dopaminergic neurones 
As detailed in the previous chapter, MPP+ causes dopaminergic toxicity by directly inhibiting 
mitochondrial complex I. LPS, on the other hand, does not exert its neurotoxicity directly on 
dopaminergic neurones, but through activation of microglia and astrocytes to release a variety 
of pro-inflammatory cytokines, such as TNF-α, IL-1α, IL-1β  and IL-6 (Castano et al., 1998; Le et 
al., 2001). 
 
As expected, increasing concentrations of MPP+ caused a concentration-dependent decrease in 
the number of viable TH positive cells with an EC50 = 3 µM. This concentration is comparable to 
the range used in previous studies (1 – 10 µM) (Otto & Unsicker, 1993; Dodel et al., 1998; Chung 
et al., 2005; Jakobsen et al., 2005). Similarly, LPS induced a concentration-dependent loss of 
dopaminergic cell with an EC50 of 40 µg/ml. This is in agreement with previously used LPS 
concentration in ranges of 30 – 80 µg/ml (Bronstein et al., 1995; MCNaught & Jenner, 1999; 
Iczkiewicz et al., 2010). 
 
Pre-treatment with SAHA (0.01 – 1 µM) and VPA (0.3 – 1.2 mM) proved to be toxic to 
dopaminergic neurones by reducing the number of viable cells following treatment alone and in 
conjunction with MPP+ and LPS at all concentrations tested. This supports the finding in the cell 
lines described in Chapter 3, but is contrary to previous work by Chen et al. (2006) and Wu et al. 
(2008), who both showed that HDAC-Is VPA, TSA and sodium butyrate protected dopaminergic 
neurones from MPP+ and LPS-induced toxicity in neurone-glia cultures (Chen et al., 2006; Wu et 
al., 2008). This protective effect was also recently confirmed with SAHA by Chen and colleagues 
(Chen et al., 2012). All three groups showed this protection to be dependent on the ability of the 
HDAC-Is to up-regulate the expression of neurotrophic factors GDNF and BDNF from astrocytes.  
 
The toxicity of HDAC-Is, as exhibited in the cell lines (Chapter 3), has to be considered as a 
contributing factor to the neuronal cell loss. HDAC-Is have inherent toxicity and their prolonged 
treatment at high doses induces neuronal death, which compromises their neuroprotective 
effect in dopaminergic neurones (Jeong et al., 2003). VPA, in particular, can exacerbate neuronal 
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death in  primary cultures of cerebellar granule neurones (Jin et al., 2005), similar to the effect 
observed in cell lines. This HDAC-I-induced toxicity may be partly due to the activation of 
transcription factor E2F1 by HDAC inhibition, which plays a part in pro-apoptotic signalling in 
these neurones and over-expression of this protein induces neuronal apoptosis (Boutillier et al., 
2002; Boutillier et al., 2003). This finding makes it less surprising as HDAC-I alone treated cells 
were observed to look damaged, which was depicted by the disintegrated cell processes, as well 
as the loss of dopaminergic neurones. 
 
Regardless of the above findings, other contributing factors to the neuronal cell loss are the 
presence of growth factors and medium composition. Growth factors produced by neurones and 
neurotrophic factors from astrocytes are known to play an important role in the development 
and survival of neurones in culture (Engele & Bohn, 1991; Walsh et al., 1992; Takeshima et al., 
1994b; Young et al., 2000). The cell density used in the present study (2 x 105) compared to 
densities in the previously mentioned studies (5 x 105) might result in the medium being 
enriched with growth factors in the latter. This would therefore have a positive effect on 
promoting neuronal survival (Peng et al., 2005; Chen et al., 2006; Wu et al., 2008). 
 
The HDAC-I administration in this study were performed in serum-free medium. This has been 
previously demonstrated to be toxic to cells (Takeshima et al., 1994a; Bar-Am et al., 2005) and 
confirmed by studies on cell lines as described in Chapter 3. This toxicity of serum-free medium 
was however not observed in characterisation studies and did not have an effect on the number 
of TH-positive cell numbers (Brzozowski, 2010, personal communication). However, it cannot be 
disputed that the absence of serum would make the cells more vulnerable to HDAC-I and/ or 
toxin treatment. HDAC-I and toxin challenges were chosen to be performed under serum-free 
conditions to ensure the protective effects of TH-positive cells was due to the HDAC-Is 
themselves and not the serum, as it contains cell survival promoters, such as fibronectin - the 
main cell attachment promoting protein in serum which encourages cell survival and growth 
(Hayman et al., 1985; Takeshima et al., 1994a).  
 
Glial cell proliferation has been reported to be suppressed in serum-free mesencephalic cultures 
(Takeshima et al., 1994a), but this study only looked at the effects of serum-deprivation from 
day 1 of seeding the cells. In the present study, cell suspensions were seeded and promoted to 
grow in serum-containing medium for 7 days prior to serum deprivation for 26 hours. Cell 
maturation, neurite elongation and complexity is complete at DIV5 and maintained till DIV10 
(Shimoda et al., 1992), thus indicating that at DIV7, the cells are in the mature phase. As 26 
hours is a short period of time, it can be assumed that serum-deprivation would have no 
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significant effect on the levels of growth factors in medium and on the neuronal survival 
(Brzozowski, 2010, personal communication). This hypothesis will however have to be tested in 
the future for confirmation and clarification. 
 
It is possible that the loss of TH-positive cells is due to the HDAC-Is affecting gene expression and 
in turn down-regulating TH expression. Indeed, experiments with HDAC-Is sodium butyrate and 
Trichostatin A reduced the mRNA levels of TH in PC12 cell lines (Aranyi et al., 2007). This theory 
is probable as the number of TH-positive cells counted in the HDAC-I alone treatments is similar 
to the number of cells accounted for in the HDAC-I and toxin concomitant treatments. But as 
mRNA levels of TH were not measured in this study, further experiments will need to be 
undertaken to confirm this hypothesis. 
 
Even though many factors mentioned above may have contributed to the loss of TH-positive 
cells, the evidence still shows that similar to cell lines, these HDAC-Is are also toxic to 
dopaminergic neurones and exacerbate the toxicity of MPP+ and LPS. 
 
4.4.3 Effect of HDAC-Is on MPP+ and LPS-induced toxicity on inflammatory changes 
This study hypothesised that HDAC-Is would modulate inflammatory processes. As expected, this 
study showed a significant increase in the number of astrocytes and microglia following MPP+ 
and LPS treatment indicated by the increase in GFAP and OX-42 positive cells, signifying the 
induction of an inflammatory response in the cultures. This proliferation of astrocytes and 
microglia has been attributed to the secretion of a variety of pro-inflammatory and neurotoxic 
factors, including IL-1β, TNF-α, NO and ROS in mesencephalic cultures (Liu et al., 2000; Gayle et 
al., 2002; Qin et al., 2002; Sofroniew, 2009). This suggests that the increase in glial cells is a 
result of cell death, but in turn become responsible for cell death. In other words, on the onset 
of neuronal damage, toxic compounds are released by the neurones and these are scavenged by 
glial cells to protect neighbouring neurones (Rosenberg, 1991; Aloisi, 2001). But the activation of 
the glial cells is associated with production and secretion of neurotoxic factors which in turn 
result in further neuronal damage. 
 
Pre-treatment of VM cultures with SAHA (0.01 – 1 µM) and VPA (0.3 – 1.2 mM) alone initiated a 
glial reaction in astrocytes and microglia. This increase in astrocytes and microglia is 
understandable, as HDAC-Is alone have been shown to be toxic to TH-positive cells, so their 
incorporation to cultures would induce an activation of inflammatory cells to exert their defence 
mechanisms. Interestingly, this was not observed by Peng et al. (2005) and Chen et al. (2007) 
who both showed that HDAC-I’s VPA, SB and TSA alone did not induce an inflammatory response 
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in their mesencephalic cultures, although this may reflect the differences in plating densities and 
medium composition to promote cell survival as discussed above. The two groups plated their 
cells at higher densities than that of this study, and also used serum-containing medium. Both 
factors have been explained to promote cell survival. 
 
Importantly, this present study observed concomitant treatment of cultures with SAHA or VPA 
with MPP+ or LPS significantly reduce the numbers of GFAP and OX-42 positive cells to levels 
similar to that of HDAC-I alone treatments. This is in agreement with Peng et al. (2005) and Chen 
et al. (2007), who also showed that VPA pre-treatment suppressed LPS-induced activation of 
microglia accompanied by a reduced release of pro-inflammatory factor TNF-α, decreased nitrite 
accumulation indicative of reduced NO production, and reduced ROS production.  
 
Even though the levels of pro-inflammatory factors were not measured in this study, it is 
proposed that the suppression of microglia may be due to the HDAC-Is inhibiting the 
transcription of the pro-inflammatory factors and in turn resulting in a reduced number of 
inflammatory cells. This effect was shown by Faraco et al. (2009), who observed a reduction in 
transcript levels of pro-inflammatory factors iNOS, COX-2 and IL-1β; and a concentration-
dependent reduction in TNF-α release following concomitant treatment with HDAC-Is SAHA and 
ITF2357 and LPS in primary mixed cultures of astrocytes and microglia (Faraco et al., 2009).  
 
Chen and colleagues (2007) suggested that the mechanism by which HDAC-Is reduced the 
inflammatory process may be due to apoptosis of microglia. This was demonstrated by typical 
hallmarks such as phosphatidylserine externalisation, internucleosomal DNA fragmentation and 
chromatin condensation. This theory is far from convincing because if the HDAC-Is were in actual 
fact inducing the apoptotic process, then one would expect little or no glial cells, in the HDAC-I 
alone treatments too, however the opposite was true. This confirms the most likely reason for 
the decrease in inflammatory cells to be due to inhibition of the transcription of pro-
inflammatory factors.  
 
4.4.4 Conclusion 
In conclusion, this study confirms the toxicity of MPP+ and LPS in VM cell culture, and shows the 
localisation of HDAC isoforms in dopaminergic neurones for the first time, as well as confirming 
their localisation in inflammatory cells. Similar to the previous chapter, the HDAC-Is did not 
protect dopaminergic neurones against MPP+- and LPS-induced neurotoxicity, and proved to be 
toxic to the neurones when they were treated alone. Pre-treatment with SAHA and VPA, on the 
other hand had an impact on inflammation by reducing the number of astrocytes and microglial 
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cells following toxin treatment. In spite of the reduction in the number of inflammatory cells, the 
change in glia did not influence the loss of TH and resulted in decreases in the number TH-
positive cells. The reason for this is unknown and was unfortunately not conclusive in the 
present study. These findings do however suggest an anti-inflammatory role for HDAC-Is. 
 
In light of the contradictory results shown in the primary culture, which may relate to the 
expression of trophic factors, is dependent on the methodology used. These data do not 
preclude a protective effect of HDAC-Is in vivo. The HDAC-Is were toxic in both cell lines and 
primary culture and resulted in an increase in the loss of TH-positive cell loss. The only exception 
was the decrease in inflammatory cells. It is therefore necessary to confirm these present 
findings in an in vivo model of PD, as it possesses physiologically relevant systems to aid in 
assessing the effects of SAHA and VPA in a living organism. It has also been suggested that a 
decrease in inflammation, as observed in primary cultures, protect dopaminergic neurones in 
vivo. This may be dependent on the cell composition. Therefore an in vivo study will be 


































Chapter 5 The effect of HDAC-Is in preventing pathological changes in 6-
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5.1 Introduction 
It was originally hypothesised that inhibition of HDAC would protect dopaminergic cells from 
toxin-mediated cell death in PD. However, when testing this hypothesis, it was found that 
treatment of neuroblastoma cell lines with the HDAC-Is, VPA and SAHA, was in fact toxic to the 
cells. Indeed, the HDAC-Is enhanced cell death following exposure to H2O2 and MPP
+. It was 
proposed that this was due to the mono-cellular composition of the cell lines, and it was 
hypothesised that other cell types, in particular glia, would enable the HDAC-Is to exert a 
protective effect. However, this hypothesis was rejected in Chapter 4 as HDAC inhibition did not 
protect dopaminergic neurones from MPP+- and LPS-induced cell death in rat E14 VM primary 
cultures where glial cells are present and have been shown to contribute to cell death. This 
finding contradicted the results of previous studies which reported that HDAC inhibition 
protected dopaminergic neurones against MPP+- and LPS-induced cell death (Chen et al., 2006; 
Wu et al., 2008; Chen et al., 2012), but this was assumed to be due to differences in protocols. 
However, the study in VM culture was not entirely negative as concomitant treatment of VM 
cultures with the HDAC-Is and MPP+ or LPS prevented the expected increase in astrocytes and 
microglia compared to the toxin treatment alone. The interpretation of this finding is difficult to 
assess, however, HDAC-Is have previously been associated with anti-inflammatory activity in 
models of rheumatoid arthritis (Grabiec et al., 2008), traumatic brain injury (Zhang et al., 2008) 
and multiple sclerosis (Gray & Dangond, 2006); and this might explain the reduction in glial cell 
number observed.  
 
Even though pro-inflammatory factors such as TNF-α and NO were not measured in the study, 
the possibility remains that HDAC-Is might protect dopaminergic neurones through an anti-
inflammatory mechanism in a more complex physiological environment such as occurs in vivo in 
the mature rodent brain. So far there has been very little in vivo investigation of the protective 
effects of HDAC-Is, however, importantly, in the MPTP-treated mouse, HDAC-I phenylbutyrate 
attenuated the depletion of striatal dopamine content and protected nigral dopaminergic 
neurones (Gardian et al., 2004). Although it was not determined whether this was mediated via 
an effect on gliosis. For this reason, the studies reported in this Chapter investigated the effects 
of the HDAC-Is, VPA and SAHA on dopaminergic neuronal survival and gliosis in the SN following 
unilateral lesioning using 6-OHDA and LPS in mice. In particular, this study addressed the 
potential mechanism through which the HDAC inhibitors might potentially exert a protective 
effect. 
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5.1.1 Hypothesis 
It was hypothesised that inhibition of HDACs protect against 6-OHDA and LPS-induced 
degeneration of dopaminergic neurones in the mouse nigrostriatal pathway in vivo through a 
reduction in glial cell activation and recruitment. 
 
5.1.2 Aims 
To test this hypothesis, this study was devised to investigate the effect of SAHA and VPA on cell 
death and inflammatory cells induced by partial 6-OHDA- and LPS-lesions of the nigrostriatal 
pathway in mice. Specifically, the aims were to: 
1. Determine the localisation of HDACs within dopaminergic and inflammatory cells in the 
SN of mouse brain. 
2. Establish whether VPA and SAHA can cross the blood brain barrier and induce 
hyperacetylation. 
3. Examine whether SAHA and VPA can protect against 6-OHDA- and LPS-induced 
dopaminergic cell loss in mouse SN. 
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5.2 Materials and Methods 
Mouse brain sections were initially double-labelled to determine the presence of HDACs within 
dopaminergic and inflammatory cells (Section 5.2.2). Following that, HDAC activity in the mouse 
brain and penetration of the HDAC-Is, VPA and SAHA, across the blood brain barrier were 
investigated by HDAC assay (Section 5.2.3.4) and Western blotting (Section 5.2.3.6), on nuclear 
and histone extracts, respectively. Once these were established, mice were treated daily with 
HDAC-Is, VPA and SAHA, for 10 days following intrastriatal 6-OHDA and LPS lesions. On 
completion of drug administration, the mice were culled and their brain tissue was processed for 
immunoperoxidase staining, where the effects of VPA and SAHA on dopaminergic and 
inflammatory cells were investigated. Detailed methodologies are described below. 
 
5.2.1 Animal husbandry  
Male C57BL/6J mice (Harlan, Bicester, UK), weighing 25-30 g, were singly housed in a 
temperature controlled room of 23oC (King’s College London Biological Services Unit) with a 12 
hour light-dark cycle and unlimited access to pelleted food and water. All experimental 
procedures were carried out in accordance with the Animals (Scientific Procedures) Act 1986 
under the UK Home Office license number 70/6898. 
 
5.2.2 Double immunoflourescence 
Mouse brains were perfused with 0.1 M PBS, pH 7.4 and post-fixed in PFA (4 %) in 0.1 M PBS for 
7 days at 4oC. This was followed by storage in cryoprotective solution composed 0.1 M PB 
containing sucrose (30 %) and sodium azide (0.05 %) also at 4oC as described in Section 2.3.1. 
The brains were cut into coronal sections (30 m) at the l         
Section 2.6.4. Double immunofluorescence staining was used to determine the co-expression of 
TH, GFAP and OX-42 with HDAC3, 4, 5 and 11 as described in Section 2.6.5. Briefly, brain sections 
were blocked with 1 % goat and donkey serum for 30 minutes at room temperature followed by 
overnight incubation in primary antibodies TH (1:200), GFAP (1:200), OX-42 (1:50) and HDAC 3 
(1:500), HDAC 4 (1:500), HDAC 5 (1:200) and HDAC 11 (1:500) (Table 2-2), at 4oC. On the next 
day, the sections were incubated with Alexa Fluor 488 (green) and Alexa Flour 594 (red) 
secondary antibodies (both 1:500) (Table 2-3) for 90 minutes in the dark. The sections were 
rinsed in 0.1 M PBS and mounted with Vectashield® Hard Set mounting medium for 
fluorescence as described in Section 2.6.5. 
 
5.2.3 Biochemical techniques 
To determine whether HDAC-Is penetrate the blood-brain barrier, mice were dosed with VPA 
(200 and 400 mg/kg; i.p) and SAHA (100 mg/kg; s.c). Post-injection, tissue was collected as 
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described in Section 5.2.3.2, and histone and nuclear extracts were collected for HDAC assay to 
determine HDAC activity, and Western blotting to determine levels of acetylated histones. 
 
5.2.3.1 HDAC-I preparation 
The HDAC-I, VPA (200 and 400 mg/kg) was freshly prepared as free base in 0.9 % saline on the 
day of the procedure. SAHA (100 mg/kg) was freshly dissolved in 5M HOP-β-CD. 
 
5.2.3.2 Tissue preparation 
Male mice were treated with single injection of VPA (200 and 400 mg/kg) or its vehicle (0.9 % 
saline; 10 ml/kg) intraperitoneally (i.p); or SAHA in HOP-β-CD (100 mg/kg) or its vehicle (5M 
HOP-β-CD; 5 ml/kg) subcutaneously (s.c). Two hours later, the animals were killed by 
decapitation using a guillotine. The brain was removed from the skull and dissected midsagitally, 
flash-frozen in liquid nitrogen and stored at -70oC until needed for nuclear or histone extraction. 
 
5.2.3.3 Nuclear extraction of brain tissue homogenates for HDAC assay 
Nuclear extraction was performed using a nuclear extraction kit according to the manufacturer’s 
instructions (Cayman Chemical supplied by Cambridge Bioscience Ltd, Cambridge). In summary, 
brain tissue was weighed, cut into small pieces, collected into an eppendorf and kept on ice. 
Tissue was homogenised in ice-cold hypotonic buffer supplemented with Dithiothreitol (DTT; 10 
mM) and Nonidet P-40 (NP-40; 10 %) in a 1:4 w/v ratio, and incubated on ice for 15 minutes. The 
homogenate was centrifuged at 300 g for 10 minutes at 4oC, and the supernatant was 
transferred into a pre-chilled eppendorf.  The pellet was resuspended in hypotonic buffer (500 
µl) and incubated on ice for 15 minutes. Subsequently NP-40 (10 %; 50 µl) was added to the 
homogenised pellet, centrifuged at 14,000 g for 30 seconds in a microcentrifuge. The two 
supernatants, containing the cytoplasmic fraction, were combined, aliquoted (100 µl) and stored 
at -70oC. 
 
The pellet was resuspended in ice-cold extraction buffer (50 µl) supplemented with protease and 
phosphatase inhibitors (Nuclear Extraction Kit, Cayman Chemical supplied by Cambridge 
Bioscience Ltd, Cambridge). The suspension was vortexed for 30 seconds at the highest setting 
and placed on ice for 10 minutes. The vortex and incubation on ice was repeated 5 more times 
to make a total of 6 cycles. After the last cycle, it was centrifuged at 14,000 g (Biofuge Fresco, 
Heraeus) for 10 minutes at 4oC. The supernatant, containing the nuclear fraction was aliquoted 
into clean chilled eppendorfs, flash frozen in liquid nitrogen and stored at -70oC until needed for 
HDAC assay (Section 5.2.3.4). 
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5.2.3.4 HDAC assay 
The HDAC assay entails incubating an acetylated lysine substrate with samples containing HDAC 
protein. Deacetylation of the substrate releases a fluorescent product which is measured. The 
assay was performed in a black clear bottom 96 well microplate, and each sample and control 
was run in duplicate. Isolated nuclear extracts (10 µl) (Section 5.2.3.3) was added to assay buffer 
(140 µl; 25 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2 ). This was followed by 
the HDAC inhibitor Trichostatin A (positive control) (TSA; 10 µl; 21 µM) supplied in kit, SAHA EC50 
concentration (10 µl, 20 µM) and VPA EC50 concentration (10 µl; 60 µM), HOP-β-CD (10 µl; 5M), 
saline (10 µl) or assay buffer (10 µl) to vehicle. SAHA and VPA EC50 concentrations were obtained 
from concentration-response assays in Figure 5-1 using this protocol. The reaction was initiated 
with HDAC substrate Boc-Lys(Ac)-7-Amino-4-Methylcoumarin (MP Biomedicals, Cambridge, UK) 
(10 µl, final concentration 200 µM). The plate was covered and incubated in an orbital shaker 
(Aerotron, Bottmingen, Switzerland) for 30 minutes at 37oC. Subsequently, HDAC developer (40 
µl) (Cambridge Bioscience, Cambridge, UK) was added to each well and incubated at room 
temperature for 15 minutes, to release the fluorescent product. Fluorescence was measured by 
spectrophotometer (Spectramax Gemini XS), and the fluorophore was analysed using an 
excitation wavelength of 350 nm and an emission wavelength of 455 nm (Figure 5-1). 
 
   
Figure 5-1 EC50 of VPA and SAHA following HDAC assay. 
Nuclear extracts from brain tissue homogenates were treated with (A) SAHA (10-3 – 10-8 M) and 
(B) VPA (10-3 – 10-8 M). HDAC activity was assessed by HDAC assay. Non-linear regression curve 
was fitted to calculate EC50. Data are expressed as mean + SEM (n=3); *p<0.05, **p<0.01 
compared to control cells (one-way ANOVA followed by Newman-Keuls test). 
 
 
5.2.3.5 Histone extraction for western blotting  
Brain tissue was homogenised (1:4 w/v) in cold buffer followed by centrifugation (Biofuge 
Fresco, Heraeus) at 800 g for 10 minutes at 4oC. The supernatant, containing the cytosolic 
fraction was discarded and the pelleted nuclei were resuspended in 0.2 M sulphuric acid (H2SO4) 
(500 µl) prior to 30 minutes incubation on ice. Centrifugation was repeated at 14000 g for 10 
minutes at 4oC. The supernatant was collected and transferred into a fresh eppendorf and 
A B 
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proteins were precipitated on ice with precipitation buffer (250 µl). After 30 minutes incubation, 
the supernatant was centrifuged at 14000 g for 10 minutes at 4oC, and the protein pellet was 
washed by centrifugation at 14000 g for 5 minutes each with ice-cold acetone supplemented 
with HCl (0.1 %), followed by ice-cold acetone. The protein precipitates were collected between 
washes, and the resulting purified proteins were resuspended in Tris-HCl (10 mM; pH 8.0), and 
stored at -80oC. 
 
Table 5-1 Buffers used for histone extraction. 
Buffer Components Source 
Lysis Buffer 10 mM  Tris-HCl, pH 6.5 
50 mM Sodium bisulfite 
1 % Triton-X-100 
10 mM MgCl2 
8.6 % Sucrose 
BDH, VWR International, Lutterworth, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
Homogenising 
Buffer 
10 mM Tris-HCl 
5 mM Sodium fluoride (NaF)   
1 mM sodium orthovanadate 
(Na3VO4)                                      
1 mM ethylenediamine 
tetraacetic acid (EDTA)                                 
1 mM ethylene glycol 
tetraacetic acid (EGTA)         
320 mM sucrose 
BDH, VWR International, Lutterworth, UK 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
 
Sigma-Aldrich, Dorset, UK 
 
Sigma-Aldrich, Dorset, UK 
 
Sigma-Aldrich, Dorset, UK 
Precipitation 
Buffer 
100% trichloroacetic acid 
4 mg/ml deoxycholic acid 
Sigma-Aldrich, Dorset, UK 
Sigma-Aldrich, Dorset, UK 
 
 
5.2.3.6 Western blotting for histone acetylation 
Western blot technique was used to detect the levels of histone H4 acetylation following HDAC-I 
treatment. The technique is described in detail in Section 2.4. Histone extracts prepared as 
described in Section 5.2.3.5, were resolved onto a SDS-PAGE gel (8-10 %) and transferred onto a 
PVDF membrane. The membrane was blocked with 5 % milk in TBS-T for 1 hour, and incubated 
with primary antibodies against Histone H4 (1:2000) overnight at 4oC. After incubation with anti-
rabbit IgG-horseradish peroxidise (HRP)-conjugated secondary antibody (1:2000) for 1 hour, 
bands were visualised by the enhanced chemiluminescence system detailed in Section 2.4.4.  
 
- 136 - 
5.2.4 The HDAC-I preparation for neuroprotection study 
5.2.4.1 VPA preparation 
The HDAC-I, VPA (200 and 400 mg/kg) was freshly prepared as described in Section 5.2.3.1. 
 
5.2.4.2 SAHA preparation 
SAHA was administered in drinking water and prepared as previously described  (Hockly et al., 
2003). To achieve this, SAHA was complexed in 5 molar equivalents of 2-hydroxypropyl-β-
cyclodextrin (HOP-β-CD) in filtered, irradiated water at SAHA concentration of 0.67 g/l which 
resulted in an estimated dose of 160 mg/kg/day.  
 
In order to solubilise the compound, the mixture was brought to a boil and kept boiling for two 
minutes before being cooled slowly to room temperature. The resultant solution was colourless.  
 
The mice were housed individually and the drinking water containing SAHA was changed every 3 
days. The stability of SAHA was confirmed by personal communication with Professor Gillian 
Bates (2011). Preliminary studies measuring the volumes of water, HOP-β-CD and SAHA 
consumed by the mice showed there was no difference between the volumes of water 
consumed. On average, 5.6 - 6 mls of liquid was drunk each day by a 25g mouse (Figure 5-2). 
 
 
Figure 5-2 Volumes of water, HOP-β-CD and SAHA consumed by C57BL/6J in 24 hours.  
Liquid intake of water, HOP-β-CD and SAHA of 25-30g mice were measured over 3 days. Data are 
mean ± SEM (n=3). Data was analysed by one way ANOVA.      
 
 
5.2.5 6-Hydroxydopamine and LPS-induced destruction of the nigrostriatal pathway  
5.2.5.1 6-Hydroxydopamine preparation 
The dose of 6-OHDA-hydrochloride (7.5 µg in 4 µl; Sigma-Aldrich, Dorset, UK) was calculated as a 
free base and dissolved in 0.9 % saline containing 0.05 % L-ascorbic acid on ice on the day of 
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surgery. Aliquots (200 µl) were protected from light exposure and stored on ice until the surgical 
procedure. 
 
5.2.5.2 Lipopolysaccharide preparation 
Purchased Lipopolysaccharide, E. coli O55: B5 (Merck Chemicals Ltd, Nottingham, UK) was 
reconstituted in 0.9 % saline following manufacturer’s instructions and stored at 4oC. On the day 
of surgery, the stock was diluted to 7.5 µg/4 µl, aliquoted (200 µl), wrapped in foil to protect 
from light exposure, and stored on ice until the surgical procedure. 
 
5.2.5.3 Intrastriatal administration of 6-OHDA and LPS 
On the day of surgery, mice were anaesthetised with isofluorane (4 % in medical oxygen) in a 
chamber for 2 – 3 minutes then placed securely into a Kopf stereotaxic frame, with the ear bars 
positioned symmetrically, where the isofluorane was maintained at 1 – 2 % in medical oxygen. 
The temperature was maintained at 37oC during the entire procedure using a homeothermic 
blanket. The mice head was shaved with excess hair cleaned first with isopropyl alcohol swabs 
and anaesthetised with 5 % EMLATM cream. An incision was made to expose the skull between 
the ears using a disposable scalpel. Scull was cleaned using a cotton bud, and hole was drilled 
above the site of injection using a sterilised hand drill (co-ordinates according to the mouse brain 
atlas of Paxinos and Watson (2004): Anterior = -0.02 mm, Lateral = +2.0 mm, and Ventral= -3.0 
mm) (Figure 5-3). Toxin injection was performed using a 10 µl 70IRN Hamilton microsyringe 
fitted with a 26s gauge Hamilton needle (Essex scientific laboratory supplies ltd, Essex, UK). 6-
OHDA and LPS (both 4 µl) or vehicle (sham, 4 µl; 0.9 % saline containing 0.05 % L-ascorbic acid; 
or 4 µl 0.9 % saline) were injected into the left striatum, at a flow rate of 1 µl per minute. The 
needle was left in the brain for an additional 4 minutes after administration and slowly 
withdrawn over a 4 minute period. All mice received a glucose saline solution (1 ml i.p. of 5 % 
glucose/ 0.9 % sodium chloride) to prevent dehydration. The skull was cleaned with isopropyl 
alcohol and the skin was sutured using 16 mm Ethicon-coated vicryl absorbable sutures 
(Johnson’s & Johnson’s, UK). The wound was treated with a few drops of Marcain Polyamp 
steripack (0.25 % bupivacaine hydrochloride; Astrazeneca UK Ltd) and the mice were allowed to 
recover in a warming chamber (Scanbur Technology, Denmark) before returning to their home 
cages. A bead steriliser (Steril-quartz, Satelec, Italy) was used to sterilise instruments in between 
procedures. Post surgery, the mice received mash (RM1 powder form; Special Diets Services, UK) 
daily until normal eating behaviour was observed. Body weight was also monitored daily until 
the mice had regained their original weight. 
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Figure 5-3 Site of 6-OHDA and LPS injection into the left striatum of mice.  
6-OHDA and LPS were injected into the left striatum of mice at co-ordinates: A= -0.02 mm, L= 
+2.0 mm and V= -3.0 mm (Adapted from Paxinos and Watson, 2004). (X) depicts the site of 
injection in the striatum (Str). 
 
 
5.2.6 Neuroprotection Study 
Male C57BL/6J (n=8 per group; 25 -30 g) were treated with VPA and SAHA 2 days prior to 6-
OHDA or LPS lesion and for ten days after surgery.  VPA (200 and 400 mg/kg) and vehicle (1 
ml/kg 0.9 % saline) were injected intraperitoneally (i.p), while SAHA (160 mg/kg/day) and vehicle 
(5 M HOP-β-CD) were administered in drinking water. The weights of all the mice were recorded 
daily. Twenty-four hours after last HDAC-I pre-treatment, the mice were lesioned with 6-OHDA 
(7.5 µg/ 4 µl) and LPS (7.5 µg/ 4 µl) or sham lesioned (vehicle) as described in Section 5.2.5. A 
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Figure 5-4 Overview of experimental timeline.  
Mice were treated daily with VPA (200 and 400 mg /kg, i.p.) and SAHA (160 mg/kg/day, in 
drinking water) or vehicle for 10 days. Intrastriatal 6-OHDA and LPS-lesions (both 7.5 µg / 4 µl) or 
sham-lesions (vehicle) were performed 24 hours after the first drug administration. Following a 
24 hour wash-out period, the mice were culled. 
 
After 10 days of HDAC-I administration, treatment was withdrawn for 24 hours and mice were 
culled by transcardial perfusion with saline under general anaesthesia and the brains were 
dissected (Section 2.3.1) and processed for immunohistochemistry (Section 5.2.7). 
 
5.2.7 Immunoperoxidase staining 
Brains were cut into coronal sections at the level of the third nerve as described in Section 2.6.4, 
and assessed for immunoreactivity of TH, GFAP and OX-42 in the SN by immunoperoxidase 
staining, as described in detail in Section 2.6.6.2. In summary, the mouse sections (30 µm) were 
incubated in 24-well plates with primary antibodies against TH (1:500), GFAP (1:500) and OX-42 
(1:100) (Table 2-2) overnight at room temperature. On the subsequent day, the sections were 
incubated with biotinylated secondary antibody (1:200) (Table 2-3) for 1 hour and further 45 
minute incubation with the ABC kit at room temperature. The staining was visualised by 
exposing the sections to DAB (0.05 %; 500 µl) for 1 minute and the reaction was initiated on the 
addition of H2O2 (30 %; 1 µl). The sections were then mounted onto poly-D-lysine coated 
microscope slides, dehydrated, cover slipped and examined as described in Section 2.6.6.2. 
 
5.2.8 Data analysis 
Positive stained TH and OX-42 cells in the SN were counted bilaterally in three sections per 
mouse at X20 and X40 magnification respectively as detailed in Section 2.6.8. GFAP-positive 
staining in the SN was determined by measuring the optical density (OD) using Image J software 
(Schneider et al., 2012). 
 
5.2.9 Statistical analysis 
Data are expressed as means ± SEM of experimental groups (n=4 – 8). GraphPad Prism software 
was used for statistical analysis. Difference between control and treatment groups was analysed 
with two-way or one-way ANOVA followed by Newman Keul’s test where appropriate. P<0.05 
was considered significant.  
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5.3 Results 
5.3.1 Co-localisation of HDACs with dopaminergic and inflammatory cells in the substantia 
nigra 
The expression of HDAC isoforms 3, 4, 5 and 11 was investigated in dopaminergic and glial cells, 
including astrocytes in the SN of naive mouse brain sections. Double-labelling by 
immunoflourescence with antibody against TH (Figure 5-5) showed that TH-positive cells 
expressed all four HDAC isoforms. 
 
HDAC3 was located primarily in the nucleus of the dopaminergic neurones (Figure 5-5-A, E, I), 
but in some cells HDAC3 was found to have some diffused cytoplasmic staining. HDACs 4 and 5 
were found to be in both the cytoplasm and nucleus of the cells (Figure 5-5-B, C, F, G, J, and K). 
However, HDAC4 did not co-localise with all TH-positive neurones. HDAC 11 was present in the 
perinuclear and cytoplasm of the dopaminergic cells (Figure 5-5-D, H, L). 
 
Double staining with antibody against GFAP (Figure 5-6), also showed no co-localisation of any 




































Figure 5-5 Double immunofluorescence staining in naive mouse brain SN showing co-
localisation of TH-positive neurones with HDAC3, 4, 5 and 11.  
Representative photomicrographs showing HDAC3, 4, 5 and 11 positive cells (red) and TH-
positive cells (green) in the SN. Nuclear staining is indicated with solid yellow arrows, 
cytoplasmic staining with broken arrows and perinuclear staining with arrow head. Scale bar = 
20µm is representative of all images. 
 
































Figure 5-6 Double immunofluorescence showing no co-localisation between GFAP-positive 
cells with HDAC3, 4, 5 and 11 in naive mouse brain SN.  
Representative photomicrographs showing HDAC3, 4, 5 and 11 (red) and GFAP-positive cells 
(green) in SN. Scale bar = 100 µm is representative of all images. 
 
 
5.3.2  Confirmation of HDAC activity in mouse brain 
Nuclear extracts of naive brain tissue were used to perform the assay to confirm the HDAC 
activity in the mouse brain. EC50 concentration of SAHA (20 µm) and VPA (60 µm) were used for 
the assay (Section 5.2.3.4). 
 
In control nuclear extracts, high fluorescence readings of 10883 ± 1704 relative units (RU) was 
attained confirming the HDAC substrate was deactylated (Figure 5-7). Incubation with known 
HDAC inhibitor TSA (positive control) in the control well, significantly reduced the fluorescence 
reading by 63%, suggesting that the HDAC substrate deacetylation was inhibited. Similary to the 
control, high fluorescence readings of 10473 ± 927 RU and 10448 ± 1440 RU show that the 
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vehicles HOP-β-CD and saline, respectively, had no effect on HDAC activity. Incubation of brain 
tissue nuclear extracts with the vehicles, saline and HOP-β-CD had no effect on HDAC activity 
compared to control. As expected, SAHA and VPA significantly reduced HDAC activity by 48 % 
and 51 %, respectively, compared to their respective vehicles. 
 
 
Figure 5-7 HDAC assay of mouse brain tissue.  
Nuclear extracts from mouse brain tissue were treated with EC50 concentrations of VPA (60 µM), 
SAHA (20 µM), HOP-β-CD (5 M) and saline. Control wells were incubated with human 
recombinant HDAC1 and treated with assay buffer or known HDAC-I, TSA (21 µM). Data are 
expressed as mean ± SEM (n=4). **p<0.01 compared to vehicles. Analysis by one-way ANOVA 
followed by Newman Keul’s post hoc. 
 
 
5.3.3 Penetration of HDAC-Is across blood brain barrier 
To determine whether SAHA and VPA penetrated through the blood brain barrier, mice were 
injected with saline (10 ml/kg, i.p) or VPA (200 mg/kg or 400 mg/kg, i.p), or treated orally in 
drinking water with HOP-β-CD (6 ml/kg/day, p.o) or SAHA (160 mg/kg/day, p.o in HOP-β-CD). 
VPA and saline-treated mice were killed after 2 hours while SAHA and HOP-β-CD-treated mice 
were culled after 24 hours of treatment. Brains were dissected and histone extractions were 
performed for Western blotting. 
 
Western blotting was used to detect acetylated levels of histone H4 in the samples (Figure 5-8). 
Very low levels of acetylated histone H4 were detected in samples extracted from naive, saline 
(1 ml/kg) or HOP-β-CD (6 ml/kg/day) animals. Both SAHA (160 mg/kg/day) and VPA (200 and 400 
mg/kg) induced a large increase in acetylated histone H4 levels of approximately 3-fold. 
 
 
















































Figure 5-8 The effect of HDAC inhibition on histone H4 acetylation.  
(A) Histones extracted from naive mice brain tissues (n=2) and those treated with HOP-β-CD, 
SAHA, saline, VPA were probed with histone H4 antibody to detect histone acetylation levels by 
Western blotting. Bottom panel shows Coomassie blue-stained poly-acrylamide gel of the total 
histones extracted from the tissue. (B) Bands quantified by Image J and expressed as optical 
density. Data are expressed as mean ± SEM of n=2 animals. Images are typical of n=2 animals. 
 
 
5.3.4 The effect of HDAC inhibition on the number of TH-positive cells in the substantia nigra 
following 6-OHDA and LPS lesioning. 
Sham lesion 
There was no effect of the sham-lesioned + vehicle treatment on the number of TH-positive cells 
in the ipsilateral SN compared to the contralateral side (Figure 5-9). Similarly, treatment with 
VPA and SAHA alone had no significant effect on the number of TH-positive cells on the 
ipsilateral side in sham-lesioned mice compared to the contralateral side. The vehicle-treated 
(0.9 % saline containing 0.05 % L-ascorbic acid, and 0.9 % saline only) sham lesioned groups were 
combined after analysis showed there was no difference in the number of surviving TH-positive 
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 6-OHDA lesion 
Intrastriatal administration of 6-OHDA (7.5 µg) significantly reduced the number of TH-Positive 
cells in the ipsilateral SN by 40 % compared to the contralateral side (Figure 5-9). Treatment with 
VPA (200 mg/kg) had no effect on the 6-OHDA-induced cell loss in the ipsilateral side of the SN. 
However, the higher dose of VPA (400 mg/kg) reduced the 6-OHDA-induced loss of TH-positive 
cells, although the difference (21 %) was not significant. However, neither was there any 
difference from vehicle-treated sham controls. On the other hand, treatment with SAHA (160 
mg/kg/day) significantly prevented 6-OHDA-induced loss of TH-positive cells whereby there was 
22 % loss of TH-positive cells in the ipsilateral side compared to the contralateral side of the SN, 
compared to 40 % in the control. 
 
LPS lesion 
Intrastriatal injection of LPS (7.5 µg) significantly decreased the number of TH-positive cells by 40 
% compared to the contralateral side (Figure 5-9). VPA protected against 6-OHDA toxicity in a 
dose-related manner such that although VPA (200 mg/kg) had no significant effect on the LPS-
induced loss of TH-positive cells in SN, the higher dose of VPA (400 mg/kg) showed 18 % 
reduction. Similarly, SAHA (160 mg/kg/day) protected TH-positive cells from LPS-induced cell 
loss, exhibiting a reduction of 23 % in the ipsilateral side compared to the contralateral side of 








- 146 - 
 Figure 5-9 The effect of VPA and SAHA on the number of TH-positive cells in SN of sham-, 6-
OHDA- and LPS-lesioned mice.  
The number of TH-positive cells in the ipsilateral and contralateral sides of SN. Data are 
expressed as mean ± SEM (n= 4-8). $$p<0.01 compared to the contralateral side; **p<0.01 
compared to sham-lesioned+vehicle ipsilateral; +p<0.05 compared 6-OHDA+vehicle ipsilateral; 
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Figure 5-10 Photomicrographs showing the 
effect of VPA and SAHA on the number of 
TH-positive cells in SN of sham-, 6-OHDA- 
and LPS-lesioned mice.  
TH immunoreactivity in ipsilateral SN in (A) 
6-OHDA-lesioned (7.5 µg/4 µl) and vehicle 
treated mice; (B) LPS-lesioned (7.5 µg/4 µl) 
and vehicle treated; (C) 6-OHDA-lesioned 
(7.5 µg/4 µl) and VPA-treated (400 mg/kg, 
i.p) mice, (D) LPS-lesioned (7.5 µg/4 µl) and 
VPA-treated (400 mg/kg, i.p) mice, (E) 6-
OHDA-lesioned (7.5 µg/4 µl) and SAHA- 
........ 
 treated (160 mg/kg/day) mice; (F) LPS-lesioned (7.5 µg/4 µl) and SAHA-treated (160 
mg/kg/day) mice; and (G) sham-lesioned and vehicle treated mice. A typical TH-positive cell is 
indicated with red arrow. Scale bar = 500 µm and inset scale bar = 50 µm are representative 
of all images.  
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5.3.5 The effect of HDAC inhibition on GFAP immunoreactivity in the substantia nigra 
following 6-OHDA and LPS lesioning. 
Sham lesion 
In the sham-lesioned vehicle-treated mice, there was no difference in the density of GFAP-
positive cells between the ipsilateral and contralateral SN (Figure 5-11). Similarly, treatment with 
VPA (200 and 400 mg/kg) and SAHA (160 mg/kg/day) alone did not affect the GFAP-
immunoreactivity between the ipsilateral and contralateral sides of the SN or compared to the 
vehicle treatment.  
 
6-OHDA lesion 
Intrastriatal injection of 6-OHDA increased GFAP-immunoreactivity in the ipsilateral SN 
compared to the contralateral side (Figure 5-11). Treatment with VPA (200 mg/kg) significantly 
reduced the 6-OHDA-induced increase in GFAP-immunoreactivity in the ipsilateral SN compared 
to the 6-OHDA alone. Similarly, the higher dose of VPA (400 mg/kg), and SAHA (160 mg/kg/day) 
reduced the 6-OHDA-induced increase in GFAP density in SN, although the differences were not 
significant. VPA (200 mg/kg) also reduced GFAP-immunoreactivity on the contralateral side of 6-
OHDA lesioned mice. 
 
LPS lesion 
Intrastriatal administration of LPS increased the density of GFAP-immunoreactivity in the 
ipsilateral compared to the contralateral side of the SN (Figure 5-11). Treatment with VPA 
decreased the density of GFAP-immunoreactivity in a dose-dependent manner such that, VPA 
(400 mg/kg) significantly decreased GFAP-immunoractivity by 34 %. Similarly, SAHA (160 
mg/kg/day) significantly decreased the GFAP-immunoreactivity density by 25 % respectively 
compared to the vehicle treated ipsilateral side of the SN. 
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 Figure 5-11 The effect of VPA and SAHA on GFAP-immunoreactivity in SN of sham-, 6-OHDA- 
and LPS-lesioned mice.  
Data are optical density of GFAP-positive cells measured in the ipsilateral and contralateral side 
of SN expressed as mean ± SEM (n= 4-8). $$p<0.01 compared to the contralateral side; **p<0.01 
compared to sham-lesioned+vehicle ipsilateral; ++p<0.01 compared 6-OHDA+vehicle ipsilateral; 
##p<0.01 compared to LPS+vehicle ipsilateral; %p<0.05 compared to 6-OHDA+vehicle 

















Figure 5-12 Photomicrographs showing 
the effect of VPA and SAHA on GFAP-
immunoreactivity in SN of sham-, 6-
OHDA- and LPS-lesioned mice.  
GFAP immunoreactivity in ipsilateral SN in 
(A) 6-OHDA-lesioned (7.5 µg/4 µl) and 
vehicle treated mice; (B) LPS-lesioned (7.5 
µg/4 µl) and vehicle treated; (C) 6-OHDA-
lesioned (7.5 µg/4 µl) and VPA-treated 
(400 mg/kg, i.p) mice, (D) LPS-lesioned (7.5 
µg/4 µl) and VPA-treated (400 mg/kg, i.p) 
mice, (E) 6-OHDA-lesioned (7.5 µg/4 µl) 
and SAHA- and SAHA-treated (160 mg/kg/day) mice; (F) LPS-lesioned (7.5 µg/4 µl) and SAHA-treated 
(160 mg/kg/day) mice; and (G) sham-lesioned and vehicle treated mice. A typical GFAP-
positive cell is indicated with a red arrow (inset). Scale bar = 500 µm and inset scale bar = 50 
µm are representative of all images.  
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5.3.6 The effect of HDAC inhibition on OX-42-positive cells in the substantia nigra following 6-
OHDA and LPS Lesioning. 
Sham lesion 
Sham-lesioned mice had very few active OX-4-positive cells per section in the ipsilateral SN with 
no significant difference when compared to the contralateral side (Figure 5-13). Treatment with 
VPA (200 mg/kg) and SAHA (160 mg/kg/day) alone had no effect on the numbers of active OX-42 
cells between the ipsilateral and contralateral sides. 
 
6-OHDA lesion 
There was no effect of 6-OHDA alone or combined with HDAC-I treatment in the number of 
active OX-42-positive cells in the SN contralateral to the lesion (Figure 5-13). Intrastriatal 
injection of 6-OHDA induced an increase in the number of OX-42-positive cells in the ipsilateral 
(84 ± 23) compared to the contralateral side (8 ± 6) of the SN. Treatment with VPA (200 mg/kg) 
or SAHA (160 mg/kg/day) had no effect on the 6-OHDA-induced increase in the number of active 
OX-42-positive cells in the ipsilateral SN compared to the 6-OHDA alone. However, there was 
some indication that VPA (400 mg/kg) decreased the number of active OX-42-positive cells in the 




There was no effect of LPS alone or combined HDAC-I treatment in the number of active OX-42-
positive cells in the contralateral SN (Figure 5-13). Administration of LPS significantly increased 
the number of active OX-42-positive cells to 80 ± 25 in the ipsilateral SN compared to 
contralateral side and the ipsilateral side of sham/vehicle treated animals. Similarly to the 6-
OHDA lesion, neither treatment with VPA (200 mg/kg) nor SAHA (160 mg/kg/day) had any effect 
on the LPS-induced increase on the number of OX-42-positive cells in the ipsilateral SN 
compared to the LPS alone. VPA (400 mg/kg) appeared to decrease the number of active OX-42-
positive cells to 59 ± 19 in the ipsilateral SN compared to LPS alone, however the difference was 
not significant compared to the vehicle treated group. 
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 Figure 5-13 The effect of VPA and SAHA on the number active OX-42-positive cell in SN of 
sham-, 6-OHDA- and LPS-lesioned mice.  
The number of active OX-42-positive cells in the ipsilateral and contralateral sides of SN. Data 
are expressed as mean ± SEM (n= 4-8). $$p<0.01 compared to the contralateral side; **p<0.01 




Figure 5-14 Images of resting and active OX-42-positive cells. 
An example of a resting microglia is depicted with a yellow arrow, and an active microglia with a 
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5.3.7 Co-localisation of HDACs with inflammatory cells in the substantia nigra following lesions 
Double staining mouse brain sections following 6-OHDA and LPS lesions with antibodies against 
GFAP (Figure 5-15) and OX-42 (Figure 5-16) showed no co-localisation of any HDAC isoforms with 


































Figure 5-15 Double immunofluorescence showing no co-localisation between GFAP-positive 
cells with HDAC3, 4, 5 and 11 in treated mouse brain SN.  
Representative photomicrographs showing HDAC3, 4, 5 and 11 (red) and GFAP-positive cells 
(green) in SN. Scale bar = 100 µm is representative of all images. 
 
































Figure 5-16 Double immunofluorescence showing no co-localisation between OX-42-positive 
cells with HDAC3, 4, 5 and 11 in treated mouse brain SN.  
Representative photomicrographs showing HDAC3, 4, 5 and 11 (red) and OX-42-positive cells 
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5.4 Discussion 
The hypothesis of this study was that inhibition of HDACs protect against 6-OHDA- and LPS-
induced degeneration of nigral dopaminergic neurones in the mouse in vivo through a reduction 
in glial cell activation and recruitment. This hypothesis was tested by investigating the effect of 
VPA and SAHA on 6-OHDA- and LPS-induced nigral cell loss in mice.  First and importantly, it was 
established that HDACs 3, 4, 5 and 11 were expressed in the SN of the mouse brain. Second, it 
was established that VPA and SAHA could cross the BBB and could inhibit deacetylation of 
histones. Third, VPA and SAHA effects on dopaminergic cell loss in the SN of 6-OHDA and LPS-
lesioned mice were determined to establish whether they exert a protective effect. Fourth, the 
effect of HDAC-Is on inflammatory cells following partial 6-OHDA and LPS lesioning was 
investigated in order to determine if the mechanism of neuroprotection was by a reduction in 
reactive gliosis. 
 
5.4.1 Expression of HDACs in mouse SN 
Immunocytochemistry studies revealed that HDAC3, 4, 5 and 11 were expressed in the SN of the 
mouse brain. These findings confirm previous reports of the ubiquitous expression of these 
proteins in the brain (Broide et al., 2007; Lucio-Eterovic et al., 2008). Cellular localisation of the 
HDACs was investigated by double immunofluorescence labelling, and showed all 4 HDACs were 
expressed on dopaminergic neurones in mouse brain, with HDAC3 mainly in the nucleus and 
HDAC4, 5 and 11 found in both nucleus and cytoplasm of the cells. This is the first time that the 
localisation of HDAC has been investigated in mouse SN, however, the findings are in agreement 
with the previous reports from Broide et al., (2007) and Janssen et al., (2010), who performed 
their studies in rat and human brain tissues, respectively.  
 
Interestingly, mouse astrocytes did not express HDAC3, 4, 5 or 11. This is very surprising, as in 
primary rat mesencephalic cultures, these HDACs were shown to be localised to astrocytes 
(Chapter 4). This finding is, however, in agreement with reports by Broide et al. (2007) who 
claimed that only rat oligodendrocytes express HDACs, and not astrocytes or microglia. Thus it 
seems likely that this is also the case in adult mice. Even though double immunofluorescence 
staining of astrocytes performed in this thesis and previous evidence have shown no positive co-
localisation with HDACs, there is a possibility that the HDAC isoforms may co-localise with 
microglial cells. This was tested, but due to the low sensitivity of the technique employed and 
differences in the antibodies used, resting microglial cells were not detected by 
immunofluorescence. In future studies, in-situ hybridisation might be used to label the HDAC 
isoforms mRNA followed by immunoperoxidase staining for the microglial cells.  
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Overall, these data suggest that HDAC3, 4, 5 and 11 are expressed on neurones, but not glial 
cells in normal naive mouse brain. The localisation of HDACs in glial cells was investigated in 6-
OHDA- and LPS-treated mouse brain tissues. Surprisingly, there was no localisation of the HDACs 
within astrocytes or active microglia and this indicates that HDAC-Is do not exert their effects 
directly on these inflammatory cells. 
 
5.4.2 Effect of 6-OHDA and LPS-lesioning in mice 
Intrastriatal injection of 6-OHDA caused a partial 40 % loss of TH-positive neurones in the SN 
ipsilateral to the lesion 10 days following toxin injection. The extent of nigrostriatal degeneration 
at this time point is in agreement with previous reports which showed that the loss of TH-
positive cells occurs within the first 7 days following toxin administration in mice (Alvarez-Fischer 
et al., 2008). Similarly, intrastriatal injection of LPS also produced a 40 % loss of TH-positive 
dopaminergic neurones in the ipsilateral SN compared to sham-lesioned controls, in agreement 
with previous reports (Hunter et al., 2007; Choi et al., 2009). 
 
The loss of TH-positive cells was most pronounced in the dorsal tier of the SNpc, which is in 
agreement with the topographical organisation of the mesostriatal DA projections confirming 
that the neurones of the dorsal SN project into the striatum (Bjorklund & Dunnett, 2007); and 
also confirming that intrastriatal 6-OHDA lesioning provides a selective destruction of DA axons 
and terminals within the striatum and a retrograde degeneration of DA neurones cell bodies in 
the SN (Debeir et al., 2005).  
 
This loss may reflect a down-regulation of TH, as death of dopaminergic neurones in the nigro-
striatal pathway per se was not determined. However, previous studies by stereology in our labs 
and elsewhere have confirmed that both 6-OHDA and LPS induce dopaminergic degeneration 
rather than a down-regulation of the TH protein (Sauer & Oertel, 1994; Przedbroski et al., 1995; 
Iravani et al., 2002; Gao et al., 2002a; Iczkiewicz et al., 2010). This loss of dopaminergic cell 
bodies in the SN mimics the early stages of disease progression, but whether it is a suitable 
model for PD, is further discussed in Chapter 6. 
 
5.4.3 Effect of HDAC-Is on dopaminergic cell death and inflammatory change in 6-OHDA and 
LPS-lesioned mice 
This is the first report of the neuroprotective effects of HDAC-Is VPA and SAHA against 6-OHDA- 
and LPS-induced loss of dopaminergic neurones in the mouse SN in vivo. Eleven days 
administration of SAHA (160 mg/kg/day) and the highest dose of VPA (400 mg/kg) preserved TH-
positive neurones from 6-OHDA and LPS intrastriatal lesions. This protective finding confirms 
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recent reports of HDAC-Is, sodium butyrate, phenylbutyrate and VPA respectively, to 
significantly protect dopaminergic neurones and striatal dopamine levels against MPTP toxicity 
in the same species (Gardian et al., 2004; Kidd & Schneider, 2011; Zhou et al., 2011), and against 
rotenone toxicity in rats (Monti et al., 2010). The mechanism of this protective effect observed 
in the present study is not certain as it counteracts the results reported in Chapter 4 where there 
was no protection of TH-positive cells. 
 
The loss of TH-positive cells in the SN was accompanied by an increase in astrocytes and 
microglia 10 days following intrastriatal injection with both 6-OHDA and LPS. This is in 
agreement with previous work where increased astroglia activation was observed 3 – 28 days 
post 6-OHDA injection, and 6 hours – 21 days post LPS lesioning in the striatum and SN (Liu, 
2006). Whether this increase in inflammatory cells is the cause of dopaminergic neuronal loss 
following 6-OHDA and LPS injection remains unclear. However, treatment of rat mesencephalic 
cultures with the non-steroidal anti-inflammatory drug (NSAID) ibuprofen, protected 
dopaminergic neurones against 6-OHDA and MPP+ toxicity (Carrasco et al., 2005). Furthermore, 
the NSAID celecoxib (selective COX-2 inhibitor) protected rat dopaminergic cells against 
intrastriatal administration of 6-OHDA in vivo (Sanchez-Pernaute et al., 2004), whereas 
treatment with ibuprofen also protected dopaminergic neurones against LPS administration in 
vivo, with a marked reduction of GFAP, OX-42, iNOS and 3-NT (Iravani, personal communication). 
Importantly, chronic NSAID users exhibited a decrease in PD incidence (Chen et al., 2003; Chen 
et al., 2005), suggesting that inflammation contributes to the degenerating process. By contrast, 
meta-analysis of NSAID observational studies concluded that NSAIDs on the whole do not modify 
PD risk, although users of COX-2 inhibitor ibuprofen showed some evidence of reduced PD 
incidence (Samii et al., 2009). Overall, these studies suggest that the inflammatory response 
observed in PD brains does contribute to cell death and this is a target for neuroprotective 
therapy.   
 
In the present study, HDAC inhibition by VPA and SAHA caused a small reduction in the number 
of 6-OHDA- and LPS-induced active microglia. In addition, VPA (200 mg/kg) significantly reduced 
the density of astrocytes in 6-OHDA-lesioned mice, and both VPA (400 mg/kg) and SAHA (160 
mg/kg/po) reduced astrocytosis in LPS-lesioned mice. Surprisingly, an opposing effect of HDAC-Is 
on inflammatory cells were observed in primary cultures, where SAHA and VPA caused a 
significant reduction in both astrocytes and microglia numbers. These data, therefore suggest 
that HDAC-Is prevented TH-positive cell death by reducing some other aspect of cell death which 
thereby causes a reduction in the glial reaction, and in this case, a reduction in astrogliosis. This 
confirms pathological studies of PD brains and animal models (Chapter 1), which reports of 
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increases in the number of reactive astrocytes in the area associated with dopaminergic cell loss 
(Forno et al., 1992).  
 
Typically, glial cells have a number of protective properties, but the main question of how HDAC-
Is decrease astrogliosis still remains unanswered. On the onset of injury and damage such as, 
following 6-OHDA and LPS administration, the inflammatory process is initiated with the 
activation of glial cells and the release of cytotoxic pro-inflammatory cytokines such as TNF-
α, IFN-γ and IL-1β, which are also potent activators of iNOS in glial cells and induce their 
expression. This subsequently releases NO which diffuses to neighbouring neurones to react 
with superoxide to form peroxynitrite and contribute to the demise of dopaminergic neurones 
through nitrative stress (Chapter 1) (Teismann & Schulz, 2004). The cytokines also act directly on 
neurones to activate caspases which results in neuronal loss via apoptosis (Hartmann et al., 
2000; Hartmann et al., 2001), and NF-κB which activates detrimental enzymes such as iNOS and 
COX-2, which contributes to ROS generation during COX-2 catalysis of prostaglandin G2 (PGG2) 
(Smith et al., 1991; Teismann et al., 2003b; Teismann & Schulz, 2004) and contribute to neuronal 
loss via oxidative stress. These dying neurones release toxic compounds which are scavenged by 
glial cells to protect neighbouring neurones (Rosenberg, 1991; Aloisi, 2001). But through a 
vicious cycle, the activation of the glial cells to remove these toxic compounds results in the 
initiation of the inflammatory process and results in further neuronal loss. 
 
At the initial stages of inflammation, it is possible that HDAC-Is may exert their protective 
mechanisms by suppressing the release of the pro-inflammatory cytokines, as shown in acute 
arthritis by HDAC-I, ITF2357 (Joosten et al., 2011). As the double immunofluorescence staining 
showed that the HDAC isoforms were not present in the inflammatory cells, namely astrocytes 
and microglia in both naive and toxin-treated mouse brain sections, it can be assumed that the 
HDAC-Is act indirectly on the inflammatory cells maybe by suppressing the release of these 
cytokines, which results in less deleterious effects on neurones by these cytokines and in turn, 
less activation of glia. Alternatively, the HDAC-Is may not have any effect on inflammation at all, 
and the reduction in glial cell number observed in the present study is a secondary effect. In 
Chapter 3, it was mentioned that HDAC-Is induce apoptosis in cancerous cells, but this is not the 
case for normal cells as HDAC-Is was shown to prevent p53-dependent and independent Bax-
mediated neuronal apoptosis (Uo et al., 2009). If this is the case, then it is plausible that the 
inflammatory process was initiated and progressed as expected after toxin lesions, but the 
HDAC-Is inhibited the neuronal death by apoptosis, which in the end resulted in less toxic 
compound release by the dying neurones and in turn less glia activation.    
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The exact mechanism of action of HDAC-Is on neuroprotection in the 6-OHDA and LPS model is 
not yet clear and prompts for further investigation, but it all seems to be related to an effect on 
glial cells. The staining results allow the assumption that HDAC-Is do not exert their effects 
directly on these inflammatory cells to protect dopaminergic neurones. It is possible they may 
act directly on dopaminergic neurones to result in protection. Even though HDAC-Is proved to be 
protective in lesioned mice, extensive research needs to be undertaken to establish their exact 
role in PD.  
 
5.4.4 Conclusion  
The hypothesis of this study is accepted as the data presented in this Chapter has shown that 
the multi-cellular populations of the animal models contributed to the protection of 
dopaminergic neurones in the 6-OHDA and LPS-unilateral lesioned mice during HDAC inhibition, 
in addition to reducing the numbers of astrocytes and microglia. But, the lack of HDACs in glial 
cells suggests that the reduction in glia was secondary to reduced neuronal damage. The precise 
mechanism of how HDAC-Is work is unknown due to the limited in vivo reports in PD models. A 
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6.1 Summary of results 
Neuroprotection is the gold standard for new treatment for PD, however, no drugs have shown 
unequivocal disease modifying effects in the clinic. As HDAC inhibitors have shown potential 
neuroprotective effects in other neurodegenerative diseases, it was hypothesised that they 
might protect dopaminergic neurones from cell death in PD. In this respect, the aim of this 
research was to establish whether HDAC inhibition was neuroprotective in experimental models 
of PD. Accordingly, the present study examined the effect of the HDAC-Is, VPA and SAHA, on 
toxin-induced cell death in cell lines, primary neuronal cultures and in mice. The following results 
were obtained in the individual studies: 
1. Inhibition of HDACs with VPA and SAHA alone was toxic and enhanced the neurotoxicity 
of H2O2 and MPP
+ in neuroblastoma cell lines. 
2. In primary mesencephalic cultures, inhibition of HDACs did not prevent dopaminergic 
neuronal death following MPP+- and LPS-induced toxicity. However, toxin-induced gliosis 
was reduced following HDAC-I treatment. 
3. In 6-OHDA-lesioned mice, high dose of VPA (400 mg/kg) and SAHA were effective in 
protecting dopaminergic neurones in the SN. 
4. In LPS-lesioned mice, high dose of VPA and SAHA protected dopaminergic neurones 
from toxin-induced cell death. 
5. In both 6-OHDA- and LPS-lesioned mice, VPA and SAHA administration induced a 
reduction in astrocytosis but not microgliosis. 
 
Overall, these results support the hypothesis that HDAC inhibition would protect dopaminergic 
neurones against toxin-induced cell death in PD. Even though protection of dopaminergic 
neurones was not observed in vitro, it was observed in vivo in addition to a reduction in 
inflammation.  
 
This protective effect of HDAC-Is observed in models of dopaminergic cell death adds to their 
neuroprotective potential. HDAC-Is have previously shown promise in animal models of other 
neurodegenerative disorders, such as HD where they decreased the neurodegenerative 
phenotype and improved the survival and motor performance of R6/2 transgenic mice (Ferrante 
et al., 2003; Hockly et al., 2003). In SMA, HDAC-I administration to transgenic mice increased 
their lifespan and improved motor symptoms (Chang et al., 2001). In ALS combined treatment 
with phenylbutyrate and riluzole (FDA-approved ALS drug) increased survival and improved 
pathological phenotype (Del Signore et al., 2009; Chuang et al., 2009). Despite this only sodium 
phenylbutyrate has progressed to phase II clinical trials of HD and ALS (ClinicalTrials.gov). The 
delay may be partly due to the failed translation of positive in vitro effects into in vivo models, 
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and this questions the suitability of the models used. Indeed this was exemplified in the present 
study where the protective effects of HDAC inhibition were only seen in vivo. 
 
6.2 Advantages and limitations of toxin-induced cell model 
Despite promising pre-clinical data, the translation of the neuroprotective effects of most if not 
all of the potential agents, from cellular and animal studies have failed in clinical studies. The 
most recent example being Cogane (PYM50028), which failed phase II/III clinical trials despite its 
effect as a neuroprotective and neurorestorative agent as seen in experimental models of 
dopaminergic cell death (Visanji et al., 2008); Phytopharm (2013)) (Table 1-2).  
 
At the start of these studies, it was hypothesised that HDAC inhibitors would decrease 
dopaminergic cell death in models of nigro-striatal loss. Since there is no unifying proposed 
action of these inhibitors, the investigations looked at HDAC-Is potential neuroprotective action 
through two mechanisms: 1. oxidative stress, by using H2O2 and MPP
+ in vitro, and 6-OHDA in 
vivo; and 2. inflammation, by using LPS in vitro and in vivo. Interestingly, the HDAC-Is were only 
found to be effective in vivo, thereby questioning the usefulness of the in vitro studies. 
 
6.2.1 Toxin-induced cell death in vitro 
Cell lines 
In the present studies, HDAC-Is had no effect on the survival of dopaminergic neurones in cell 
lines and primary cultures, but they did reduce the number of inflammatory cells in primary 
cultures. Similar findings have been reported for other potential neuroprotective agents that 
had no effect on SH-SY5Y cell line survival, but had positive effects in vivo (Presgraves et al., 
2004; Kou et al., 2008), with a typical example being osteopontin (Ailane et al., in preparation, 
personal communication). 
 
Cell culture systems are widely used to study the pathological mechanism involved in cell death 
in PD and to investigate the effects of potential neuroprotective agents (Gazdar et al., 2010). 
Indeed, immortalised cell lines are widely used as they have several practical advantages. They 
are convenient, robust, grow and divide quickly and easily in culture, which allows the 
conduction of multiple experiments in a short period of time. Overall, experiments on cell lines 
are less expensive and less time consuming than testing compounds in primary cultures or in 
whole animals, and their functional and biochemical properties similar to dopaminergic 
neurones, makes them useful in PD research as they mimic aspects of the dopaminergic 
neuronal death observed in PD when treated by neurotoxins such as MPP+ and 6-OHDA (Xie et 
al., 2010). 
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 Despite these advantages, there are limitations of cell lines that may have affected the results of 
the present study. Array-based comparative genomic hybridization studies have shown that the 
dopaminergic neurones of cell lines have significantly different characteristics from native 
dopaminergic neurones in vivo genetically and phenotypically (Skibinski & Finkbeiner, 2011). 
These differences start with the origins of the cell lines, where SH-SY5Y cell line is a thrice cloned 
subline of neuroblastoma cell line SK-N-SH, originally established from a bone marrow biopsy of 
a neuroblastoma patient with sympathetic adrenergic origin (Biedler et al., 1978); and N1E-115 
cell line, is derived from murine brain neuroblastoma also with cholinergic and adrenergic origin 
(Amano et al., 1972; Biedler et al., 1978; Richelson, 1973). The cancerous origin means these 
cells are continuously dividing, so their numbers increase during the course of an experiment, 
making it difficult to distinguish whether the compounds tested influence the proliferation or 
cell death rate (Datki et al., 2003). SH-SY5Y cells, particularly expresses low levels of dopamine 
synthesising enzymes and DAT, which makes them respond differently to exogenous stimuli in 
comparison to mature neurones (Presgraves et al., 2004). In addition, cell lines are also less 
sensitive to neurotoxins and neuroprotective agents (Storch et al., 2000). This was evident in 
Chapter 3, where the EC50 of MPP
+ was 1000 fold greater in cell lines than in primary cultures. 
This is because in cell lines, DAT is required for MPP+ toxicity in vivo, but in cell lines low DAT 
levels may mean that MPP+ is either not taken into cell lines or it exerts effects via non-DAT 
mechanisms (Gainetdinov et al., 1997; Xie et al., 2010).  
 
Another important aspect to consider is the lack of cell heterogeneity. The homogeneous cell 
population of SH-SY5Y and N1E-115 cell lines means they lack inflammatory cells, meaning that 
they do not represent a true physiological environment as occurs in vivo where neurones and 
glial cells co-exist. Cell cultures may therefore not truly reflect the actions of HDAC-Is as they 
would in vivo. However, in the absence of glial cells in this investigation, HDAC-Is had no effect 
on dopaminergic cell viability, suggesting that they do not act directly on neurones. Finally, the 
fact that cell lines originate from malignant cells makes them unsuitable candidates for HDAC 
inhibition studies, as the HDAC-Is have been shown to induce tumour-cell selective apoptosis in 
the cell cultures (Bolden et al., 2013).  
 
Primary culture 
Primary cell culture in particular the VM cell cultures used in these studies, addresses some of 
the limitations of cell lines. They are good candidates as a source of dopaminergic neurones 
which have not been immortalised. Since they are derived from the brain and not tumours, they 
overcome the problem of HDAC-Is selectively inducing apoptosis in cancerous cells. The 
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dopaminergic neurones are cultured within a heterogeneous population with other neuronal 
and glial cells as in the SN, making a more physiological environment in which to examine the 
potential protective action of HDAC-Is.  
 
Despite these advantages, there are also limitations. First, these cells are sensitive and 
immature, as they are derived from embryos. They are also slow in proliferation, have limited 
life-span, and it is difficult to produce optimal survival and growth in the primary cell cultures. 
This may be due to the stress of the isolation procedure and ‘foreign environment’ of the culture 
process which causes only 1 - 10 % of harvested cells to survive (Heyer, 1984; Halliwell, 2003). 
Dopaminergic neurones dissected from foetal rat VM make up ~5 % of the total culture (Chapter 
4) compared to 50 % of cells harvested from mid-brain cultures derived from post-natal rodents  
(Rayport et al., 1992). Furthermore, the environment in which the cells are grown, from the cell 
culture medium to the incubator, potentially increases cellular oxidative stress (Halliwell, 2003). 
The presence of high oxygen, free iron ions and the deficiency of antioxidants provide a pro-
oxidant environment and force cells to adapt for survival by increasing their anti-oxidant 
defences.  This is by down-regulating the expression of ROS-generating enzymes and altering 
cellular targets of oxidative damage to become more resistant to damage by ROS (Halliwell, 
2003). These culture conditions cause the characteristics that the neurones display in culture to 
vary in comparison to how they would behave in vivo.   
 
However, in the current investigation, important findings were obtained from the primary 
culture studies which gave insight into the actions of HDAC-Is. Even though the inhibitors did not 
promote cell survival in these heterogeneous cell cultures, they did reduce inflammatory cell 
proliferation and they did not exacerbate the effects of the toxins as found in cell lines. This 
suggests that glial cells do not control dopaminergic neuronal loss in these model systems. The 
fact that a reduction in astrocytes was also seen in the in vivo model as well as protection of 
dopaminergic neurones, shows that despite the limitations of primary cultures, they do mimic 
the brain in terms of the relevant cell types, and the difference in results may be due to the 
extensive cellular connections in the brain compared to the culture plate. However, cells 
dissected in an embryonic form and grown in culture are not optimal as a model for age-related 
changes in physiology or late-onset disease as they are not representative of the mature brain 
(Eide & McMurray, 2005). Neurones in developmental stages are still growing and maturing and 
therefore behave differently in terms of pharmacology, electrophysiology, development, and 
regenerative and pathological characteristics; whereas those of the mature brain are maintained 
in a homeostatic complex network for synaptic plasticity (Arenas et al., 1995; Brewer & Torricelli, 
2007). This could be the reason for the observation of HDAC expression on both neurones and 
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glia in primary culture, compared to their expression on neurones only in brain tissue sections. 
There might also be differences between the species, as the cultures were generated from rats 
whereas mice were used for the in vivo study. In addition, although primary cultures contain glia, 
their phenotype may be different to mature glia in the SN. This questions the validity of using 
immature cultures to mimic a disease which affects the middle to old age individuals, and 
therefore emphasises that experiments performed in vitro need to be validated in in vivo models 
of adult brain.  
 
To conclude, cell lines and primary culture models provide a good starting point to investigate 
the properties of potential neuroprotective agents. Although caution needs to be taken when 
examining the effects of compounds in cell cultures, as neither cell lines nor primary cultures 
represent the true physiological conditions and neuronal behaviour that occur in vivo.  
 
6.2.2 Toxin-induced cell death in vivo 
Animal models are useful for modelling neurological disorders to study their pathology and for 
testing neuroprotective or neurorestorative therapeutic strategies. Animal models have offered 
insights into the understanding of the cell death process, aetiology, pathology as well as 
molecular mechanisms in PD (Blesa et al., 2012). However, no model is perfect due to the 
complexity of the events occurring during neuronal loss which are still not fully understood. 
However, these models are important as they allow preclinical screening of potential new 
treatments. In this study, unilateral lesioning with neurotoxins 6-OHDA and LPS was used to 
produce models of nigro-striatal destruction. 
 
Intrastriatal injection of 6-OHDA is widely used for investigating neuroprotective strategies (Kirik 
et al., 1998) because it induces a lesion similar to early symptomatic stage in PD, where there is 
50 – 60 % loss of dopaminergic neurones, and when neuroprotective therapy would be started. 
The intrastriatal 6-OHDA model is easily replicated, and it provides a more prolonged time frame 
for the neuroprotective agents to be effective due to the retrograde nature of cell death. This 
contrasts with SNpc and MFB lesioning where there is almost a complete loss of nigral cells 
(Emborg, 2004).  
 
The bacterial endotoxin LPS has been a useful tool to investigate the role of neuro-inflammation 
in dopaminergic cell death (Liu & Bing, 2011). Intrastriatal LPS administration has not been well 
characterised, compared to its intranigral application. However, it produces a progressive 
degeneration of the nigrostriatal pathway similar to degeneration in PD which is driven by the 
toxic inflammatory factors released from the activated microglia and astrocytes. It also helps in 
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explaining the contribution of the various pro-inflammatory and neurotoxic factors to 
dopaminergic neurodegeneration and aid in the design of specific potential therapeutic agents 
and identifies early stage-diagnostic biomarkers (Dutta et al., 2008; Hunter et al., 2009). 
However, the degree of inflammation is several orders of magnitude greater than that seen in 
PD in man, and thus raises the question as to whether it truely reflects the pathology or 
pathogenic process. 
 
Importantly, neither the 6-OHDA nor LPS model mimics all the pathological features of PD. For 
example, there is no real progression of cell death, non-dopaminergic areas are unaffected and 
no lewy bodies are observed. They do induce some of the pathogenic process such as, oxidative 
and nitrative stress, inflammation and mitochondrial impairment. The main difference between 
these 6-OHDA and LPS models is the mechanism by which neuronal cell death occurs. In the 6-
OHDA model, the cell death mechanism involves accumulation of toxin in the dopaminergic 
neurones followed by oxygen radicals followed by semiquinone production which mediate 
cellular damage, and in turn induce activation of glial cells (Cicchetti et al., 2002; McCoy et al., 
2006). LPS on the other hand is not directly toxic to neurones but causes their degeneration 
through activating glial cells to induce an inflammatory reaction leading to increased release of 
cytokines, iNOS induction, oxidative and nitrative stress, and decreased secretion of the 
neurotrophic factors BDNF and GDNF (McNaught & Jenner, 1999; McNaught & Jenner, 2000; 
MCNaught & Jenner, 2000; Dutta et al., 2008).   
 
The question as to whether these models truely reflect the pathology of PD needs to be 
considered as 6-OHDA induces destruction of the dopaminergic nigro-striatal tract, however, it 
has no effect on other brain regions affected in PD as it is injected focally into the striatum. Even 
though it provides a reproducible model of nigral cell death, there is still variability between 
animals in the extent of the lesion and this is overcome by using large groups of animals to 
average out these differences. Although the 6-OHDA-lesioned rodent remains a widely used 
model of PD, its success stems from its usefulness in the search for symptomatic agents, rather 
than neuroprotective therapies. While it mimics some of the mechanisms of cell death in PD, it 
fails to reflect the progressive nature or extensive pathology seen in PD. Maybe this is one 
reason why no neuroprotective agents have been successfully developed through its use. 
 
LPS induces widespread inflammation in the brain and may therefore not be a model specific to 
PD (Qin et al., 2007). It induces microgliosis, but also results in astrocytosis, which is not a major 
component of the glial reaction occurring in PD (Duty & Jenner, 2011). The main limitation of the 
LPS model is the method of application. Several models of LPS-induced nigral cell death have 
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been created via intranigral, intrastriatal, and systemic injection (Hunter et al., 2009). However, 
there are disagreements on which route of LPS injection causes dopaminergic 
neurodegeneration. For example, a single i.p. administration of LPS has been shown to cause 
dopaminergic neuronal degeneration (Qin et al., 2007) but is yet to be reproduced. The debate is 
mainly between intrastriatal used in this study and intranigral lesions. Recent characterisation of 
these routes concluded that intranigral LPS administration causes localised microgliosis in the SN 
accompanied by nigrostriatal degeneration and stable motor deficits, whereas intrastriatal 
administration only induced localised microgliosis in the striatum and no dopaminergic neuronal 
loss and transient motor dysfunction (Hoban et al., 2013). The findings from the present study 
contradict this report, as intrastriatal LPS resulted in cell loss accompanied by localised 
microgliosis in the SN. The discrepancy between these reports is the species used, where 
evidence in favour of intranigral LPS administration used rats and that in favour of intrastriatal 
administration, like the present study, used mice. The size difference between the rat and 
mouse brain could be a factor, as LPS may diffuse a shorter distance to get to the SN of the 
mouse compared to the rat. An alternate explanation could be species difference in LPS 
sensitivity. A similar example is MPTP, which rats are resistant but causes neurodegeneration in 
mice (Chiueh et al., 1984; Boyce et al., 1984).  
 
As mentioned earlier, LPS causes dopaminergic neuronal death through activation of glial cells. A 
decrease of this inflammatory response coupled with neuronal survival was achieved with 
ibuprofen and dexamethasone, where a marked reduction of GFAP, OX-42, iNOS and 3-NT was 
observed (Iravani, Personal communication). This report then supports the anti-inflammatory 
potential of HDAC-Is exhibited in vivo which was accompanied with dopaminergic neuronal 
survival. This however questions whether the VM culture may be too immature or may need a 
greater reduction in glial cells in order to get protection of dopaminergic cells. This is because a 
decrease of inflammatory cells without dopaminergic neuronal preservation was observed, and 
therefore emphasises the requirement of validating in vitro studies in in vivo models.  
 
An alternative model to better predict the effect of HDAC-Is is the MPTP-treated mouse and 
primate model which is commonly utilised, as it causes selective loss of the nigro-striatal tract. 
This is because previous studies have already investigated the effects of HDAC-Is in MPTP-
treated mice and observed the protection of dopaminergic neurones (Kidd & Schneider, 2011; 
Zhou et al., 2011). MPTP is systemically active and readily crosses the BBB to be converted to the 
toxic moiety MPP+ by MAO-B in glia and serotonergic neurones (Chiba et al., 1985). Being 
systemically active means MPTP does not require the skilled stereotaxic surgery, as performed in 
this study; and it produces a bilateral degeneration of the nigro-striatal tract, more reflective of 
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that seen in PD, such as elevated acetylcholine (Hadjiconstantinou et al., 1985), and extracellular 
glutamate levels associated with the induction of programmed cell death (Meredith et al., 2009). 
However, as with every model, there are limitations. It would be ideal to investigate the effects 
of the inhibitors on MPTP-treated primates, as they are closely related to humans. But 
limitations of this model such as acute cell death processes induced by MPTP and lack of lewy 
body-like inclusions (Shimoji et al., 2005), questions the validity of this model as a model of PD. 
Indeed, it too has been widely used to predict the efficacy of neuroprotective agents, but all 
have failed in human trials so far. 
 
So to conclude, there is no perfect cell culture or animal model that completely models the 
pathology of PD. However, each in vitro and in vivo model used in the present study provided a 
key piece of the puzzle into the role of HDAC-Is in cell death processes, and this has enabled the 
mechanism of the inhibitors actions to be understood and deduced.  
 
6.3 Proposed mechanism of HDAC-I’s protection of dopaminergic neurones 
The results from the studies described in this thesis showed that in the absence of inflammatory 
cells, there was no protection of dopaminergic neurones by HDAC-Is against toxic insults. 
Interestingly, when inflammatory cells were present in primary cultures, there was still no 
protection of dopaminergic neurones but there was a reduction in the number of astrocytes and 
microglia, suggesting that in primary culture these glial cells do not control cell death. By 
contrast, in vivo rodent models, there was protection of dopaminergic neurones in addition to a 
reduction in astrocytes number. However, since the data from primary cultures suggest that glial 
cells do not control cell death, the protection of dopaminergic neurones in vivo suggests that the 
HDAC-Is may be acting through other cell death pathways.  
 
Studies from post mortem PD brains and animal models of the disease have shown an increase 
in the number of reactive astrocytes and microglia in areas associated with dopaminergic cell 
loss (McGeer et al., 1988b; McGeer et al., 2003; Forno et al., 1992). This suggests that an 
inflammatory reaction may contribute to neuronal death via the release of pro-inflammatory 
cytokines, e.g. TNF-α, IL-1β and IL-6. They activate enzymes iNOS and COX-2 to contribute to 
nitrative and oxidative stress, and activate caspases, such as capase-1 and 3, to induce apoptosis 
of cells. This results in further activation of these glial cells to scavenge the toxic compounds 
released by the dying cells (Nagatsu et al., 2000; Teismann & Schulz, 2004; Dutta et al., 2008; 
Lima et al., 2012) (Figure 6-1).  
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HDAC-Is can reduce the production of pro-inflammatory cytokines, thereby preventing the 
damaging effects of these cytokines on neurones and further activation of glial cells, thus  
preserving the surviving ones. Evidence for this comes from studies by Leoni et al. (2002) who 
demonstrated that SAHA pre-treatment suppressed LPS-induced cytokine release, such as TNF-
α, IL-1β, IL-6, and IFN-γ by 50 % in mice (Leoni et al., 2002), and this inhibited macrophage NO 
release stimulated by TNF-α and IFN-γ. This reduction in cytokine release was also observed with 
HDAC-I ITF2357 in peripheral blood mononuclear cells (Leoni et al., 2005). In both studies, there 
was a marked reduction in LPS-induced increase of TNF-α and IFN-γ mRNA, but no change in IL-
1β mRNA, however a reduction in the secretion of IL-1β was observed. This suggests that HDAC-
Is may affect proteins, e.g. NLRP3 inflammasome,  that are required for the activation of 
caspase-1, which cleaves pro-IL-1β to a mature, active and secretable form that binds to IL-1 
receptor (Hoffman & Wanderer, 2010). Indeed, inhibition of caspase-1 has been shown to delay 
the onset of motor abnormalities in mouse models of HD (Ona et al., 1999). However, the 
mechanism for the decrease in IL-1β secretion is unclear as ITF2357 did not inhibit the enzymatic 
activity of caspase-1 in LPS-stimulated monocytes (Leoni et al., 2005). HDAC inhibition may 
prevent the secretion of IL-1β via a specialized secretory lysosomal pathway, where a subset of 
secretory lysosomes allows the cytokine to bind to lysosomal enzymes (Andrei et al., 2004). This 
takes place through activation of phosphatidylcholine-specific phospholipase C and A2, which 
facilitates the passage of caspase-1 to pro-IL-1β and, consequently, pro-IL-1β processing in these 
secretory lysosomes (Andrei et al., 2004). This certainly is speculative with respect to PD 
pathology and will need to be explored further. 
 
An alternative mode of action of HDAC-Is may be via oxidative stress and/or apoptosis pathways, 
which results in a decrease in inflammation and inflammatory cells as highlighted briefly in 
Chapter 5. The idea for this notion comes from numerous studies showing that HDAC-Is up-
regulate the acetylation of transcription factors and expression of genes that confer resistance 
to oxidative stress, such as Sp1, Foxo3a and Mt2 (Ryu et al., 2003; Shimazu et al., 2013).  
 
In contrast to the deleterious roles of microglia, astrocytes have a neuroprotective role via the 
release of the antioxidant glutathione. This protein acts as a defence against oxidative and 
nitrative stress by scavenging free radicals and reactive oxygen species including hydroxyl 
radical, lipid peroxyl radical, peroxynitrite, and H2O2 directly or through a series of enzymatic 
reactions (Wu et al., 2004). Glutathione is present at higher concentrations in astrocytes (~3.8 
mM) than in neurones (~2.5 mM), and once there is an increase in ROS levels, glutathione is 
released into the extracellular space to increase its availability to neurones, thereby making 
them less susceptible to the damaging species (Rappold & Tieu, 2010). Ryu and colleagues 
- 170 - 
(2003) showed that on glutathione depletion, Sp1, an apoptosis-associated transcription factor is 
activated. HDAC-Is were able to abrogate oxidative stress-induced death induced by glutathione 
depletion by augmenting Sp1 acetylation, Sp1 DNA binding and Sp1-dependent gene expression, 
which confer resistance to oxidative stress, thereby preventing neuronal loss in vitro and in vivo 
(Ryu et al., 2003). Most recently, it has been reported that the transcription of two genes, 
namely Foxo3a and metallothionein 2 (Mt2), encoding oxidative stress resistance are increased 
in response to exogenous administration of an endogenous HDAC-I, β-Hydroxybutyrate (βOHB) 
to protect paraquat-treated mice against oxidative stress (Shimazu et al., 2013). Examination of 
kidney tissue sections for oxidative stress markers: protein carbonyl and 4-Hydroxynonenal (4-
HNE), found paraquat to significantly increase these markers, but this increase was suppressed 
in βOHB treated mice. An explanation for this result is that antioxidant enzymes, mitochondrial 
superoxide dismutase (MnSOD) and catalase are targets of Foxo3a. Once oxidative stress is 
triggered, Foxo3a activates the transcription of MnSOD and catalase, which scavenge superoxide 
and hydrogen peroxide respectively (Chiribau et al., 2008) and contribute to the protective 
activity of Foxo3a against oxidative stress (Kops et al., 2002; Shimazu et al., 2013).  
 
In addition to preventing oxidative stress, supporting evidence of HDAC-Is preventing apoptosis 
highlights another mechanism by which they may exert their neuroprotective properties. In 
postnatal cultured murine cortical neurones HDAC-Is were shown to protect neurones from p53-
dependent and independent Bax-mediated neuronal apoptosis by selectively suppressing p53-
dependent PUMA (p53 up-regulated modulator of apoptosis) expression, thereby preventing 
post-mitochondrial events including cleavage of caspase-9 and caspase-3 (Uo et al., 2009). This 
effect was not observed in SH-SY5Y neuroblastoma cells, thus confirming that HDAC-Is 
selectively induce apoptosis in malignant cells and not in non-malignant cells such as the primary 
neurones (Shao et al., 2004; Uo et al., 2009). In addition, anti-apoptotic protein B cell lymphoma 
protein-2 (bcl-2) is markedly increased by HDAC-I VPA in the frontal cortex of rats (Chen et al., 
1999). Moreover, HDAC inhibition up-regulated heat-shock protein (HSP) 70 and attenuated the 
up-regulation of apoptotic-protease-activating factor-1 (apaf-1) and increased the binding 
between the two to block apoptosome formation and reduced the release of cytochrome c and 
activation of caspase-3, thereby inhibiting the apoptotic pathway (Zhang et al., 2012). 
 
Typically, astrocytes confer neuroprotection by releasing trophic factors, such as GDNF, BDNF 
and MANF (mesencephalic astrocytes-derived neurotrophic factor), that can support neuronal 
function. In vitro studies in rat midbrain neuron-glia cultures reported that HDAC inhibition 
increased the expression of GDNF and BDNF in astrocytes to protect dopaminergic neurones 
(Wu et al., 2008). If this increased expression of the trophic factors also occurs in vivo, that 
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would contribute to the survival of dopaminergic neurones as intrastriatal injection of MANF in 
6-OHDA lesioned mice was found to be neuroprotective (Voutilainen et al., 2009). 
 
Even though there is evidence reporting that HDAC-Is suppressing oxidative stress and 
apoptosis, this theory is not supported by the in vitro studies reported in this thesis. Particularly 
in cell lines where H2O2 and MPP
+ both act via increasing oxidative stress. This may have been 
primarily due to the origin of the cell lines being malignant. Numerous studies in cancer have 
found HDAC-Is to be ideal cancer therapeutic agents because they selectively induce apoptosis 
in tumours. The cell lines, SH-SY5Y and N1E-115 cell lines are both derived from neuroblastoma 
and this may have overcome the protective effects of the anti-apoptotic enzymes such as, 
glutathione, superoxide dismutase and catalase. In addition, the concentrations of the toxins 
H2O2 and MPP
+ used were extremely high and this toxicity may have enabled them to induce cell 
death by acting on pathways other than the mitochondria. This is especially the case for H2O2 as 
it is a non-selective mitochondrial toxin. 
 
Similarly, the data from the primary culture studies do not support the theory of HDAC-Is 
suppressing oxidative stress and apoptosis, as inhibition of the mitochondria with MPP+ also 
increases oxidative stress in cells. The HDAC-Is did not prevent MPP+-induced cell death, but they 
did prevent exacerbation of MPP+ toxic effect. However, the toxicity of the inhibitors may have 
played on the vulnerability and sensitivity of the primary cultures, and promoted the cell loss 
observed in the presence and absence of the toxin. 
 
In summary, even though the data from the in vitro studies fail to support the mechanisms 
described, the data from the in vivo study best support the mechanism of HDAC-Is suppressing 
the secretion of pro-inflammatory cytokines, which initiates the vicious cycle of inflammation 
and cell death. How they do this is still very unclear, as immunostaining images in Chapter 5 
showed that the HDACs are not found within these inflammatory cells and requires further 
investigation. The latter notion that HDAC-Is target another pathway and their effect on 
inflammatory cells is secondary seems very plausible as shown by the numerous evidence 
reported. Their ability to suppress oxidative stress and apoptosis means there would be less 
number of dopaminergic dying and releasing cell debris which would require the activation of 
glial cells to scavenge, and therefore impact the number of glial cells activated as observed in 
this thesis. 
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Figure 6-1 Mechanism of HDAC 
inhibition on inflammatory 
pathway. 
HDAC-Is inhibit secretion of cytotoxic 
compounds such as cytokines (IFNγ, IL-1β) 
which decreases CD23 expression and 
subsequently reduces iNOS expression and 
NO release. HDAC-Is inhibit TNF-α 
activation and decreases TNF-α-induced 
NFκB activation. This affects the NFκB 
mediated transduction pathways and 
prevents the activation of deleterious 
enzymes (COX-2, iNOS) and ROS 
generation, which contribute to oxidative 
stress. This damaging stress is prevented 
by increased expression of oxidative stress 
resistance genes (Sp1, FOXO3A, MT2). 
HDAC inhibition also prevents apoptosis 
through caspase-3 cleavage and activation, 
increase binding of HSP 70 and apaf-1 to 
prevent apoptosome formation, and 
prevent p53 and Bax mediated apoptosis. 
Upregulation of neuroprotective proteins 
GSH and bcl-2 and neurotrohic factors 
(GDNF, BDNF) aid to protect the neurone. 
Abbreviations: MAO-B, monoamine oxidase 
B; COMT, catechol-O-methyl transferase; 
GPx, glutathione peroxidise; GSH, 
glutathione;  NAPDH nicotinamide adenine 
dinucleotide phosphate; NF-κb, nuclear 
factor-κb; TNF-α, tumour necrosis factor-α; 
IκB, Inhibitor of κB; iNOS, Inducible nitric 
oxide synthase; NO, nitric oxide; IFN-γ, 
interferon-γ; CD23, macrophage cell 
surface antigen Fc R11; apaf-1, apoptotic 
protease activating factor-1. (Adapted and 
modified from Leoni et al., 2002; Ryu et al., 
2003; Teismann & Schulz, 2004; Wu et al., 
2008; Uo et al., 2009; Rappold & Tieu, 
2010; Zhang et al., 2012; Shimazu et al., 
2013). 
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6.4 Is HDAC inhibition the way forward for PD? 
From the in vivo studies reported in this thesis, it was shown that inhibition of HDACs reduced 
inflammation and prevented toxin-induced dopamine cell loss. However, the in vitro studies 
suggest that these two effects are independent, and that HDAC inhibition can decrease glial cell 
number without protecting the neuronal cells. 
 
Recently, there have been an increasing number of studies reporting the neuroprotective effects 
of HDAC-Is in both in vitro and in vivo models of dopaminergic cell death. For example, VPA 
protected rat nigro-striatal neurones from cell death initiated by the mitochondrial complex I 
inhibitor, rotenone, and reversed striatal dopamine depletion through hyperacetylation of 
histone H3 which correlated with a decrease in HDAC activity (Monti et al., 2010). In addition, 
VPA prevented nuclear localisation of monoubiquitinated α-synuclein, where it has been 
described to induce histone acetylation inhibition (Monti et al., 2010). Furthermore, DJ-1 
protein, which acts as an antioxidant and its mutant form is associated with early-onset 
autosomal recessive PD (Chapter 1), was increased to approximately 260% following 
phenylbutyrate treatment as well as rescuing dopaminergic neurones from MPTP-induced cell 
death in mice (Zhou et al., 2011). Additionally, phenylbutyrate and sodium butyrate increased 
DJ-1 transcription elevating protein levels to approximately 300% compared to control in N27 
dopaminergic cell line, thereby rescuing cells from H2O2- and 6-OHDA-induced oxidative stress 
and A53T mutant α-synuclein toxicity  (Zhou et al., 2011). This evidence contributes to the 
theory that HDAC-Is suppress oxidative stress, as DJ-1 is a protective protein and HDAC-Is 
elevate its levels to increase cell survival from toxin-induced oxidative stress, even though 
neuronal protection was not seen in cell lines and primary culture following H2O2 and MPP
+ 
treatment in cell lines. 
 
Despite these optimistic reports of HDAC-Is exhibiting neuroprotective effects, these inhibitors 
have a number of actions, including cell cycle arrest, apoptosis, angiogenesis, and immune 
modulation, which are potentially toxic (Bolden et al., 2006). This is probably due to the 
selectivity of the individual inhibitors for HDAC classes rather than isoforms and/ or nonhistone 
substrates (Grayson et al., 2010). For this reason, HDAC isoform-specific inhibitors need to be 
designed. This is because most of the inhibitors currently available are class- and not isoform-
specific inhibitors. Not all HDACs need to be inhibited in order to observe a protective effect (as 
mentioned in Chapter 1). In some cases, inhibition of some HDACs can prove to have detrimental 
effects rather than protective ones. For example, inhibition of HDAC1 results in p25-induced 
DNA damage and aberrant cell cycle activity, and over-expression of HDAC1 rescues neurones 
from p25 toxicity (Kim et al., 2008).  
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 Besides, class-specificity, HDAC-Is have also been shown to exert cell-type- and region-
specificity, which serves to be a problem (Svechnikova et al., 2008). For example, HDAC-I MS-275 
has been reported to be brain region-selective and up to 100 times more potent than VPA in 
increasing histone acetylation in vivo; but failed to increase acetylation in the striatum in doses 
up to 120 μmol/kg compared to VPA (Simonini et al., 2006). MS-275, like VPA and SAHA, show 
beneficial properties for not only cancer treatment, but also psychiatric and neurodegenerative 
disorders, but their lack of specificity in different brain regions and organs are associated with 
non-specific cytotoxicity and significant in vivo side effects, including cognitive dysfunction, 
headaches, sedation, nausea and vomiting, thrombosis and a reduction in both blood cell count 
and blood electrolytes (Grayson et al., 2010; Durham, 2012). Therefore, in order to overcome 
this issue, mRNA profiling studies of HDAC-Is effects in different brain regions including cortex, 
striatum, cerebellum, hippocampus, SN, etc in response to systemic drug administration needs 
to be compared to similar profiles obtained from organs including the kidney, liver, heart and 
pancreas of the same treated animals, to deduce the full effect of the candidate HDAC-I 
(Grayson et al., 2010). Moreover, as HDAC-Is target a wide range of histone and nonhistone 
proteins such as transcription factors, identifying biomarkers and/ or specific mRNAs of proteins 
which are up- or down-regulated following HDAC inhibition could be used as indicators of drug 
inhibitor efficacy (Grayson et al., 2010), and also improve the understanding of the mechanisms 
of these inhibitors and the pathophysiology of PD.  
 
 
6.5 Other models for future studies 
Recent positive reports of the neuroprotective effects of HDAC inhibition encourage the notion 
of these inhibitors to be investigated in other models of PD. In particular transgenic animal 
models based on gene defects in familial PD, as HDAC-Is are thought to work primarily at the 
level of transcription. These defects include α-synuclein, LRRK-2 and PINK1 among others 
(Chapter 1). For some reason the transgenic approach has failed to produce an effective animal 
model of PD in mice where the genetic defects exhibits the pathological changes with which they 
are associated in man (Duty & Jenner, 2011). However, this problem has been overcome by 
recombinant adeno-associated virus (rAAV) vector overexpression of α-synuclein in mice and 
primates which closely reproduce the pathology of the human condition, particularly the 
nigrostriatal tract degeneration (Kirik et al., 2002). This model is of interest as increasing 
evidence confirms nigrostriatal degeneration initiates at the level of the axonal terminals in the 
putamen and cell loss is either caused or exacerbated by the presence of α-synuclein 
immunopositive neuronal inclusions (Chung et al., 2009; Chu et al., 2012). HDAC-I treatments 
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could slow down or potentially attenuate the degeneration of the nigrostriatal neurones as 
reported  by Kontopoulos and group (2006) who showed that HDAC-Is were able to prevent α-
synuclein neurotoxicity and prevent cell death (Kontopoulos et al., 2006).   
 
Furthermore, genetic models in multicellular model organisms are also emerging. These include 
the fruitfly Drosophila melanogaster, the nematode Caenorhabditis elegans model and the 
zebrafish Danio rerio as they have highly conserved homologues of the human genes associated 
with PD, such as parkin, UCH-L1, PINK1, DJ-1 and LRRK2 (Whitworth et al., 2006; Duty & Jenner, 




As hypothesised, the data presented in this thesis coupled to previous studies on the effects of 
HDAC-I in PD models suggest that HDAC-Is are promising potential neuroprotective agents 
worthy of further investigation for future treatment of PD. The ability of these inhibitors to 
protect neurones from inflammation-mediated neurodegeneration, as in rheumatoid arthritis, 
and their beneficial properties observed in neurodegenerative disorders, particularly HD (Hockly 
et al., 2003), makes them a potential candidates for neurodegenerative disorder treatments. 
However, a vast amount of further work needs to be completed to fully understand the 
mechanism of these inhibitors due to their multi-targets, and the fact that they have been 
proven to be useful in treating malignant conditions.  
 
To take this field further, isoform-specific HDAC-Is need to be developed and tested as this 
would probably reduce the toxicity observed following the use of pan-inhibitors in the present 
study. In fact, HDAC1-specific HDAC-I, MS-275, is currently on the market but has not yet been 
tested in animal models of PD. Such investigations would provide better understanding of the 
role of the isoform and its potential neuroprotective role following inhibition. Second, the 
effects of the inhibitors need to be tested in genetic models such as the rAAV vector α-synuclein 
over-expressed mice and transgenic multicellular organisms, to determine and confirm the role 
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Table of statistics 
Figure reference Test F value, (df), p value 
Figure 3-7 Cell death in N1E-115 
and SH-SY5Y cells following H2O2 





(A) N1E-115: F (2,6) = 3.24, p = 0.0748 
(B) SH-SY5Y: F (2,7) = 18.60, p < 0.0001 
MPP+ 
(C) N1E-115: F (2,7) = 5.60, p = 0.0163 
(D) SH-SY5Y: F (2,7) = 16.41, p = 0.0002 
Figure 3-8 Viable N1E-115 and SH-
SY5Y cells following H2O2 




(A) N1E-115: F (2,5) = 2.70, p = 0.1156 
(B) SH-SY5Y: F (2,5) = 2.67, p = 0.1179 
MPP+ 
(C) N1E-115: F (2,5) = 0.85, p = 0.4566 
(D) SH-SY5Y: F (2,5) = 1.23, p = 0.3344 
Figure 3-9 Effect of H2O2 on cell 





(A) N1E-115: LDH assay 
Interaction: F (7,32) = 4.60, p = 0.0012 
SAHA: F (7,32) = 1.68, p = 0.1488 
H2O2: F (1,32) = 74.24, p < 0.0001 
(B) SH-SY5Y: LDH assay 
Interaction: F (7,32) = 5.11, p = 0.0006 
SAHA: F (7,32) = 15.98, p < 0.0001 
H2O2: F (1,32) = 1236.68, p < 0.0001 
(C) N1E-115: Trypan blue assay 
Interaction: F (7,32) = 1.55, p = 0.1850 
SAHA: F (7,32) = 6.65, p < 0.0001 
H2O2: F (1,32) = 34.40, p < 0.0001 
(D) SH-SY5Y: Trypan blue assay 
Interaction: F (7,32) = 1.72, p = 0.1392 
SAHA: F (7,32) = 2.46, p = 0.0391 




(A) N1E-115: F (2,15) = 8.02, p = 0.0016 
(B) SH-SY5Y: F (2,15) = 9.98, p = 0.0005 
Trypan blue assay 
(C) N1E-115: F (2,15) = 11.11, p = 0.0002 
(D) SH-SY5Y: F (2,15) = 21.59, p < 0.0001 
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Figure 3-10 Effect of H2O2 on cell 





(A) N1E-115: LDH assay 
Interaction: F (7,32) = 0.51, p = 0.8219  
VPA: F (1,32) = 1.19, p = 0.3368 
H2O2: F (7,32) = 85.16, p < 0.0001 
(B) SH-SY5Y: LDH assay 
Interaction: F (7,32) = 1.20, p = 0.3312 
VPA: F (7,32) = 0.75, p = 0.6317 
H2O2: F (1,32) = 330.01, p < 0.0001 
(C) N1E-115: Trypan blue assay 
Interaction: F (7,32) = 0.82, p = 0.5752 
VPA: F (7,32) = 2.13, p = 0.0682 
H2O2: F (1,32) = 51.42, p < 0.0001 
(D) SH-SY5Y: Trypan blue assay 
Interaction: F (7,32) = 2.54, p = 0.0336 
VPA: F (7,32) = 2.35, p = 0.0468 




(A) N1E-115: F (2,15) = 40.15, p < 0.0001 
(B) SH-SY5Y: F (2,15) = 3.37, p = 0.0479 
Trypan blue assay 
(C) N1E-115: F (2,13) = 2.35, p = 0.1158 
(D) SH-SY5Y: F (2,15) = 21.40, p < 0.0001 
Figure 3-11 Effect of MPP+ on cell 





(A) N1E-115: LDH assay 
Interaction: F (7,32) = 2.21, p = 0.0594 
SAHA: F (7,32) = 3.49, p = 0.0068 
MPP+: F (1,32) = 24.41, p < 0.0001 
(B) SH-SY5Y: LDH assay 
Interaction: F (7,32) = 1.70, p = 0.1448 
SAHA: F (7,32) = 48.53, p < 0.0001 
MPP+: F (1,32) = 306.68, p < 0.0001 
(C) N1E-115: Trypan blue assay 
Interaction: F (7,32) = 1.20, p = 0.3318 
SAHA: F (7,32) = 4.53, p = 0.0013 
MPP+: F (1,32) = 50.37, p < 0.0001 
(D) SH-SY5Y: Trypan blue assay 
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Interaction: F (7,32) = 0.79, p = 0.60 
SAHA: F (7,32) = 3.73, p = 0.0047 




(A) N1E-115: F (2,15) = 11.31, p = 0.0002 
(B) SH-SY5Y: F (2,15) = 0.88, p = 0.4248 
Trypan blue assay 
(C) N1E-115: F (2,15) = 5.75, p = 0.0077 
(D) SH-SY5Y: F (2,15) = 21.59, p < 0.0001 
Figure 3-12 Effect of MPP+ on cell 





(A) N1E-115: LDH assay 
Interaction: F (7,32) = 0.64, p = 0.7189 
VPA: F (7,32) = 0.44, p = 0.8718 
MPP+: F (1,32) = 60.20, p < 0.0001 
(B) SH-SY5Y: LDH assay 
Interaction: F (7,32) = 0.49, p = 0.8387 
VPA: F (7,32) = 0.89, p = 0.5248 
MPP+: F (1,32) = 91.43, p < 0.0001 
(C) N1E-115: Trypan blue assay 
Interaction: F (7,32) = 1.28, p = 0.2895 
VPA: F (7,32) = 2.24, p = 0.0565 
MPP+: F (1,32) = 50.30, p < 0.0001 
(D) SH-SY5Y: Trypan blue assay 
Interaction: F (7,32) = 0.11, p = 1.00 
VPA: F (7,32) = 1.05, p = 0.4198 




(A) N1E-115: F (2,15) = 1.77, p = 0.1882 
(B) SH-SY5Y: F (2,15) = 54.97, p < 0.0001 
Trypan blue assay 
(C) N1E-115: F (2,8) = 14.80, p = 0.0002 
(D) SH-SY5Y: F (2,15) = 2.06, p = 0.1446 
Figure 4-7 The effect of MPP+ and 




(A) MPP+: F (7,34) = 25.54, p < 0.0001 
(B) LPS: F (1,7) = 6.85, p = 0.0346 
Figure 4-8 The effect of SAHA and Two-way (A) Interaction: F (3,16) = 3.60, p = 0.0370 
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VPA on the number of TH-positive 
cells following MPP+ and LPS 
induced toxicity. 
ANOVA SAHA: F (3,16) = 6.07, p = 0.0058 
MPP+: F (1,16) = 7.72, p = 0.0134 
(B) Interaction: F (3,16) = 5.30, p = 0.0100 
VPA: F (3,16) = 5.64, p = 0.0078 
MPP+: F (1,16) = 18.56, p = 0.0005 
(C) Interaction: F (3,16) = 5.85, p = 0.0068 
SAHA: F (3,16) = 11.02, p = 0.0004 
LPS: F (1,16) = 2.95, p = 0.1050 
(D) Interaction: F (3,16) = 11.97, p = 0.0002 
VPA: F (3,16) = 13.77, p = 0.0001 
LPS: F (1,16) = 37.55, p < 0.0001 
One-way 
ANOVA 
(A) F (2,7) = 5.51, p = 0.0172 
(B) F (2,7) = 0.22, p = 0.8092 
(C) F (2,7) = 1.92, p = 0.1838 
(D) F (2,7) = 1.56, p = 0.2450 
Figure 4-10 The effect of SAHA 
and VPA on the number of GFAP 















(A) Interaction: F (3,16) = 7.08, p = 0.0031 
SAHA: F (3,16) = 0.38, p = 0.7653 
MPP+: F (1,16) = 7.39, p = 0.0152 
(B) Interaction: F (3,16) = 6.38, p = 0.0048 
VPA: F (3,16) = 0.39, p = 0.7641 
MPP+: F (1,16) = 4.75, p = 0.0447 
(C) Interaction: F (3,16) = 3.51, p = 0.0398 
SAHA: F (3,16) = 1.64, p = 0.2208 
LPS: F (1,16) = 2.28, p = 0.1504 
(D) Interaction: F (3,16) = 13.46, p = 0.0001 
VPA: F (3,16) = 6.61, p = 0.0041 
LPS: F (1,16) = 13.87, p = 0.0018 
One-way 
ANOVA 
(A) F (7,16) = 4.25, p = 0.0078 
(B) F (7,16) = 3.58, p = 0.0165 
(C) F (2,7) = 1.30, p = 0.3045 
(D) F (2,7) = 6.58, p = 0.0097 
Figure 4-12 The effect of SAHA 
and VPA on the number of OX-42-




(A) Interaction: F (6,24) = 6.58, p = 0.0003 
Toxin: F (2,24) = 29.28, p < 0.0001 
SAHA: F (3,24) = 2.71, p = 0.0677 
(B) Interaction: F (6,24) = 11.82, p < 0.0001 
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Toxin: F (2,24) = 14.98, p < 0.0001 
VPA: F (3,24) = 8.46, p = 0.0005 
One-way 
ANOVA 
(A) F (11,24) = 9.65, p < 0.0001 
(B) F (11,24) = 11.48, p< 0.0001 
Figure 5-1 EC50 of VPA and SAHA 
following HDAC assay 
One-way 
ANOVA 
(A) F (5,12) = 83.78, p<0.0001  
(B) F (5,12) = 84.43, p<0.0001 
Figure 5-2 Volumes of water, 
HOP-β-CD and SAHA consumed by 
C57BL/6J in 24 hours 
One-way 
ANOVA 
F (2,15) = 0.07, p =0.1627 
Figure 5-7 HDAC assay of mouse 




F (2,18) = 25.73, p < 0.0001 
Figure 5-9 The effect of VPA and 
SAHA on the number of TH-
positive cells in SN of sham-, 6-





Interaction: F (6,74) = 1.52, p = 0.1826 
Treatment: F (6,74) = 2.57, p = 0.0259 
Lesioned side: F (1,74) = 27.10, p < 0.0001 
LPS lesion 
Interaction: F (6,80) = 3.02, p = 0.0102 
Treatment: F (6,80) = 3.73, p = 0.0025 
Lesioned side: F (1,80) = 50.63, p < 0.0001 
One way 
ANOVA 
6-OHDA lesion: F (13,76) = 4.61, p < 0.0001 
LPS lesion: F (13,80) = 8.16, p < 0.0001 
Figure 5-11 The effect of VPA and 
SAHA on GFAP-immunoreactivity 
in SN of sham-, 6-OHDA- and LPS-





Interaction: F (6,70) = 0.98, p = 0.4456 
Treatment: F (6,70) = 12.10, p < 0.0001 
Lesioned side: F (1,70) = 22.68, p < 0.0001 
LPS lesion 
Interaction: F (6,76) = 0.85, p = 0.5388 
Treatment: F (6,76) = 14.28, p < 0.0001 
Lesioned side: F (1,76) = 23.02, p < 0.0001 
One way 
ANOVA 
6-OHDA lesion: F (13,70) = 8.18, p < 0.0001 
LPS lesion: F (13,76) = 9.04, p < 0.0001 
Figure 5-13 The effect of VPA and 
SAHA on the number active OX-
42-positive cell in SN of sham-, 6-





Interaction: F (6,72) = 20.08, p < 0.0001 
Treatment: F (6,72) = 20.20, p < 0.0001 
Lesioned side: F (1,72) = 128.49, p < 0.0001 
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LPS lesion 
Interaction: F (6,78) = 25.19, p < 0.0001 
Treatment: F (6,78) = 25.01, p < 0.0001  
Lesioned side: F (1,78) = 171.69, p < 0.0001 
One way 
ANOVA 
6-OHDA lesion:  
F (13,72) = 27.05, p < 0.0001 
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Negative staining controls 
































































Figure 7-1 Negative staining images for immunofluorescence in cell lines. 
(A) Primary antibody against TH and secondary antibody (Alexa fluor 594) omitted in N1E-115 
and SH-SY5Y cell lines. (B) Primary antibodies against HDAC3, 4, 5 and 11, and secondary 
antibody (Alexa fluor 594) omitted in both cell lines. No immunoreactivity is visible. Scale bar = 
100 µm is representative of all images. 
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Figure 7-2 Immunoperoxidase and 
immunofluorescence negative control images 
for VM primary culture. 
(A) Primary antibodies against TH, GAD and 
GFAP and biotinylated secondary antibody 
were omitted in VM cultures during 
immunoperoxidase staining. Cresyl violet was 
used to counterstain cells. (B) Primary 
antibody against OX-42 and secondary 
antibody (Alexa flour 488) omitted in 
immunofluorescence staining. (C) Primary 
antibodies against HDAC3, 4, 5, 11, TH and 
GFAP and secondary antibody (Alexa fluor 594 
and Alexa flour 488) omitted in 
immunoflourescence staining. No 
immunoreactivity is visible in any image. Scale 
bar = 100 µm is representative of all images. 
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Figure 7-3 Negative staining images for mouse brain sections. 
(A) Primary antibodies against HDAC3, 4, 5, 11, TH, GFAP and OX-42, and secondary antibodies 
Alexa fluor 594 and 488 were omitted in immunofluorescence staining. (B) Primary antibody 
against TH, GFAP and OX-42 and biotinylated secondary antibody omitted in mouse brain 
sections during immunoperoxidase staining. No visible immunoreactivity is seen. Scale bar = 100 
µm (A), and 50 µm (B), is representative of the respective images. 
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